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Abstract 
 
Standard therapy for patients with chronic lymphocytic leukaemia involves the 
use of DNA damaging drugs. If the cellular DNA damage response has been 
compromised then these standard therapies will be ineffective at inducing 
apoptosis. Central to this response is the protein, p53. Loss of the 
chromosome containing the gene TP53, which encodes the protein p53 
and/or mutation of the gene, occurs in approximately 5-10% of newly 
diagnosed CLL patients. This rises to over 30% in patients who relapse after 
therapy. In addition another important protein within the DNA damage 
response, the protein-kinase ATM, may be deleted and/or mutated in a further 
20-30% of CLL cases. Loss of the chromosomal loci containing either TP53 or 
ATM has been shown to predict a poor response to treatment and shorter 
overall survival. It is now known that detecting loss alone is insufficient as 
miss-sense or non-sense mutation of these genes alone can lead to an 
equally poor outcome. Screening these genes for mutations is not carried out 
routinely and can be technically challenging. In addition to this it is not fully 
understood to what degree other genes may be involved in dysfunction of the 
DNA damage response. 
Functional assays provide an alternative method for testing the integrity of the 
p53-dependant DNA damage response without needing to focus upon specific 
genomic abnormalities. A flow-cytometry based assay, utilising 
etoposide/nutlin3a and developed in our laboratory, has already been shown 
to detect and discriminate between p53 and ATM abnormalities in a small 
series of patients. This project aims to assess the clinical value of the 
etoposide/nutlin3a functional assay for detecting abnormalities of the p53-
dependant DNA damage response which would contra-indicate treatment with 
DNA damaging drugs in samples referred from around the UK. 
A total of 472 samples from participating centres around the UK have been 
tested using the functional assay and also assessed for deletion of ATM and 
p53. The assay is largely unaffected by transport of whole blood samples 
across the UK if transit time is no greater than 48 hours and the sample is not 
stored above room temperature. Dysfunctional assay results have been 
shown to have a highly significant association with deletion of the genes for 
p53 and ATM. The use of nutlin3a has been shown to discriminate between 
dysfunctional cases with deletion of ATM or loss/mutation of p53. The assay 
has been shown to detect patients with mutation of the p53 gene who do not 
have concurrent deletion of the second allele. A novel dysfunctional response 
pattern involving p21 expression has been shown to associate with 
abnormalities of p53 rather than single nucleotide polymorphisms. The results 
also show that deletion of p53 and particularly ATM does not per se lead to a 
dysfunctional response as currently detected by the assay. This suggests that 
other mechanisms or genes are involved in resistance to DNA damage 
induced apoptosis. 
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 Overview 1.1
Non-surgical treatment of cancer historically relied on using radiation or 
DNA damaging drugs to induce apoptosis. When there is a clinical indication 
for treatment, most patients with chronic lymphocytic leukaemia (CLL) 
respond well to DNA damaging chemotherapeutics such as alkylating agents 
(alk) and purine analogues (PA). This response is improved by addition of the 
anti-CD20 antibody, Rituximab (Hallek et al., 2008). Tumour cell apoptosis 
induced using DNA damaging agents is reliant upon an intact p53-dependant 
DNA damage response pathway. Fluorescent in-situ hybridisation (FISH) is 
the currently employed method for detecting abnormalities of this pathway. 
This is achieved by identifying the loss of genetic material on chromosomes 
17 and 11 which encompass the genes TP53 and ATM respectively. These 
abnormalities are associated with a poorer response when treated with 
alkylating agents and purine analogues. Deletion of the short arm of 
chromosome-17 (17p) results in loss of TP53, the gene coding for p53 
protein. This occurs in 5-10% of treatment naïve patients, increasing to over 
30% in patients who have become refractory to standard DNA damaging 
therapy (Zenz et al., 2009). Deletion of a region on the long arm of 
chromosome-11 (11q22.3), which encompasses the ATM gene, is detected in 
10% of CLL patients with early stage disease. This increases to 25% of 
untreated patients with advanced disease (Hallek, 2013b). Mutation screening 
of either gene is not yet routinely performed, yet it is known that mutations of 
p53 and ATM can occur alone and can have a similar impact upon outcome 
as deletion detected by FISH (Zenz et al., 2008b). A mutation of p53 in the 
absence of a deletion of 17p13.1 detected using FISH occurs in a further 5-
10% of untreated CLL patients and in up to 50% of patients who are refractory 
to first line therapy administering alkylating agents and purine analogues 
(Zenz et al. 2012). Some patients who fail to respond to standard treatment 
have no detectable abnormalities of p53 or ATM. Curiously, a minority subset 
of patients with early stage CLL have abnormalities of p53 yet follow a benign 
clinical course, a phenomenon also observed in some patients with splenic 
marginal zone lymphoma (SMZL) (Best et al., 2008a, Tam et al., 2009). 
Determining what factors may be responsible for this benign course in the 
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presence of high-risk abnormalities could have clinical and therapeutic 
applications. 
In this project a functional assay designed to detect defects within the 
ATM/p53-dependant DNA damage response will be performed for CLL 
patients prior to initial or subsequent treatments. The functional study results 
will be compared to FISH and mutation screening data for p53 and ATM and 
then correlated with clinical information where available. The primary aim is to 
determine whether the assay described herein is able to detect mutations 
and/or deletions of the TP53 and ATM genes. The secondary aim is to 
determine whether the assay can differentiate between dysfunctional 
responses of the p53-dependant DNA damage response caused by either of 
the aforementioned genes. The tertiary aim is to assess the clinical relevance 
of the assay for predicting the response to treatment with DNA damaging 
chemotherapeutics.  
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 Definitions and nomenclature 1.2
It would at this point be worth clarifying the nomenclature of the 
genes/proteins that are going to be frequently mentioned throughout this 
thesis.  
The HUGO Gene Nomenclature Committee is the organisation responsible for 
providing guidelines on the naming of human genes and for the approval of 
new gene names and genes symbols. They define a gene as “a DNA 
segment that contributes to phenotype/function. In the absence of 
demonstrated function a gene may be characterised by sequence, 
transcription or homology”. As well as a name, a gene is assigned a gene 
symbol, an often abbreviated form of the name in which all letters are 
capitalised and presented in italics. For example one gene of interest is ATM. 
This is the gene symbol for the gene named, Ataxia telangiectasia mutated. In 
this case the gene name is taken from the congenital disorder which 
prompted the research which led to its discovery. The gene symbol of the 
other gene of interest in this work is TP53. Its gene name, tumour protein p53 
differs from ATM in that it is not named for a disease. Both ATM and TP53 are 
protein coding genes and so the protein product also has a name. For most 
cases it is simply the same as the gene symbol except without the italics eg, 
ATM is the protein encoded by the ATM gene. This, however, is not the case 
for the protein product of the TP53 gene. This is known as p53. 
This understanding of the different names for the genes and proteins 
mentioned herein is important to avoid confusion eg, when discussing the 
relationships between mutations of the gene and the effect this has upon the 
protein. 
 Chronic Lymphocytic Leukaemia (CLL) 1.3
Chronic lymphocytic leukaemia (CLL) is the most common form of adult 
leukaemia in the western world (Montserrat et al., 1991, Oscier et al., 2012). 
Data from the National Cancer Institute’s SEER (Surveillance Epideimology 
and End Results) review from 2005-2009 found the median age at diagnosis 
for CLL was 72 years (Oscier et al. 2012). The overall 5-year survival for CLL 
patients, relative to the general population, is 78.8%. In the United Kingdom 
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the age-standardised rate of new CLL diagnoses is 5.7 cases per 100,000 of 
the population per year (Cancer Research UK 2015). The incidence of CLL is 
approximately twice as high in males as in females for unknown reasons. The 
incidence of CLL also appears to be affected by race/ethnicity, with 
Caucasians showing the highest incidence rate. Table 1-1 contains the data 
on CLL incidence by Race reported in Howlader et al, (2013).  
 
Table 1-1: Incidence rates of CLL by Race/Ethnicity:  
 
 
 
 
Statistical evidence for some genetic influence in CLL was found during a 
study of Swedish population data available on diagnoses made between 
1958-2005 (Landgren et al., 2008). The rate of lympho-proliferative disorders, 
including CLL, in 26,947 first degree relatives of 9,717 CLL patients was 
compared to the same rate between 38,159 matched controls and 107,223 of 
their first degree relatives. Although the overall risk of familial CLL was very 
low, first degree relatives of CLL patients had an increased risk of developing 
CLL (HR=8.5; 95% CI=6.1-11.7) compared to controls as well as the non-
Hodgkin lymphomas Lymphoplasmacytic lymphoma / Waldenström’s 
macroglobulinemia (HR=4; 95% CI=2.0-8.2) and Hairy cell leukaemia 
(HR=3.3; 95% CI=1-10.9) (Goldin et al., 2009, Landgren et al., 2008). 
Genome wide SNP analysis has identified several alleles associated with risk 
of developing CLL and which appeared to have a cumulative effect upon the 
odds ratio of developing CLL (Crowther-Swanepoel et al., 2010).   
Diagnosis of CLL is based upon a persistent (> 3 months) B-cell 
lymphocytosis of greater than 5x109/L as assessed by a full blood count and 
Race/Ethnicity Male Female
All Races 5.8 per 100,000 3.0 per 100,000 
White 6.1 per 100,000 3.2 per 100,000 
Black 4.3 per 100,000 2.0 per 100,000 
Asian/Pacific Islander 1.3 per 100,000 0.7 per 100,000 
American Indian / Alaskan Native 2.5 per 100,000 
Hispanic 2.4 per 100,000 1.5 per 100,000 
The highest incidence of CLL occurs in Caucasian populations which may 
support the role of genetic factors in the ontology of CLL. Table 
reproduced from (Howlader et al. 2013). 
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identified as monoclonal using flow cytometry (Bene et al., 2011). A 
recommended flow cytometry scoring system of five markers is used to 
identify CLL: expression of weak surface immunoglobulin (sIg), CD5, CD23, 
and low/ absent expression of FMC7 and CD79b (Moreau et al., 1997). Four 
or five of these markers correctly indicates ninety-two percent of CLL cases 
(Cro et al., 2010).  
CLL is incurable using chemotherapy and heterogeneous in its progression 
with overall survival ranging from months to decades (Oscier et al, 2012). 
Patients may fall into three broad categories: early stage with a low tumour 
burden, early stage at diagnosis with progression over time or advanced 
stage disease at diagnosis. 
The Binet and Rai scales are the accepted systems for staging CLL at 
diagnosis (Rai et al., 1975, Binet et al., 1981, Hallek et al., 2008). These 
systems are summarised in Table 1-2 and Table 1-3, and are sometimes 
combined into A(0), A(I), A(II); B(I), B(II); and C(III), C(IV) stages.  
 
Table 1-2: The Binet CLL staging system. 
 
 
Binet 
stage
Areas of 
lymphoid 
involvement
Anaemia and/or 
thrombocytopenia
A Less than 3 No
B 3 or more No
C Any number Yes
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Table 1-3: The RAI CLL staging system. 
 
 
 
 
A number of biological markers have been discovered which inform on CLL 
patient prognosis. These associate with parameters such as time to first 
treatment (TTFT) and overall survival (OS) in CLL patients. They can be 
divided into intrinsic and extrinsic factors depending upon whether they affect 
the underlying genetics of the CLL cell, or influence the interactions between 
the CLL cell and its microenvironment, respectively (Dal-Bo et al., 2009).  
Sequence analysis of the rearranged immunoglobulin heavy chain variable 
(IGHV) region of the B-cell receptor (BCR) of the patients B-CLL clone was 
found to accurately differentiate between patients with indolent or aggressive 
disease. An IGHV sequence that is unmutated or has greater than 98% 
similarity to the germline sequence is associated with an aggressive disease 
(Damle et al., 1999, Hamblin et al., 1999). In addition to the percentage 
mutation relative to the germline, the use of particular stereotyped BCR 
genes, such as V3-21, has also been shown to be an independent prognostic 
marker (Tobin et al., 2002).  
IGHV analysis is generally considered to be the gold standard for determining 
prognosis but other molecular features of poor prognosis have been identified. 
In particular, methods which are suited to flow cytometry have been 
developed as this is a platform which is particularly suited to the analysis of 
 
 
 
 
RAI stage Required observation
May or may not 
be present
O Lymphocytosis only n/a
I
Lymphocytosis and 
enlarged nodes
n/a
II
Lymphocytosis and 
organomegaly (Liver or 
Spleen)
Enlarged nodes
III
Lymphocytosis and 
anaemia
Organomegaly or 
enlarged nodes
IV
Lymphocytosis and 
thrombocytopenia
Organomegaly, 
enlarged nodes or 
anaemia
Lymphocytosis requires clonal B-cell 
lymphocyte count >5x109/L as obtained 
by routine whole blood analysis. 
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samples derived from blood. A number of prognostic markers have been 
identified for this purpose.  
Zeta-chain-associated protein kinase 70kDa (Zap-70) is a tyrosine-protein 
kinase involved in T-cell signalling which is normally expressed in T-cells and 
natural killer cells (Chan et al., 1992). It was shown to be aberrantly 
expressed in a subset of CLL patients and was associated with unmutated 
IGHV genes, a poorer clinical outcome and increased BCR signalling 
(Wiestner et al., 2003) (Chen et al., 2002) which lead to it being suggested as 
a surrogate marker for IGHV status(Crespo et al., 2003).  B-CLL cells 
circulating in the peripheral blood have lower levels of ZAP-70 compared to 
their counterparts within lymph nodes suggesting that factors within the node 
micro-environment which promote proliferation are responsible for increasing 
ZAP-70 levels (Boelens et al., 2007). The expression of ZAP-70 protein has 
been shown to be suppressed by methylation of the ZAP-70 gene at the 
intron1-exon2 boundary (Corcoran et al., 2005). Zap-70 remains a prognostic 
marker of limited value as there are still questions regarding its stability over 
time, reproducibility of results between different centres and the best 
methodology for detection.  
The surface antigen CD38 (cyclic ADP ribose hydrolase) is a regular feature 
of the B-CLL phenotype and its expression was linked to prognosis at the 
same time as V-Genes (Damle et al., 1999) and then subsequently shown to 
be predictive of survival in CLL patients (Mainou-Fowler et al., 2004, Morabito 
et al., 2001). The role of CD38 is thought to be linked to cell signalling in the 
micro-environment of proliferation centres such as the lymph nodes. CD38 
has been shown to ligate to CD31, aka PECAM-1 (platelet endothelial cell 
adhesion molecule-1), a surface marker expressed on endothelial cells, 
platelets, macrophages, lymphocytes and granulocytes. This binding 
increases growth and survival of the CLL cells brought about by changes in 
their gene expression profile affecting up to 85 separate cellular pathways. Of 
these 85 pathways, 30% were shown to be involved in lymphocyte adhesion, 
movement and/or signalling (Deaglio et al., 2010). It has been shown that the 
levels of CD38 may change throughout the course of the disease (Hamblin et 
al., 2002). CD38 analysis can be combined with ZAP-70 analysis for flow 
cytometric analysis (Hassanein et al., 2010).  
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More recently another cell surface marker, CD49d (Integrin Subunit Alpha 4), 
has been shown to have strong prognostic value in CLL. Following a large 
study of 2972 CLL cases CD49d is now considered to be one of the strongest 
predictors of overall survival that can be determined using flow cytometry 
(Bulian et al., 2014). The Bulian study found that cases showing CD49d 
expression on ≥30% of the tumour cells reliably identified subsets of patients 
who had poor outcomes in terms of overall survival and treatment free 
survival. The authors found that there was no further prognostic information 
added by the analysis of either CD38 or ZAP-70 (Bulian et al., 2014).  
It could be argued that at the point of needing treatment, predictive rather than 
prognostic tests are required. These are focused on detecting the intrinsic, 
high-risk genetic abnormalities that are associated with treatment failure, an 
approach that will be used in this study. 
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 Treatment of chronic lymphocytic leukaemia 1.4
Aside from a minority of patients with prolonged disease free survival following 
allogeneic bone marrow transplant, CLL remains incurable. Treatment is 
currently recommended for patients showing signs of progressive or active 
disease (Hallek et al., 2008, Hallek, 2013b). 
Recommended standard first line therapy for physically fit patients combines 
the purine analogue fludarabine, the alkylating agent cyclophosphamide and 
the anti-CD20 antibody, rituximab (FCR). This combination has been shown to 
give the best overall response rates (OR), complete remission rates (CR) and 
progression free survival (PFS) (Hallek et al., 2008). For patients who are less 
fit the single alkylating agent chlorambucil is used in combination with anti-
CD20 antibodies (Hallek, 2013a). 
If a patient does not relapse for 2 years after therapy then the first line therapy 
may be repeated when relapse does occur. For those patients who do relapse 
within this time-frame the mustard based compound, bendamustine, is 
recommended, alone or in combination with antibody therapy (Hallek, 2013b)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1:TP53 abnormalities and survival in patients 
treated with FCR.  
 The overall survival of patients with any abnormalities of TP53 is 
greatly reduced when compared to normal patients treated with 
fludarabine/cyclophosphamide and rituximab (FCR) (Zenz and 
Stilgenbauer, 2009, Zenz et al., 2010)  . 
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Rituximab has additional benefit for patients with del11q and has been tested 
in combination with chlorambucil or bendamustine as a first line treatment 
(Zenz and Stilgenbauer, 2009). Fludarabine based therapy is ineffective for 
CLL with del17p and/or mutation of the TP53 gene as is shown in Figure 1-1 
which is reproduced from Zenz et al. (2010). 
Fludarabine use in patients with del17p in less than 20% of the CLL clone has 
been shown to kill non-del17p CLL cells and enrich for del17p, fludarabine-
resistant cells (Zenz et al., 2008a). The danger in these cases is that new 
mutations caused by DNA damaging agents could generate more aggressive 
sub-clones. Drugs that do not kill using DNA damage include 
immunotherapies such as the anti-CD20 antibody, Rituximab (Mabthera®) 
which may be used alone or in combination with other agents depending on 
patient fitness (Hallek et al., 2008). Other therapies showing activity in 
patients with del17p include the thalidomide derivative lenalinomide and the 
immunotherapy ofatumumab and these are currently being trialled (Coiffier et 
al., 2008, Ferrajoli et al., 2008).  
New classes of drugs that target B-cell receptor mediated signalling are 
showing promise for CLL patients independently of del17p. The Brutons 
tyrosine kinase (BTK) inhibitor, ibrutinib (Imbruvica®), was licensed for the 
treatment of CLL in the UK in 2014 following impressive results in a phase III 
study in relapsed/refractory CLL patients (Byrd et al., 2014a).  
A novel adaptation to the off-license, DNA damaging chemotherapeutic drug 
chlorambucil, has also been shown to have activity in cell lines which are 
normally resistant to chlorambucil (Fonseca et al. 2011). The use of a 
polypeptide bound to chlorambucil (mt-Chlor) actively targeted the alkylating 
agent to the mitochondria. In cell lines that were shown to be resistant to 
chlorambucil, mt-Chlor rescued the level of apoptosis induced to that seen in 
chlorambucil sensitive cell lines. In addition Fonseca et al also showed in-vitro 
that mt-Chlor had selective activity in primary CLL cells when compared to 
peripheral blood stem cells or erythrocytes and mononuclear cells from 
healthy donors (Fonseca et al., 2011). 
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 Genomic abnormalities in CLL 1.5
Alterations of the genome are highly associated with cancer initiation and 
progression and there are several techniques for detecting them. This section 
will look at how the most recurrent abnormalities in CLL affect the disease.   
Chromosome banding facilitates the visual identification of the entire human 
karyotype and is well suited to haemato-oncology (Sanchez et al., 1973, 
Yunis and Sanchez, 1975, Crowther-Swanepoel et al., 2010). Large gains, 
losses or translocations of genetic material that occur regularly in CLL are 
screened for using other techniques, in particular fluorescent in-situ 
hybridisation (FISH) is a robust methodology utilising fluorescent DNA probes 
to detect specific loci within the genome (Sandberg, 1981, Dohner et al., 
1997a, Dohner et al., 1999, de Oliveira et al., 2010). New technologies for 
detecting copy number variants (CNVs) and loss of heterozygosity (LOH) with 
higher specificity, such as comparative genomic hybridisation to micro-arrays 
(array-CGH) (Pinkel et al., 1998, Tyybakinoja et al., 2007) and single 
nucleotide polymorphism (SNP) arrays (Ouillette et al., 2008, Sellick et al., 
2005), may eventually supersede FISH and karyotyping. Cheaper options 
such as multiplex ligation-dependant probe amplification (MLPA) (Schouten et 
al., 2002) are also available. 
Several loci, frequently altered in CLL, are regularly screened using FISH. 
Based upon previous studies (Dohner et al., 1999, Dohner et al., 1997a, 
Dohner et al., 1997b, Juliusson et al., 1990), Dohner et al, (2000) determined 
a hierarchy of common chromosomal abnormalities, stratified by median 
survival Table 1-4. With regards predicting response to chemotherapy the 
most relevant of these is loss/deletion of material on chromosomes 11q22-23 
or 17p13.1 (del11q and del17p). 
The poor prognosis, reduced overall survival (OS) and increased involvement 
of lymph nodes associated with del11q in CLL is thought to be due to loss of 
the ATM gene (Dohner et al., 1997b, Monni and Knuutila, 2001). The very 
poor prognosis of del17p is due to the loss of the gene for p53 (TP53), a 
central component of cell cycle and DNA repair pathways (Wei et al., 2006). 
Loss of one allele of TP53 is advantageous for tumour cells allowing evasion 
of senescence and apoptosis pathways and resistance to DNA damaging 
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therapies. This is reflected in the recurrent detection of p53 abnormalities in 
all forms of cancer. Clinical trials have repeatedly shown that del17p is highly 
associated with a poor response to first line chemotherapy and shorter 
overall- and progression-free survival (OS/PFS) (Zenz et al. 2012). 
 
Table 1-4: The hierarchy of CLL related chromosomal 
abnormalities detected using fluorescent in-situ hybridisation 
and genes involved. (Dohner et al, 2000) 
Abnormality 
detected using 
FISH 
Median survival 
(months) 
Gene/s involved 
Deletion 17p13.1 32 TP53 
Deletion 11q22-23 79 
ATM, MRE11, 
H2AFX 
No abnormalities 111 n/a 
Trisomy-12 114 
Numerous 
candidates including 
MDM2 
Deletion 13q14 only 133 
miRNA’s, DLEU1 & 
DLEU2 
 
 
In addition to deletion of chromosomes, the genes for ATM and TP53 are also 
affected by mutations within the protein-coding DNA sequence. Non-sense 
mutations result in the production of truncated proteins or no protein at all. 
Miss-sense mutations may lead to the production of a full length protein with 
altered properties.  
Dysfunction of the ATM gene through mutation is known to be the cause of 
the recessively inherited congenital condition, ataxia-telengiectasia (A-T) 
(Stankovic et al., 1998). In CLL cells ATM mutations result in defective DNA 
damage signalling and pro-apoptotic responses (Stankovic et al., 2004, 
Stankovic et al., 2002, Stankovic et al., 1999). Detecting mutations of ATM is 
complicated by the size and complexity of the gene (68 exons) (Stankovic et 
al., 1997). It was thought that mutation of the remaining copy of the ATM gene 
in CLL patients with del11q could be an important determinant of therapy 
resistance (Austen et al., 2007). An analysis on the impact of bi-allelic ATM 
gene abnormalities in 224 patient samples from the UKCLL4 trial, who 
received first line treatment with chlorambucil or fludarabine with and without 
cyclophosphamide, supports this hypothesis (Skowronska et al., 2012). This 
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retrospective study determined the status of both alleles for both the ATM and 
TP53 genes, using FISH screening and mutational analysis, and then 
compared the median progression free survival (PFS) between groups. It 
found that cases with biallelic inactivation (mutation of one allele and deletion 
of the other) had a significantly shorter median progression-free survival than 
normal cases with no abnormalities (7.4 v 28.6 months). The effect was 
similar to that seen in patients with mono-allelic TP53 alterations (6.7 v 28.6 
months). In contrast there appeared to be little or no impact upon median PFS 
for ATM mutated cases which retained a second wildtype allele (30.8 v 28.6 
months). With a median OFS of 17.1 months, cases with deletion of one allele 
without mutation of the second appeared to be intermediate between biallelic 
alteration (mutation and deletion) and wildtype cases. This suggests that 11q 
deletion may have a greater impact upon the disease than inactivation of the 
ATM gene via mutation, possibly through the loss of other genes located on 
chromosome 11.   
Li-Fraumeni syndrome (LFS) and Li-Fraumeni-like syndrome (LFL) are 
congenital conditions usually involving a germline heterozygous mutation of 
TP53 and a predisposition to cancer, the incidence rates are shown in Table 
1-5 (Varley et al., 1997).  
 
Table 1-5: Incidence of cancers in normal, Li-Fraumeni syndrome and Li-Fraumeni 
like syndrome individuals. Adapted from (Varley et al., 1997) 
 Incidence of cancer 
 < 30 years old < 50 years old 
General population 2% 11% 
Li-Fraumeni syndrome 56% 100% 
Li-Fraumeni like 
syndrome 
44% 78% 
 
Somatic TP53 mutations are predominantly single base, miss-sense 
transitions or transversions that cluster in exons 5-9 (Figure 1-2), which is the 
region which encodes the protein’s DNA binding domain (DBD). Mutations 
within the DBD result in altered affinity for p53 response elements (REs). In 
addition, mutations within the DBD abrogate p53’s transcription-independent, 
sequestering of pro-apoptotic proteins (Vaseva and Moll, 2009). Small 
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insertions and deletions occur less frequently and tend to occur outside of 
exons 5-9 (Cho et al., 1994, Soussi et al., 2006). Mutations may be classified 
as either contact or conformational mutants depending on whether the 
mutation affects amino acids that come into contact with DNA or alter the 
tertiary structure of the protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The effects of TP53 gene mutation on p53 protein function can be described 
in three ways: (i) Loss of function is effectively a p53-null phenotype whereby 
p53 loses the ability to bind DNA; (ii) Gain of function involves p53 acquiring 
new properties, not seen in wildtype p53 (wtp53); and (iii) Dominant negative 
refers to mutant p53 interacting with the remaining wildtype p53 and inhibiting 
its normal action. These effects are not mutually exclusive and their 
occurrence may be influenced by cell type (Blagosklonny, 2000, Brosh and 
Rotter, 2009). While the first two of these effects refer to the transcriptional 
activity of the mutant p53 protein itself, the dominant negative effect may only 
occur in cells which have a heterozygous mutation with expression of both 
wildtype and mutant p53 protein within the cell. It has been shown in-silico 
that the presence of both results in the loss of transcription of familiar p53 
transcriptional targets such as p21 and MDM2 (Junk et al. 2008). The authors 
 
Figure 1-2: The distribution of types of TP53 mutation and their relative 
incidence within the TP53 gene according to the IARC TP53 Mutation 
Database. (Brosh and Rotter, 2009) 
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in Junk et al (2008) were able to show that the ability of wildtype p53 to bind 
the promoters of 324 targets genes was almost completely lost when mutant 
p53 was introduced. 
An example of a gain of function is shown in a study of cell lines known to 
harbour common p53 mutations. Di Agostino et al (2006), found that in 
response to DNA damage mutant p53 protein interacted with the nuclear 
transcription factor complex, NF-Y. This in turn led to an increase in the 
expression of NF-Y targets genes such as cyclinA, cyclinB1, cdc25 and cdk1, 
ultimately leading to increased DNA synthesis. Under the same conditions 
wildtype p53 would normally co-localise with NF-Y to repress the expression 
of these genes. The authors of this study were able to show that this change 
in expression of cell cycle genes was due to the presence of the mutant p53 
and not due to loss of the wildtype and therefore can be classified as a gain of 
function (Di Agostino et al., 2006).  
In CLL, TP53 mutation is commonly accompanied by del17p but between 6-
23% of patients with mutations may have no detectable loss using FISH 
(Malcikova et al., 2009, Rossi et al., 2009). However, mono-allelic mutation 
cases have similar survival rates to bi-allelic cases (Zenz et al., 2008b) 
therefore mutation detection is an important analysis that should be used to 
complement FISH. Interestingly, a small subset of patients with these high risk 
genomic defects (del17p, TP53 mutation) has been reported with clinically 
benign disease (Best et al., 2008a, Tam et al., 2009). It is thought that this 
may relate to the clinical heterogeneity of CLL as most of these benign 
patients have mutated IGHV sequences and may therefore lack proliferative 
capacity (Best et al., 2008a).  
Detection of aberrant p53 protein stability in tumour cells is associated with 
TP53 mutations (Chang et al., 2010, Chang et al., 2007). However evidence 
that p53 over-expression is context dependant suggests that its use alone 
may lead to error prone results (Colomer et al., 2003, Terzian et al., 2008, 
Zenz et al., 2008a). 
Detecting mutations within ATM and particularly TP53 is of importance due to 
the significant impact they have upon response to therapy. Detecting 
mutations by direct sequencing of genomic DNA has limited sensitivity as 
mutations in less than 20% of the sample become increasingly difficult to 
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detect. Time and labour are also factors that influence the use of sequencing, 
especially for large genes. To increase the sensitivity of mutation detection 
techniques have been developed to either enrich for mutated DNA in a 
sample or detect mutations with much higher sensitivity. Many of these 
screening techniques exploit the thermodynamic and conformational 
differences between wildtype and mutant DNA. High-resolution melting (HRM) 
analysis detects differences in melting temperature (Tm) between 
homoduplexes and heteroduplexes formed during PCR amplification of 
samples containing mutant DNA. Co-amplification at lower denaturing 
temperatures (COLD)-PCR preferentially amplifies mutant DNA during PCR 
and can be applied to increase the sensitivity of other PCR based 
technologies eg, Sanger-sequencing (Sanger et al., 1977) and 
pyrosequencing (Ronaghi et al., 1996). 
A recent investigation of the UK CLL4 trial used capillary-electrophoresis 
single strand conformation (CE-SSCP) to detect TP53 mutations (Gonzalez et 
al., 2011). This study analysed patient samples from 529 of the 777 trial 
participants. This study is particularly important as the CLL4 trial is now 
beyond the five year follow up point and all the participants were previously 
untreated. The study detected forty-three TP53 mutations in forty (7.6%) 
patients. The three patients with two mutations detected were then analysed 
using FASAY and the mutations were confirmed as being located on separate 
alleles. As expected, this study found that the presence of a TP53 abnormality 
was significantly associated with lower overall response rates (classified 
according to NCI criteria) and this was true whether for patients with del17p 
and a TP53 mutation or those who had either del17p or TP53 mutation alone. 
In addition, TP53 mutations were significantly associated with shorter overall 
survival and shorter progression free survival. Importantly this study detected 
TP53 mutations in the absence of del17p in about 3% of cases. 
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 Biological and Molecular aspects of p53 1.6
In over thirty years since its discovery there have been paradigm shifts 
concerning the role of p53 in normal and cancerous cells (Bienz et al., 1984, 
Crawford et al., 1981, DeLeo et al., 1979, Gohler et al., 2002, Hinds et al., 
1989, Liu et al., 1999, Pennica et al., 1984). It is an orchestrator of numerous 
cellular processes including apoptosis, and responds to a variety of intra- and 
extra-cellular stresses (Figure 1-3). Its main role is as a transcription factor 
(Calabretta et al., 1986, Mercer et al., 1984, Shohat et al., 1987). In 1994 it 
was named ‘Molecule of the Year, 1993’ (Beijnen, 1994). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In unstressed cells p53 is constitutively expressed but tightly regulated to 
prevent inappropriate activation of apoptotic or senescent genes. The 
activation of p53 occurs as a response to numerous forms of stress signalling. 
Oxidative stress, nutrient deprivation, hypoxia, DNA damage, loss of 
telomeres, miRNA processing and activation of oncogenes can all result in 
p53 activation. It is the role p53 has in control of the DNA damage response 
which is most relevant in terms of induction of apoptosis in tumours due to the 
DNA damaging nature of many chemotherapeutics. 
The p53 protein responds to a wide variety of cellular stresses and through 
regulation of downstream gene expression is able to influence the cellular 
outcome of these stresses. (Vousdan and Lane, 2007) 
Figure 1-3: The p53 nexus. 
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1.6.1 Introduction to the DNA damage response 
Before introducing the role of p53 specifically it is important to introduce the 
overall cellular response to different types to DNA damage. DNA damage 
occurs within cells daily and the sources of this damage are varied. It can 
occur as a result of environmental insults such as ultraviolet radiation or 
chemicals, including those produced in tobacco smoke. By-products of cellular 
metabolism such as reactive oxygen species can lead to DNA lesions. Also, 
DNA can also be damaged as a part of normal cellular processes such as 
breaks formed during DNA replication during the cell cycle. The type of 
damage that can occur to DNA is also varied, including base-pair mismatches 
and cross-linking of nucleotides, or single and double stranded breaks in the 
DNA.  
In order to maintain the integrity of the genome cells have developed systems 
which sense damaged DNA, signal their presence and ensure their repair. 
Because there are differing types of DNA damage there are different 
mechanisms that are employed in their repair. Mismatches and 
insertion/deletions introduced during DNA replication are dealt with by the 
mismatch repair pathway (MMR) involving the creation of a single strand 
incision which is then acted upon by nuclease, polymerase and ligase 
enzymes. The base excision repair (BER) pathway detects and replaces 
damaged bases. Nucleotide excision repair (NER) is employed if adducts are 
detected which affect the structure of the helix, such as those caused by UV 
light. MMR, NER and BER are the pathways that deal with breaks affecting 
only a single strand of DNA. Double stranded DNA breaks can be repaired by 
either homologous recombination (HR) or by non-homologous end-joining 
(NHEJ). NHEJ is known to be error prone and results in the deletion of DNA 
bases but it can be employed at any stage in the cell cycle. It is also one of 
the mechanisms employed during V-D-J and class switch recombination as a 
part of normal B-cell maturation. Homologous recombination can repair 
double stranded breaks more accurately than NHEJ as this process uses the 
second allele as a template. Because of this reliance on the sister chromatid, 
HR can only be employed during the synthesis and G-2 stages of the cell 
cycle (Jackson & Bartek 2009). 
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1.6.2 The p53 dependant DNA damage response 
The cellular response to DNA damage varies according to the type of damage 
itself. The ATM mediated response to oncogene activation or double stranded 
DNA damage is illustrated in Figure 1-4 (p36). In the response to double 
strand DNA breakages the initial sensor of DNA damage is the Mre11-Rad50-
Nbs1 (MRN) complex, which displays a high affinity for the ends of double 
stranded DNA ensuring rapid association to the ends of broken DNA  (Lisby et 
al., 2004, Petrini and Stracker, 2003). The MRN complex acts as a flexible 
tether, binding two ends of DNA and uncoiling them so that they are 
accessible to the kinase ATM (de Jager et al., 2001, Paull and Gellert, 1999). 
ATM perpetuates the DNA damage signal by phosphorylating the MRN 
complex, the histone H2Ax, and checkpoint-kinase-2 (Chk2) (Cai et al., 2009). 
ATM mediated phosphorylation of MDM2, MDM4 and p53 results in the 
interruption of p53 turnover and the rapid accumulation of p53 protein in the 
nucleus where it is then free to carry out its activities as a homo-tetrameric 
transcription factor (Dzikiewicz-Krawczyk, 2008, Hirao et al., 2000, Khosravi et 
al., 1999, Matheu et al., 2008). MDM2 is itself a target of p53 controlled 
transcription so if the DNA damage signal ceases MDM2-mediated 
degradation of p53 will resume, quickly restoring the cellular levels of p53 to a 
pre-stressed state. Interestingly, a SNP within the first intron of MDM2 may 
adversely affect p53 function and is being evaluated for independent 
prognostic value in CLL (Asslaber et al., 2010, Merkel et al., 2010, Willander 
et al., 2010). 
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Activation of ATM results in phosphorylation of p53, Chk2, MDM4 and MDM2. Stabilised 
p53 protein is then subject to multiple modifications, mainly targeted to Lysine residues. 
Tetramers of p53 recognise response elements in DNA and activate transcription of 
target genes involved in diverse cellular processes. Among these is MDM2 which, if p53 
activation signals are not continued, closes the negative loop by ubiquitinylating p53 and 
targeting it to the cytoplasm (mono-ubiquitinylation) for degradation by the proteosome 
(poly-ubiquitinylation). Ub = Ubiquitin; P = Phosphorylation; Me = Methylation; Ac = 
Acetylation 
Figure 1-4: the p53 response pathway including the MDM2-p53 negative feedback loop 
and MDM4/Chk2 regulators 
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1.6.3 P53-DNA binding 
The function of p53 as a transcription factor is intrinsically linked to its ability to 
recognise and bind to specific regions within the genome. The p53 DNA-
binding domain (DBD) binds to degenerate DNA sequences known as 
response elements (REs) found within promoter regions or introns of 
hundreds of potential target genes (Cho et al., 1994, Gohler et al., 2002, Wei 
et al., 2006). Figure 1-5 below shows the model DNA binding motif 
determined experimentally by Wei et al, (2006). It shows the two, 10-
nucleotide long, palindromic half-sites with the heights of the letters 
representing the relative occurrence of a given nucleotide at a given position 
in the sequence. 
  
 
Figure 1-5: Model p53 response element (Wei et al, 2006). 
 
The variable dissociation constant between the p53-DBD and different REs 
creates a sensitive, dose-dependent mechanism for controlling the sequence 
of genes targeted by p53. Notably the response elements of cell cycle arrest 
genes have a higher affinity for the p53-DBD than those of apoptosis related 
genes (Jordan et al., 2008, Weinberg et al., 2005).  
 
1.6.4 p53 protein modifications 
Further fine tuning of p53 activity is achieved via a variety of post-translational 
modifications. Table 1-6 shows a summary of these modifications and the 
proteins known to catalyse their addition and removal (Carter and Vousden, 
2009). 
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Table 1-6: Post-translational modifications of p53 protein. 
 
 
 
  
Of particular importance to the regulation of p53 protein is the E3-ubiquitin 
ligase, MDM2, which binds to p53, catalysing the addition of ubiquitin 
molecules. Mono-ubiquitylation exports p53 from the nucleus to the cytoplasm 
(Marchenko et al., 2007) where it has cytoplasmic, non-transcriptional roles 
(Erster et al., 2004, Kojima et al., 2006, Steele et al., 2008). Poly-
ubiquitylation causes exportation from the nucleus and subsequent 
degradation in the proteasome. MDM4, a structural homologue of MDM2, 
inhibits p53 controlled transcription by binding to p53 but it does not have E3-
ubiquitin ligase activity (Shvarts et al., 1996). 
Acetylation of lysine residues has been shown to be indispensable for 
activation of p53 transcriptional programs. Acetylation of residues in the 
carboxy terminus of p53 by the acteyltransferase p300/CBP has been shown 
to enhance the sequence specific binding of p53. P300/CBP has also been 
shown to acetylate a residue within the DNA binding domain. Regulation of 
p300 acetylase activity is therefore an ancillary way of regulating p53 activity. 
P300 protein expression has been shown to be repressed by the chromatin 
remodelling protein in response to UV induced DNA damage, SMAR1 (Sinha 
et al., 2012). SMAR1 was also shown to interrupt p53-p300 interaction. 
The protein p53 is known to control expression of genes involved in both the 
intrinsic and extrinsic apoptosis pathways and these are summarised in Figure 
Protein 
modification
Modifier Effect Reference
MDM2 Negative feedback loop Momand et al , 1992
E4F1 Cell cycle arrest, not apoptosis Cam et al, 2006
CHIP p53 degradation Esser et al,  2005 
COP1 Negative feedback loop Dorman et al , 2004
Pirh2 Negative feedback loop Leng et al , 2003
FBX011 Inhibits p53 transcriptional activity Abida et al, 2007
MDM2 Inhibits p53 transcriptional activity Xirodimas et al, 2004
Pcaf Cell cycle arrest via p21
CBP/p300 Apoptosis
Set8 Inhibits activation of highly responsive p53 targets Shi et al, 2007
p53 stabilisation Chuikov et al, 2004
Haplo-insufficiency causes loss of p21 and PUMA expression Ivanov et al, 2007
Smyd2 Mono- and di-methylation control of 53Bp1 binding to p53 Huang et al, 2006
SUMOylation PIAS family proteins 1-4 Inhibits p53 transcriptional activity Wu and Chiang, 2006
DNA damage response Nardinocchi et al, 2009
Upregulates tumour suppressor Pten Meulmeester, 2008
Serine-15 phosphorylation Khanna et al, 1998
Inhibition of p53-MDM2 interaction Khosravi et al, 2009
Set7/9
HIPK2
ATM
Liu et al, 1999
NEDDylation
Acetylation
Methylation
Phosphorylation
Ubiquitination
A variety of modifications may be made to p53 which influence its stability and responsiveness 
to certain transcriptional targets. Some of these interactions are competit ive such as E4F1 
mediated ubiquitination competing with Pcaf mediated acetylation. The table above is not an 
exhaustive list of p53 modifications. 
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1-6 and Figure 1-7, respectively. The intrinsic pathway is activated by the use 
of DNA damaging therapies. The increased p53-dependant expression of pro-
apoptotic Bcl-2 family proteins results in the sequestering of anti-apoptotic 
proteins of the same family (Vaseva and Moll, 2009). This allows the 
oligomerisation of BAX and BAK, also p53-targets, in the mitochondrial 
membrane, forming lipid pores that result in mitochondrial outer membrane 
permeabilisation (MOMP). MOMP is the apoptotic ‘point of no return’ (Dewson 
and Kluck, 2009). MOMP initiates the proteolytic caspase-cascade, breaking 
down the components of the cell in what was once termed ‘death by a 
thousand tiny cuts’ (Berg et al, 2002. p521).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition to its transcriptional effects, p53 also has non-transcriptional pro-
apoptotic functions in the cytosol. In particular it has been shown that p53 
protein can directly interact with the protein BAX leading to mitochondrial 
outer membrane permeabilisation, release of cytochrome-c and activation of 
the caspase cascade (Chipuk et al. 2004). 
Micro-RNA transcription has been shown to be under the influence of p53 (He 
et al., 2007). miR-34a and miR-29c are significantly down-regulated in p53 
abnormal CLL patients compared to normal CLL patients. This association 
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Figure 1-6: Transcriptional targets of p53 within the intrinsic apoptosis pathway.  
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suggests that the analysis of certain micro-RNAs may be useful as a marker 
of p53 function (Asslaber et al., 2010, Merkel et al., 2010, Mraz et al., 2009, 
Zenz et al., 2009). Numerous non-transcriptional roles involving the 
mitochondria have been discovered for p53. In response to irradiation or 
etoposide p53 has a direct and rapid apoptotic role at the surface of 
mitochondria (Erster et al., 2004, Kojima et al., 2006, Steele et al., 2008). The 
p53-DBD binds anti-apoptotic Bcl-2, enabling Bax and Bak oligomerisation in 
the mitochondrial outer membrane (Vaseva and Moll, 2009) and there is 
evidence that p53 is imported into the mitochondria where it is involved in 
DNA repair during oxidative stress (Wong et al., 2009). p53 is also involved in 
microRNA processing(Suzuki et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The varied roles of p53 and the functional mutability of its DNA binding 
domain means the effects of deletion and miss-sense mutation are likely 
distinct from one another and may act synergistically when they co-occur. The 
protein-kinase ATM is integral to a normal DNA damage response but 
questions remain concerning the effects of haplo-insufficiency versus 
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mutation of ATM in CLL. It can also be seen that there are many other 
proteins involved in the cellular response to DNA damage that could, through 
dysfunction, inhibit or abrogate the apoptotic outcome. This is important as 
roughly half of CLL patients who are refractory to first line therapy have no 
detectable abnormalities of p53 or ATM. 
 
1.6.5 p53 isoforms 
The understanding of mechanisms that influence the behaviour of p53 has 
recently become more complex with the discovery that the TP53 gene can be 
expressed in numerous different isoforms due to the presence of two different 
promoters, an internal START motif in intron 2, and a differential splicing site 
in intron 9 (Bourdon et al. 2005; Anensen et al. 2006). These result in the 
presence of four different amino acid termini eg full length p53 containing the 
entire transactivation domain (TAp53), ∆40p53, Δ133p53 and Δ160p53. In 
addition the alternative splicing of intron 9 leads to 3 different Carboxy termini 
eg full length p53 containing the entire oligomerisation domain (p53α), p53β 
and p53γ. It has been shown that these different isoforms can affect p53 
transcriptional activity and that the α and β isoforms are expressed differently 
in CLL cells when compared to healthy B-cells (Sellmann et al. 2012; Bourdon 
et al. 2005). There is an inherent difficulty in taking isoforms in to account 
when using flow cytometry for measuring protein expression as it is not 
possible to differentiate between proteins of different lengths, something 
which can be achieved with some success using western blotting for example. 
In addition there are no commercially available anti-bodies that can 
discriminate between different isoforms. 
 
1.6.6 p53 family members, p63 and p73 
The protein p53 is one member of a family of transcription factors which share 
a similar structure and homology. These other family members are called p63 
and p73. The roles that these different proteins have within the cell have a 
certain amount of overlap but p63 and p73 have been found to have other 
functions distinct from the functions of p53. The full length proteins of this 
family all have an N-termini TA domain, responsible for the transcriptional 
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activity of these proteins. They all have a core DNA-binding domain and an 
oligomerisation domain. In addition to these regions, p63 and p73 have an 
additional domain at the C-terminus called a Sterile Alpha Motif (SAM) which 
has protein-protein interaction functions. Similarly to p53, both p63 and p73 
can be expressed as a variety of alternatively spliced isoforms. Importantly 
both can be expressed as ΔN variants lacking the N-termini transactivation 
domain (TAD) and so therefore lose the ability to trans-activate target 
promoters (Allocati et al. 2012). These ΔN variant isoforms are known to exert 
a dominant negative effect on the full length, transcriptionally active p53 family 
members and therefore have important roles in the negative regulation of p53 
activity. Depending on the expressed isoform the outcome of DNA damage 
induced phosphorylation can have opposing effects. For example, it is known 
that c-Abl mediated phosphorylation of TAp63 in mammalian oocytes leads to 
the formation of active tetramers of the protein resulting in active transcription 
of target genes (Deutsch et al. 2011). Alternatively, it has been shown that in 
head and neck squamous cell carcinoma that phosphorylation of ΔNp63 by 
ATM leads to its degradation, resulting in the activation of TAp63 and the 
induction of apoptosis (Huang et al. 2008). Similarly to p63, TAp73 is also 
activated by protein modifiers such as p300, c-Abl, Chk1 and Chk2 and that 
the cell requires ΔNp73 to be degraded in order for apoptosis to proceed. 
Indeed high levels of ΔNp73 have been correlated with resistance to 
chemotherapy (Nicolai et al. 2015). Whilst the roles of p63 and p73 in 
promoting apoptosis have often been considered as an overlap with the role 
of p53 due to shared homology, it has also been shown that the combined 
loss of both p63 and p73 leads to a failure to undergo apoptosis in response 
to DNA damage, even in cells with fully functional p53 (Flores et al. 2002). 
There are other mechanisms of apoptosis which both p63 and p73 are 
involved in. TAp63/p73 can induce apoptosis via the mitochondria by 
upregulating the expression of BAX and PUMA, via the endoplasmic reticulum 
by increasing the expression of SCOTIN. It is also known that p73 regulates 
the extrinsic apoptosis pathway via upregulating the expression of CD95 
whilst p63 can upregulated TRAIL-R1 and –R2 as well as TNF-R1. TAp63 and 
TAp73 also have roles in regulating the cell cycle via the upregulation of p21 
and p57/KIP2 (Allocati et al. 2012).  
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In CLL there is little evidence to suggest a role of p63 in pathogenesis or 
chemo-refractoriness. However there is some evidence of a role for wildtype 
p73. For example it has been shown that in cells which are p53 dysfunctional, 
treatment with platinum based compounds can still induce cell cycle arrest 
and apoptosis as TAp73 leads to upregulation of p21 and BID (Tonino et al. 
2015). Tonino et al (2015) also made the observation that the increased 
activity of TAp73 after treatment was due to post-transcriptional changes as 
the mRNA expression of p73 did not change. 
 MicroRNAs and p53 1.7
MicroRNAs are endogenously expressed RNA molecules that once fully 
processed are between 18-25 nucleotides in length. They are involved in the 
regulation of gene expression by targeting complementary sequences in the 
3′UTR of one or more mRNAs. The end effect of this regulation depends on 
the level of complementarity between the miRNA and target sequence in the 
mRNA. Partial complementarity leads to repression of target mRNA 
translation whereas exact matches between the miRNA sequence and target 
mRNA leads to cleavage of the target. In mammals the primary mode of 
action appears to be translational repression through partially matching 
sequences (Bartel, 2004, Bartel, 2009). 
Initially, miRNA is expressed as a primary miRNA transcript (pri-miRNA) 
which forms a 70-100 nucleotide hairpin structure. This is then processed in 
the nucleus by the ribonuclease, Drosha, to form a precursor miRNA (pre-
miRNA) (Lee et al., 2003). Pre-miRNAs are then exported from the nucleus 
into the cytoplasm by the protein Exportin (Yi et al., 2003) where the 
ribonuclease, Dicer, processes the pre-miRNA into its shorter mature form 
(21-25 nucelotides) (Hutvagner et al., 2001). The mature miRNA then binds to 
the RNA-induced silencing complex (RISC) which then binds to the target 
mRNA facilitating either degradation, or more commonly in mammals, 
repression. 
Micro-RNA regulation of mRNA translation was discovered in 1993. The gene, 
lin-4, was found in the nematode worm (C.elegans) to not code for a protein 
but instead its products were short RNA transcripts. These transcripts were 
found to cause the translational repression of the nuclear protein Lin-14, 
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leading to regulation of larval development. The authors speculated that this 
was due to the anti-sense complementarity between the RNA transcript 
sequence and the 3′-untranslated region (UTR) of the lin-14 mRNA (Lee et al., 
1993). The next discovery of a miRNA, let-7, was not for several years but 
was also involved in the regulation of developmental timing in C.elegans 
(Reinhart et al., 2000).  
To date there have been hundreds of miRNAs characterised. The Sanger 
Institute maintains miRBase, an online database that catalogues each 
discovery and which is publicly available. Some individuals miRNAs have 
been shown to repress over a hundred target mRNAs and it is thought that 
approximately half of all cellular mRNA may be regulated by miRNAs (Cullen, 
2011). 
The roles that these miRNAs have in post-transcriptional regulation of gene 
expression is now understood to be involved in many cellular processes 
including cell cycle control, the DNA damage response and apoptosis.  
Networks of microRNAs have been implicated in the direction of neuronal 
development and in maintaining plasticity of synapses later in life. Some 
microRNAs having also been linked to various behaviours in rodents with the 
miR-34 family implicated in learning and memory, exploration behaviour and 
anxiety (Olde Loohuis et al., 2012). Other non-coding RNAs (ncRNAs), 
including both long-noncoding RNAs and microRNAs, are being found to be 
important in understanding neurological conditions including drug addiction 
(Sartor et al., 2012) as well as regulation of the mu opioid receptor (MOR) by 
the micro-RNA, Let-7 (He & Wang 2012).  
Viral MicroRNAs discovered in 2004 have been shown to be involved in 
certain viral infections, both in terms of the virus deregulating the endogenous 
expression of miRNAs as well as introducing exogenous viral microRNAs in to 
the cell (Cullen, 2011). In mice, miR-34a has been found to increase 
expression in later life. This increase was detected in the brain as well as 
plasma and peripheral blood mono-nuclear cells (PBMC) of mice (Li et al., 
2011). These studies plus many others have shown that research into 
miRNAs is relevant to all areas of cell biology research. 
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1.7.1 P53 and miRNA transcription 
The relationship between p53 and miRNAs has been shown to be 
transcriptional and non-transcriptional.  Certain miRNAs are under the direct 
transcriptional control of p53 and are expressed in response to stresses that 
activate p53 such as DNA damage (Feng et al. 2011). The first miRNAs to be 
identified as under the direct transcriptional control of p53 were the hsa-mir34 
family and these were shown to be involved in the apoptotic response (Chang 
et al. 2007). miR-34a, the product of a single transcript on chromosome 1p36, 
is expressed in most tissues. miR-34b and miR-34c are both transcribed from 
a single transcript on chromosome 11q and are primarily expressed in lung 
tissue. 
 
1.7.2 P53 and miRNA processing 
P53 has also been shown to be involved as a chaperone to the post-
transcriptional maturation of certain miRNAs. For example in response to 
doxorubicin, p53 has been shown to promote the Drosha mediated 
processing of some miRNAs with growth suppressive functions. These 
included miR-143 which targets K-Ras and miR-16-1 and miR-145 which both 
target CDK6. K-Ras and CDK6 are both regulators of cell cycle and 
proliferation. This interaction of p53 with Drosha also required the presence of 
the DEAD box RNA helicases, p68 and p72. The same study also showed 
that two TP53 mutants, R175H and R273H, reduced the processing of pri-
miRNAs by Drosha and resulted in lower levels of mature miRNAs, including 
miR-16-1, miR-143 and miR-145 (Suzuki et al., 2009). This suggests that 
mutation of TP53 can lead to deregulation of miRNA expression. 
In addition to aiding the maturation of certain miRNAs, wildtype p53 also 
responds to disturbances in miRNA. Knockdown of Dicer to prevent the 
processing of pre-miRNAs into their mature forms has been shown to activate 
p53, causing a senescent phenotype in mouse embryonic fibroblasts. Deleting 
p53 rescued this effect allowing cells to continue to proliferate (Mudhasani et 
al., 2008). The miRNA, miR-504 has been shown to negatively regulate p53 
protein expression by binding to two sites within the 3’UTR of TP53 mRNA 
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(Hu et al. 2010). This provides a mechanism by which disruption of miRNA 
processing can lead to activation of p53. 
These studies show that loss or mutation of p53 can lead to deregulation of 
cellular miRNA expression through several mechanisms and is not limited 
only to those microRNAs directly under p53s transcriptional control. 
 
1.7.3 miRNAs in Chronic lymphocytic leukaemia 
Due to its known relationship with p53 activation the microRNA, miR-34a, has 
been a subject of interest in the field of CLL research. It was shown a number 
of years ago in the p53 wildtype cell line, HCT116, that there is a positive 
feedback loop between p53 acetylation / activation, miR-34a expression, and 
SIRT1 mRNA translation (Yamakuchi et al. 2008). SIRT1 (silent information 
regulator 1), is a deacetylase which targets and inactivates p53 protein, 
preventing p53-dependant activation of apoptosis related genes such as p21 
and PUMA. It was shown that miR-34a targets the 3’UTR of SIRT1 mRNA, 
blocking translation and consequently increasing p53 acetylation. Therefore a 
p53-dependant increase in miR-34a expression leads to further acetylation 
and activation of p53 protein via repression of SIRT1 translation leading to 
activation of apoptosis genes including PUMA and p21 (Yamakuchi et al. 
2008). It has also been established that absence of wildtype p53 leads to a 
reduction in the expression of miR-34a (Chang et al. 2007).  
It has been previously shown that in CLL the expression of miR-34a is 
negatively affected by either deletion of 17p13.1 or by mutation of the TP53 
gene (Mraz et al. 2009; Dijkstra et al. 2008). It has been shown that CLL cells 
which are resistant to ionising radiation induce lower levels of miR-34a after 
DNA damage and this included cases with no detected abnormalities of p53 
suggesting that miR-34a levels could be a more specific predictor of treatment 
resistance in CLL (Zenz et al. 2009). The authors of this study also found that 
the basal level of miR-34a was higher in wildtype CLL cells than TP53 mutant 
CLL cells. This suggests that miR-34a is constantly expressed at low levels as 
a direct result of basal p53 activity. This is supported by the finding that 
variable basal of miR-34a in CLL cells is associated with a single nucleotide 
polymorphism of the MDM2 gene, which is already known to affect p53-
 47 
protein regulation (Asslaber et al. 2010; Merkel et al. 2010). Taken together 
this suggests that miR-34a could be measured in unstimulated cells to predict 
treatment response. This could be advantageous for laboratories without a 
culturing facility. 
 
 Principals of molecular techniques used in this work 1.8
 
In order that the reader has an understanding of the common molecular 
biology techniques used in this study, the following section gives an 
introduction to the principals of the polymerase chain reaction (PCR), DNA 
sequencing using the Sanger method, pyrosequencing, restriction fragment 
length polymorphism analysis (RFLP) and finally Taqman™ probe based 
technologies. 
1.8.1 Polymerase Chain Reaction 
The polymerase chain reaction (PCR) is an in-vitro technique for generating 
millions of copies of DNA, spanning a selected region within the genome. It 
forms the basis of many molecular biology methodologies used in this study. 
The technique was developed in the 1980s and revolutionised molecular 
biology (Mullis et al. 1986). Polymerases are a class of enzyme which 
synthesise long chains of nucleotides along a template of DNA or RNA, 
utilising an oligonucleotide ‘primer’, bound to the template, as the initiation site 
for the strand to be synthesised. Complimentary copies of the template are 
created by sequentially incorporating deoxynucleoside triphosphates (dNTPs) 
in accordance with base-pair interactions with the template strand (Figure 
1-8). 
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Figure 1-8: Diagram illustrating the thermally controlled, targeted synthesis of 
complementary DNA during 1 cycle of a polymerase chain reaction 
 
Polymerases synthesise DNA in only one direction, requiring a ‘primer’ as a 
starting point for this synthesis. This is due to the enzyme binding the 
phosphate group found on the fifth sugar group carbon (5') of free dNTPs to 
the free hydroxyl group on the third sugar group carbon (3') of the previously 
incorporated nucleotide, eliminating a molecule of pyrophosphate (PPi) in the 
process. The primer is therefore essential as it provides the first free 3'-
hydroxyl group from which the enzyme may begin synthesising a 
complementary strand. The direction of synthesis along the copied strand is 
described as being 5'3', reflecting the orientation of the carbon atoms in the 
ribose sugar group of each nucleotide. The polymerase enzyme itself travels 
along the template strand ‘reading’ it in the 3'5' direction. One of the most 
commonly used polymerase enzymes, Taq, was isolated from the 
thermophillic bacterium Thermus aquaticus, and becomes active at 72oC 
(Chien et al. 1976), allowing easier temperature control of polymerase in-vitro. 
Many improvements have been made to this and other polymerase enzymes 
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and four key characteristics are the focus of that work: Specificity, thermo-
stability, fidelity and processivity.  
At the beginning of a PCR reaction, before the initial denaturation stage, the 
polymerase can prematurely extend primers which have mis-primed as well 
as some primer-dimers therefore reducing the specificity of PCR amplification 
products. In order to improve specificity it is possible to manually add 
polymerase during the denaturation stage. This is described as a hot-start. A 
method to reversibly inactivate the polymerase enzyme so that it could be 
added to the reaction with the other reagents was developed in 1994. 
Researchers generated monoclonal antibodies which bound to and inhibited 
Taq at lower temperatures but which were denatured at 90oC, therefore 
liberating the enzyme (Kellogg et al. 1994; Sharkey et al. 1994). Thermo-
stability refers to the half-life of the enzyme at a given temperature. The half-
life of Taq is sufficient for many applications but it may become a problem if 
prolonged high temperatures are required or the number of cycles will be very 
high. Alternative polymerases with higher thermo-stability have now been 
derived from hyperthermophilic bacteria, for example the enzyme Pfu is 
derived from the bacteria Pyrococcus furiosus (Lundberg et al. 1991). Fidelity 
refers to the error rate a particular enzyme displays and this is affected by the 
enzymes proofreading ability. Proofreading relies on the 3'5' exonuclease 
activity of the enzyme in order to remove mis-matched nucleotides. 
Processivity describes the rate at which a polymerase incorporates 
nucleotides. There is a trade-off between fidelity and processivity as the 
exonuclease activity present in high fidelity polymerases reduces the 
processivity of the enzyme.  
By designing and synthesising oligo-nucleotide primers in the laboratory in 
pairs that bind to opposite DNA strands at known locations and at 
temperatures approximately between 50-60oC, it then becomes possible to 
use thermodynamics alone to denature DNA in a sample, control the 
annealing of primers to that DNA and then activate polymerases to begin 
extension of the primer across the sequence of interest. Figure 1-9 below 
illustrates a typical profile of the changes in temperature over time.   
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Figure 1-9: Temperature profile of a standard polymerase chain reaction 
 
By ensuring that there is an excess of available dNTPs to synthesise the new 
DNA strands and free magnesium in the solution, this temperature controlled 
process can be continued for many repeating cycles potentially producing an 
exponentially increasing number of copied DNA products.  
 
1.8.2 DNA sequencing 
Sequencing of DNA is most often performed using the Sanger method 
(Sanger et al., 1977). The full title of the technique is the Sanger dideoxy 
chain termination method. This method requires a pool of template DNA 
containing the region of interest which is generated in a standard PCR 
reaction. The products of this PCR are then used in the Sanger chain 
termination reaction. 
During PCR the incorporation of nucleotides into a newly synthesised strand 
of DNA by polymerase requires the free availability of the four possible 
deoxynucleoside triphosphates (dNTPs). For the Sanger sequencing reaction, 
dideoxynucleosides (ddNTPs) are added to the reaction alongside dNTPs and 
these are incorporated into the copied strands randomly during extension by 
polymerase. The difference between ddNTps and dNTPs is loss of the 3' 
hydroxyl group in the former. If a ddNTP is incorporated instead of a dNTP 
then the lack of a hydroxyl group at the 3' carbon of the extending strand 
abrogates the addition of any further dNTPs to that particular amplicon, it is for 
this reason that the method is referred to as ‘dideoxy chain termination’. The 
post-reaction solution contains millions of molecules of DNA which have been 
halted at random during extension. Therefore, across this population, every 
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nucleotide of the sequence is present as the terminal dideoxynucleotide of a 
replicated strand. Using electrophoresis it is then possible to resolve this 
population of amplicons by size and, therefore, by sequence. By labelling the 
ddNTPs in some way it is then possible to determine which ddNTPs have 
been incorporated and in which order, thus determining the sequence of a 
given region of DNA. This used to be achieved using a radio-isotope tag on 
ddNTPs for detection, and therefore required four separate reactions 
containing radio-labelled dideoxy-adenosine triphosphate, dideoxy-thymine 
triphosphate, dideoxy-cytosine triphosphate or dideoxy-guanine triphosphate. 
The electrophoresis of these reaction products would be performed in parallel 
and a radiogram would be prepared which could be read by eye.  
Modern Sanger sequencing uses four, differently coloured, fluorescently 
labelled ddNTPs in the reaction solution. This allows the chain terminated 
products to be analysed concurrently using capillary electrophoresis to 
separate the amplicons by size and a laser-optics system to detect and 
discriminate fluorescence from the four differing ddNTPs. A software package 
then converts the signal data and generates an electropherogram showing the 
obtained sequence. Figure 1-10 below shows an example of an 
electropherogram obtained using the Sanger sequencing method for one of 
the cases used in this study.   
 
Figure 1-10: Example electropherogram showing a short DNA sequence 
 
1.8.3 Pyrosequencing 
Pyrosequencing differs from the Sanger method with respect to both 
chemistry and methodology. It is a chemiluminescent, enzymatic reaction 
requiring no electrophoresis. The sequence of a target region by determined 
by detecting the successful incorporation of deoxynucleoside triphosphate 
(dNTP) (Nyrén & Lundin 1985; Alderborn et al. 2000; Ronaghi et al. 1996). 
Figure 1-11 below gives a basic overview of the chemistry involved.  
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Figure 1-11: Diagram showing the basic chemistry of pyrosequencing. 
 
Pyrosequencing requires template DNA produced by a standard PCR 
reaction. Only one strand will be pyrosequenced so one of the primers used 
during PCR is biotinylated, allowing that strand to be isolated through binding 
to streptavidin. A single primer, designed to bind 5' to the target to be 
sequenced, is hybridised to the template DNA. The extension of the primer 
over the target site is carried out in a repeating sequence of reactions, in 
which only one of the four possible dNTPs is made available to synthesise the 
new DNA strand. When the reaction solution containing the required dNTP is 
added, DNA polymerase catalyses its incorporation into the new strand and a 
molecule of pyrophosphate (PPi) is released for every molecule of dNTP 
added. The enzyme ATP sulfurylase then combines this PPi molecule with a 
molecule of adenosine’5 phosphosulphate (APS) to form one molecule of 
ATP. This molecule of ATP is then used by another enzyme, luciferase, to 
convert one luciferin molecule to oxyluciferin, a reaction which releases a 
detectable amount of light. This light is detected using a charge coupled 
device (CCD) camera and displayed as a peak on a pyrogram, an illustration 
of which is shown in Figure 1-12. Due to the equimolar relationship of this 
reaction, the peak height is directly proportional to the number of nucleotides 
incorporated therefore in the example in Figure 1-12 the sequence can be 
read as CGGAG.  
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Figure 1-12: An example pyrogram for a five nucleotide sequence: CGGAG. 
 
The nucleotide degrading enzyme, apyrase, constantly removes unused 
dNTPs allowing the sequential addition of the four dNTPs. An important note 
is that deoxyadenosine alpha-thio triphosphate (dATPαS) is used instead of 
deoxyadenosine triphosphate for incorporation into the copied strand during 
pyrosequencing. Whilst dATPαS is still efficiently used by DNA polymerase it 
cannot be used by luciferase. 
1.8.4 Restriction-fragment length polymorphism analysis 
Preliminary, low-cost analysis of single nucleotide polymorphisms (SNPs) was 
performed using restriction-fragment length polymorphism (RFLP) analysis on 
PCR amplified DNA. The use of restriction enzymes to detect polymorphisms 
was developed in the late seventies as a method for detecting a DNA 
polymorphism which is associated with sickle cell anaemia (Kan and Dozy, 
1978). The technique can be adapted to detect other polymorphisms of 
interest. A summary diagram of RFLP is shown in Figure 1-13.  
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Figure 1-13: Principal of Restriction fragment length polymorphism 
analysis 
In this example, the enzyme BstUI recognises the nucleotide 
tetramer 5'-CGCG-3' within a sequence which it then cleaves 
between the central guanine-cytosine phosphodiester bond 
(allele 1). This restriction endonuclease can therefore be used 
to detect variant alleles if the presence of a single nucleotide 
polymorphism (allele 2) eliminates the binding motif. 
 
Restriction endonucleases are a class of enzyme which recognise and 
cleave DNA at, or near to, sequence-specific regions of DNA called 
restriction sites. The cut is achieved by hydrolysing the phosphodiester bond 
between two nucleotides on each strand of DNA. A PCR reaction is 
performed, amplifying the loci containing the SNP of interest. The products of 
this reaction are subsequently incubated with the selected endonuclease. 
The digested and/or undigested products of this reaction are then separated 
by size in an agarose gel, using electrophoresis. The number and relative 
size of the bands can be used to determine either homozygosity or 
heterozygosity for the SNP of interest. 
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1.8.5 Taqman™ hydrolysis probe technology 
Taqman™ hydrolysis probes were utilised in two methodologies during this 
study, Endpoint genotyping and relative quantification. Whilst the two methods 
differ slightly there is good cause to explain the chemistry of Taqman probes 
first. The underlying chemistry behind Taqman™ probe technology is based 
on the phenomenon of Förster resonance energy transfer (FRET), and on the 
5'-3' exonuclease activity of Taq polymerase (Heid et al. 1996). Figure 1-14  
below illustrates the principal of using a Taqman™  probe to detect the activity 
of polymerase during a PCR reaction.  
 
Figure 1-14: Principal of Taqman assay. 
 
FRET describes a process of energy transfer between two light sensitive 
molecules in which one molecule described as the quencher, accepts the 
photons released by the second, described as the reporter. Whilst in close 
proximity to the reporter, the quencher effectively abrogates the light signal. 
This quenching effect is inversely proportional to the distance between the 
dyes. A Taqman™ probe is an oligonucleotide designed to bind within a given 
PCR amplicon. The probe has a reporter dye molecule bound to the 5' end 
and a quencher dye molecule bound to the 3' end. Whether in the reaction 
solution or bound to the target template, the oligo-bound quencher dye is 
close enough for FRET to prevent any light being released by the reporter 
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dye. During the annealing phase of amplification the probe binds to its target 
site within the amplicon being generated. During the extension phase, as 
polymerase reaches the bound probe, the 5'-3' exonuclease activity of the 
enzyme degrades the Taqman probe. This releases the reporter and then 
quencher dyes into solution. No longer held within proximity of the quencher 
dye, the reporter dye fluoresces and this light is measured. Therefore, a 
quantifiable light signal is released every cycle of PCR that is proportional to 
the number of copies of template that have been generated. 
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 Functional assays 1.9
The term ‘functional assay’ is used within this work extensively in reference to 
the flow cytometric assay of intra-cellular p53 and/or p21 protein levels in 
primary CLL cells which have been treated in-vivo with DNA damage agents 
(Carter et al., 2004a, Best et al., 2008b). It should be remembered that in a 
broader sense functional assessment can take many forms and have many 
targets of interest, in many areas of cell biology research.  
1.9.1 Functional assessment of ATM/p53 in cancer 
Assessing the p53 pathway in-vitro using patients B-CLL cells may help to 
predict responses to DNA damage inducing therapies used to treat CLL. DNA 
damage responses may be elicited using ionising radiation or DNA damaging 
agents (Best et al., 2008b, Carter et al., 2004b, Pettitt et al., 2001). Activation 
of p53 may also be achieved by interrupting its steady-state turnover by 
MDM2. The small molecule, nutlin3a, directly inhibits the activity of MDM2, 
increasing the level of p53 and activating cell cycle and apoptosis genes in 
CLL cells (Secchiero et al., 2006). It does not appear to have this effect within 
cells in which p53 is mutated (Saddler et al., 2008, Terzian et al., 2008). The 
ability to induce a p53 response independently of the ATM mediated DNA 
damage signal is exploited for the functional assay used in this project (Best 
et al., 2008b). Interestingly, the inhibition of p53 by MDM4 cannot be 
disrupted by nutlin3a, although some putative dual-inhibitors of MDM2 and 
MDM4 have been identified (Barakat et al., 2010, Patton et al., 2006).   
The fact that p53 is involved in the regulation of many proteins and in different 
pathways means there are many possible targets that could be measured to 
give an indication of abnormal p53 function either at the protein or mRNA 
level, including microRNAs (Asslaber et al., 2010, Merkel et al., 2010). The 
cell cycle arrest protein p21 is a well-documented and highly sensitive 
indicator of p53 activation that has been previously identified and used in work 
of a similar nature to this project (Carter et al., 2004a, Pettitt et al., 2001). 
Analyses of cases which do not respond to DNA damaging therapy have 
highlighted other proteins which could be used as predictors of response, 
such as polo-like kinase-2 (PLK2) (de Viron et al., 2009) and DNA protein 
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kinase (DNA-PK). DNA-PK expression shows a negative correlation with 
p53/ATM function, being higher in cells with the del11q or del17p 
abnormalities (Willmore et al., 2008) making it potentially of use as a 
surrogate marker of these high risk abnormalities. 
One established technique for the functional assessment of TP53 mutations 
on the transcriptional activity of p53 protein is the FASAY assay (functional 
assessment of separated alleles in yeast). This is an in-vitro assay in which 
TP53 mRNA is reverse transcribed then amplified using PCR. The resulting 
PCR products, representing the expressed transcripts from within the cell, are 
then cloned in to a linear expression vector, pSS16, and introduced in to a 
yeast system. The yeast strain, yIG397, is a mutant exhibiting deficient 
adenine synthesis due to a mutation in the ADE2 gene. When grown on a 
medium containing reduced adenine the yeast produces metabolites giving 
the colonies a red colour. The yeast also contains a second copy of the ADE2 
gene which is under the control of a p53 responsive promoter. Once the 
expression vector containing the copied TP53 coding region is introduced in 
to the yeast system it will produce p53 protein. If the expressed p53 is 
wildtype or otherwise retains transcriptional activity then the ADE2 gene will 
be activated and the yeast will be able to metabolise adenine resulting in 
colonies appearing white. If the inserted TP53 coding region contains a 
mutant that affects the transcriptional activity of p53 protein then the yeast will 
still be unable to metabolise adenine and the colonies will appear red. In 
addition, if the inserted gene retains only partial transcriptional activity then 
the colonies may appear pink. This is a fairly simple assay to perform and 
provides a robust method for determining the effect of a specific TP53 
mutation on the expressed proteins transactivation ability (Flaman et al. 1995; 
Ishioka et al. 1993).  
Newer technologies allow the investigation of greater numbers of target genes 
than has been achievable with western blotting or flow cytometry. The use of 
real-time PCR based technology on microarray platforms enables the analysis 
of thousands of genes allowing the investigation to changes of the 
transcriptome in response to various stimuli. Drawbacks to the use of 
microarray technology include the obvious bias towards genes that have been 
selected for the array. Saturation means that an array may not always detect 
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significant differences in expression between genes. RNA sequencing (RNA-
seq), an application of high throughput, deep sequencing technology, can 
analyse the entire transcriptome down to a single nucleotide resolution 
without being restricted to known genes in model organisms, or referring to 
reference genomes. It also detects a greater fold change in expression than 
micro arrays (Wang et al., 2009). An example of the potential use of RNA-seq 
in functional analysis of cellular responses is the analysis of changes to the 
transcriptome in HepG2 cells exposed to the carcinogen, benzo[a]pyrene (van 
Delft et al., 2012). There are currently a number of potential drawbacks to the 
use of RNA-seq. Firstly, RNA-seq tends to produce very large quantities of 
data. This data requires very powerful tools to analyse and typically users will 
need to use super-computers with high speed network connections and high 
volume data storage. Currently, software is not standardised and will often 
require bioinformatics specialists to work with the data prior to analysis. This 
may result in a lack of repeatability and inter-operator variability with results. 
In addition to this the matching of sample reads to reference genomes may be 
complicated by the presence of alternatively spliced isoforms or paralogous 
genes. Also, with cancer research, comparing data derived from a tumour cell 
to a normal counterpart can be difficult, especially if that normal counterpart / 
cell of origin is unknown. Cost is also one factor that is associated with almost 
all new technologies however this can be expected to drop over time. 
This technology could be applied to functional assessment of the DNA 
damage response in CLL cells. Although use of RNA-Seq may be over-
powered for regular use, it would be a powerful tool for the detection of novel 
alterations to the transcriptome after DNA damage.  
 
1.9.2 Functional assays in CLL 
 
The earliest use of functional assessment of the ATM/p53 DNA damage 
response pathway in CLL cells used ionising radiation to induce an ATM 
dependant damage response which was detected using western blotting to 
detect the presence of p53 and ATM proteins (Pettitt et al. 2001). The 
categorisation of dysfunctional samples in this paper was based upon two 
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observations of abnormal behaviour; either constitutive expression of p53 in 
control cells, which the authors termed as Type-A, and, failure to increase 
expression of p53 and p21 in response to DNA damage, coined Type-B. 
These two categories were found to be associated with genetic abnormalities 
of p53 and ATM respectively (Pettitt et al. 2001). In later work the same group 
showed that this form of assessment could be performed using a flow-
cytometer instead of western blotting (Carter et al. 2004).  
A third response pattern (Type-C), in which p53 but not p21 expression 
increases after IR treatment of cells, has also been reported (Johnson et al., 
2009). To date, this failure of p21 to respond normally has been associated 
with polymorphisms of the CDKN1A (p21) gene (Johnson et al. 2009).  
A fourth response category has also been observed in a small number of 
cases and is currently titled, Type-D. This pattern shows a failure of p53 
measurements to increase beyond its accepted cut-off, yet p21 
measurements increase above the accepted p21 cut-off (Johnson et al. 
2009). 
The ionising-radiation based functional assay has also been utilised to 
analyse 278 samples from the CLL4 trial (Lin et al., 2012). The published 
table showing associations between ATM-p53-p21 pathway defects and other 
biological variables is shown in Table 1-7, (p62). This cohort was not 
significantly different from the remainder of the CLL4 study (n=777) in terms of 
any of the clinical or biological parameters except that the number of samples 
with deletion of 11q was increased. This study detected Type A, B, C, and D 
dysfunction in 6 (2.2%), 146 (52.5%), 13 (4.7%) and 29 (10.4%) cases 
respectively. This left only 84 (30%) of the samples with a ‘normal’ functional 
response. An initial criticism of this therefore is the sheer number of 
dysfunctional samples found in a cohort of previously untreated patients; in 
particular the Type-B responders outnumber the normal responders. Also the 
Type-B group did not share the same poor outcomes as the Type-A and –C 
responders despite having similarly low levels of p21. To explain this 
discrepancy the authors suggest that ionising radiation may not recreate the 
effects of alkylating agents and purine analogues. This may be a drawback if 
an assay is attempting to predict the response to therapy in patients. In terms 
of detecting patients who have abnormalities of TP53, this study also failed to 
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accurately detect 15/21 (71.4%) of the TP53 mutations and 13/18 (72.2%) of 
the 17p13.1 deletions. Unfortunately the authors were unable to analyse the 
Type-C cases for polymorphisms of the CDKN1A gene. This would have been 
a useful opportunity to increase the data available on this phenomenon.  
A final concern is whether the functional assessment of cells that have been 
in storage for over five years is advisable, especially when the aim of these 
tests is to determine beforehand whether a patient B-CLL clone will respond 
to therapy. Unlike genetic analysis, functional analysis is almost certainly 
affected by extrinsic variables and the minimisation of these is of paramount 
importance. 
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Table 1-7: Results summary from Lin et al, 2012 
 
1.9.3 Nutlin3a in the functional assay of CLL cells 
The use of nutlin in the functional assessment of CLL cell responses in order 
to detect clinically significant abnormalities has been investigated in a 2013 
paper (Pozzo et al., 2013). In this study they adopted an RT-PCR approach 
that used only control versus nutlin treatment. In the methods the authors 
detail testing alternative assays including the combination therapy used in this 
study but the sample size was very small (n=10) including 3 cases with 
monoallelic mutation of TP53 and 3 more with no detected deletion of 11q or 
17p. The authors state that:  
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“with the only exclusion of 2 out of 4 11q deleted cases, no relevant 
differences were detected in terms of type of response among experiments with 
the alternative treatments” (Pozzo et al., 2013).  
 
This statement doesn’t reflect the fact that half of the cases (2/4) with deletion 
of 11q22.3 did show value in the use of combination treatment which in itself 
represents 20% of a small, selected cohort. The details of the ten samples 
used, available in the supplementary data for the article, details that no ATM 
mutation screening had been performed on the four 11q deleted cases. In 
addition to this the clone size for one case which responded normally was just 
10% of the cells observed and so could be reasonably interpreted as an issue 
of sensitivity. The author’s study itself uses a training cohort of 100 and a 
validation cohort of 40 in order to test the single agent use of nutlin in 
detecting clinically relevant abnormalities of TP53 (deletion and mutation) and 
ATM (deletion only). The training cohort contained 14 cases with a detectable 
deletion of 11q22.3, in the absence of TP53 mutation / deletion. All of these 
cases gave a normal response when assessed by Western blot. If the authors 
had assessed the combination treatments on all of these cases they may 
have detected differences such as those seen in the original work by Best et 
al (2008). Furthermore, the validation cohort also demonstrated that the single 
agent assay cannot discriminate between cases with or without ATM and/or 
TP53 abnormalities. In the 42 cases listed in the supplementary data there 
were 6 cases with deletion of 11q22.3 of which 2 had concurrent involvement 
of TP53. The remaining four cases all tested normal using the single agent 
nutlin assay. One of the benefits of using Western blotting as opposed to flow 
cytometry to detect p53 protein, highlighted by the author, is the detection of 
frameshift mutations. These would be undistinguishable from full length p53 if 
using flow cytometry yet they can be easily discerned by relative size on a 
Western blot. 
One study has investigated using a dual agent in-vitro functional assay in 
order to detect ATM mutations in CLL (Navrkalova et al. 2013). The authors 
exploit the different mode of action of the two chemotherapeutics, doxorubicin 
and fludarabine, in order to discriminate between cases with and without ATM 
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mutation. Both drugs lead to a p53-dependant increase in p21 expression 
however only doxorubicin does so in an ATM dependant manner. The authors 
used a custom resequencing micro-array platform to screen for ATM 
mutations in a cohort of 140 cases. Positive screens were then confirmed by 
direct sequencing. In total they identified 28 ATM mutations in 22 patient 
samples. The functional test they employed identified 16 cases as having 
ATM dysfunction, 4 cases gave normal responses and 2 cases were 
disregarded due to concomitant TP53 abnormalities. 
They also showed a definite functional difference between cases with sole 
deletion of 11q and sole ATM mutation. However they also found that in terms 
of time to first treatment both abnormalities had an equally detrimental effect 
compared to wildtype cases (Navrkalova et al. 2013). 
 
 
 
 65 
1.9.4 The etoposide and nutlin functional assay in CLL 
The flow-cytometry assay developed by Best et al (2008) and used in this 
project is modelled after the methodology of Carter et al (2004) with several 
key differences which are illustrated in Figure 1-15. DNA damage is induced 
using the topoisomerase II inhibitor, etoposide, rather than ionising radiation 
which avoids the need for specialist facilities. The small molecule nutlin3a is 
used to further stratify the Type-B dysfunctional response identified originally 
by Pettitt et al (2001). In most other respects the assays are the same, 
measuring the same targets (p53 and p21), and using the same antibody 
clones to detect them. The different systems of response classification are 
described below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The increased stratification due to the use of nutlin3a requires different 
nomenclature than that used by Carter et al (2004). Figure 2-3 (p81) in the 
methods section shows the strategy for assigning samples to functional 
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The assay uses two methods to induce p53/p21 
responses, one of which is not reliant upon 
functional ATM. A) Etoposide induces DNA DSBs 
leading to an increase in p53 protein via the MRN 
complex and ATM signalling. B) Nutlin3a inhibits 
the interaction of MDM2 and p53 leading to 
accumulation of p53 by avoiding degradation by 
the proteosome (Best et al, 2008). 
 
Figure 1-15: p53 induction using combination 
treatment of etoposide and nutlin 
 66 
categories. A normal response is characterised as an increase in expression 
of p53 and p21 in response to etoposide alone; the categorisation of 
dysfunction is then determined by the responses to etoposide plus nutlin. An 
MFI of greater than 8 for p53 in the control culture was classed as p53 over 
expression (p53oe) and is analogous to ‘Type-A’ dysfunction as defined by 
Carter et al, (2004). Cases which fail to increase expression of p53 and p21 in 
response to etoposide and etoposide plus nutlin3a were categorised as ‘non-
responders’. The nutlin-responder category identifies samples in which the 
use of nutlin3a recapitulates a normal response. Cases that fail to increase 
expression of p21 despite a normal p53 response to nutlin are referred to as 
p21-negative. This category is analogous to the Type-C response identified by 
Carter et al (2004) and Johnson et al (2009). The cut-offs used to define 
normal responses for p53 (≥30% increase in MFI) and p21 (≥15% increase in 
MFI) were previously derived by receiver operator characteristics (ROC) curve 
analysis (Best et al, 2008).  
During the original development of this assay it was found that the non-
responder and nutlin-responder dysfunctional responses occurred only in the 
presence of a mutation in the TP53 or ATM genes respectively; loss of 
17p13.1 or 11q22.3 alone did not confer a dysfunctional response (Austen et 
al., 2008, Best et al., 2008b).  
The current explanation for approximately half of p21-negative/Type-C 
responders is interacting SNPs within CDKN1A, the gene encoding p21 
(Johnson et al., 2009). In addition, the same group have now reported a fourth 
category of dysfunction, termed Type-D, in which p21 responds normally but 
p53 does not. 
Compared to specific molecular tests, including FISH and DNA sequencing, 
functional assays represent a holistic, systems biology based approach that 
should be able to detect samples which may have multiple gene defects 
within the DNA damage response pathway. 
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 Primary Hypothesis 1.10
The primary hypothesis to be dealt with in this thesis is as follows: 
‘The functional assay response categories associate with specific 
abnormalities of ATM and p53’. 
 
The null hypothesis is therefore: 
‘The functional assay response categories do not associate with specific 
abnormalities of ATM and p53’. 
 
Further questions will be addressed in subsequent result chapters; therefore a 
specific hypothesis statement will be made at the beginning of each. 
 
 Aims and Objectives 1.11
The aims of this project are as follows: (i) to determine the value of the 
etoposide/nutlin3a functional assay for detecting patients with abnormalities of 
the ATM-p53-dependant DNA damage response which would contra-indicate 
treatment with alkylating agents or purine analogues; (ii) to test the ability of 
the assay to discriminate between ATM and p53 abnormalities as these have 
differing prognostic impact in CLL. The objectives to be met for the completion 
of these aims are as follows: 
 
1. Laboratory work 
A cohort of patients, assembled as part of a Leukaemia Research Foundation 
(LRF) funded study, will be fully characterised using the etoposide/nutlin 
functional assay, FISH for 11q22-23 and 17p13.1 and mutation screening of 
TP53 and ATM using HRM analysis. Additional, potentially relevant, markers 
of p53 DNA damage response dysfunction, including miR34a levels and 
functional single nucleotide polymorphisms, will be investigated using 
appropriate techniques. 
 
2. Data analysis 
The results of the functional analyses will be compared to other markers of 
DNA damage pathway dysfunction including FISH and mutation screening. 
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Associations between the assay result categories and other markers will be 
assessed using Fishers exact test. 
Assay results will be correlated with clinical data (PFS and response to 
treatment) in order to determine whether the functional assay adds new 
predictive power over FISH and mutation screening. 
A validation of the data will be performed by statistically testing for differences 
in the assay data between the samples that were sourced from the local clinic 
(Royal Bournemouth and Christchurch Hospital) and those samples which 
were sourced from referral centres and thus had extended amounts of time 
between venesection and processing/storage. 
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2 Chapter Two: 
 
 
 
 
 
 
Materials & Methods  
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 CLL patient samples 2.1
Samples of peripheral whole blood (20ml) were collected, with informed 
consent, in accordance with the Declaration of Helsinki, from Centres around 
the UK. A copy of the standard patient information sheet and standard 
consent form can be found in Appendix I (p204), and Appendix II (p208) 
respectively. All samples were anonymised, labelled, recorded and stored in 
accordance with the Human Tissue Act (2004). Work was ethically approved 
under the auspice of the Lym1 study, ‘Identification and characterisation of 
prognostic factors in chronic B-cell lymphoproliferative disorders’, MREC 
number 06/Q2202/30. All diagnoses were made by referring clinicians. 
Clonality of B-cell disorder was previously established at referring centres as a 
part of the routine diagnostics. 
The anti-coagulant preservative, lithium-heparin, was used for all collected 
samples. Selected prognostic and predictive markers were analysed for all 
samples.  
All antibodies, materials and reagents were purchased from recognised 
commercial suppliers. Details on antibodies can be found in appendix III, p211 
and materials and reagents in appendix IV, p212.  
 
 Study design 2.2
The final design of this PhD would partly be dictated by the number of 
samples which could be successfully collected and fully analysed as testing 
the functional assay across a large cohort was the primary aim.  
Samples were primarily taken from cases with active disease which ensured 
that the samples were relatively enriched for tumour cells. This also reflects 
the envisaged use of the etoposide/nutlin functional assay, namely to give 
additional information to clinicians when considering treatment. 
All samples will be tested using the functional assay and their responses used 
to place them into predefined categories. All samples tested using the 
functional assay will also have sequence analysis of the TP53 gene and 
mutation screening of the ATM gene performed. Results of FISH analysis of 
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chromosomal loci 11q22.3 and 17p13.1 of the same samples will be made 
available for the dataset.  
Due to the relative rarity of CLL patients with TP53 and ATM mutations and/or 
deletion of chromosomes 11q or 17p it was decided to not place restrictions 
on eligibility of cases such as clinical stage or IGHV status. 
 
 Sample processing 2.3
All open handling of patient blood was undertaken in a class-2 biological 
safety cabinet in the molecular pathology lab of the Royal United 
Bournemouth and Christchurch Hospital (RBCH). Personal protective 
equipment was used (Gloves, glasses and labcoat). Disposable glassware 
and plastic waste was collected and removed in accordance with local 
guidelines.  
Upon receipt of whole blood samples, a 500 µl aliquot was removed kept 
aside for CD38 analysis and a 5 ml aliquot was kept for chromosome banding 
by Giemsa staining (Performed by AG, SM, SG). The remaining whole blood 
was separated by density gradient centrifugation using an equal volume of 
Ficoll Histopaque (Sigma Aldrich, UK). The lymphocyte / mononuclear cell 
fraction was collected from the interphase between the plasma and ficoll 
histopaque. The collected cells, further referred to as ‘peripheral blood mono-
nuclear cells’ or PBMCs, were washed once in 3 ml phosphate buffered saline 
solution (PBS), enumerated and washed once more. The cells were then 
suspended in foetal calf serum containing 10% DMSO at a density of 2x107 
cells/ml.  
Aliquots of cells (1ml) were placed in a Mr-Frosty™ tub (Nalgene, UK) 
containing 250ml iso-propanol and placed in a to -70oC freezer in order to 
slow the cooling rate to -1oC/minute. After 48 hours at this temperature the 
aliquots were transferred to liquid nitrogen (-175oC) cooled containment for 
long term storage. 
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 Thawing and enumeration of viable PBMC samples 2.4
When an aliquot of frozen PBMCs were required for use it was important to 
reduce the impact that the thawing process may have upon cell viability. 
Aliquots were retrieved from the liquid nitrogen storage and transported on 
dry-ice to the laboratory. The aliquots were thawed rapidly in a water bath 
(37oC) till partly thawed. Using a sterile Pasteur pipette, the contents of the 
aliquot were then transferred to a 5 ml, round bottomed flow cytometry tube 
containing 3 ml of pre-warmed (37oC) media or PBS, depending upon 
required usage. The sample was then pelleted in a centrifuge and the 
supernatant discarded. The pellet was resuspended in solution with 1 ml of 
media or PBS. 
To determine how many viable cells had been recovered a 10 µl aliquot of the 
sample suspension was mixed 1:1 with the dye Trypan blue. Trypan blue 
selectively stains dead cells or cells which are lacking an intact cell 
membrane. The total numbers of viable and non-viable cells in a known 
volume were counted manually using a haemo-cytometer mounted on a light 
microscope. The data was then used to determine the total numbers of viable 
and dead cells in the sample suspension. 
 
 DNA extraction 2.5
In order to obtain nucleic acids for molecular analysis, DNA and RNA were 
extracted from PBMCs.  
Genomic DNA was extracted from 5x106 PBMCs using QIAmp DNeasy™ mini 
kits (Qiagen, UK) according to manufacturer’s protocol for DNA extraction 
using spin-columns and a microcentrifuge. Briefly, cells were pelleted in the 
microcentrifuge at low speed (4000rpm). The supernatant was removed and 
the pellet was resuspended in a total volume of 200 µl of phosphate buffered 
saline solution (PBS). To this was added 20 µl of proteinase K and 4 µl of 
RNase A. This was mixed by vortexing and then left for 2 minutes at room 
temperature. To this was added 200 µl of the lysis buffer, then the sample 
was mixed thoroughly and incubated in a heat block at 56oC for ten minutes. 
200 µl of ethanol (96-100%) was added to the sample and mixed by vortexing. 
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A DNeasy spin column was placed in to a clean collection tube and then the 
sample solution was pipetted in to the column. This was centrifuged for 1 
minute at 8000rpm. The flow through and collection tube were then discarded 
and the column placed in to a clean collection tube. 500 µl of the wash buffer 
(AW1) was added to the column and centrifuged for 1 minute at 8000rpm. The 
flow through and collection tube were discarded and the column placed in to a 
new collection tube. 500 µl of the second wash buffer (AW2) was added to the 
column before centrifuging at 14,000rpm for 3 minutes. Finally, place the 
column in to a clean 1.5 ml microcentrifuge tube and carefully pipette 100 µl of 
the elution buffer (AE) on to the membrane in the column. Allow the elution 
buffer to incubate on the membrane for 1 minute at room temperature and 
then spin for 1 minute at 8000rpm in order to elute the extracted DNA.  
The eluted DNA was quantified using a Nanodrop-1000™ spectrophotometer. 
Extracted DNA samples were stored at -20oC or used immediately as 
required. 
 
 RNA extraction 2.6
RNA required for the analysis of micro-RNAs was extracted from 1x107 
PBMCs using MirVana™ extraction kits (Life Technologies, UK). This product 
was used according to the manufacturer’s protocol. Briefly, the cells were 
washed in cold PBS then pelleted in a microcentrifuge at low speed (4000 
rpm). Cells were lysed by adding 600 µl of lysing solution. A 60µl volume of 
homogenising solution was added and the sample was left on ice for ten 
minutes. Working in a fume hood, 600 µl of phenol/chloroform solution was 
added and the solution was inverted by hand until it became milky in 
appearance. It was centrifuged at full speed (10,000rpm) for 5 minutes. From 
the clear, upper phase of the resulting solution 500 µl was removed by pipette 
in to a clean 1.5ml eppendorf. To this solution, 1.25 volumes of ethanol (625 
µl) was added and the sample was then mixed. This solution was then 
pipetted into a mirVana filter column in a clean collection tube. This was 
centrifuged at 10,000 rpm for 15 seconds. The flow through was discarded 
and the same step was repeated using the remaining sample. 700 µl of the 
supplied Wash solution-1 was added to the column and then the sample was 
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centrifuged at 10,000 rpm for 15 seconds discarding the flow through 
afterwards. This washing step was repeated a further two times using wash 
solution-2/3. After discarding the flow through the column was centrifuged for 
1 minute to ensure all the solution was removed. The column was then 
transferred to a clean 1.5 ml collection tube and 100 µl of the elution buffer, 
pre-heated to 95oC, was added. The sample was centrifuged at full speed 
(13,000 rpm) for 30 seconds and the collected solution could then be stored 
or used as required. 
 
 Polymerase chain reactions (PCR) 2.7
PCR was performed using Titanium™ Taq polymerase and buffer system 
(Clontech, USA). Oligonucleotide primers were designed using PSQ assay 
design software (Biotage, UK) and used at a final concentration of 400nM. 
Thermal cycling was performed on a Veriti® thermal cycler (Applied 
Biosytems, US). Oligonucleotide primer sequences used in this work are listed 
in appendix V, p213.  
Successful PCR was confirmed by electrophoresis in 1.5% agarose gels 
containing GelRed (1:10,000). A 5 µl aliquot of the 50 µl PCR reaction was 
mixed with 1 µl of 6xTrackIt Cyan-Orange sample buffer and then loaded into 
wells. After electrophoresis, results were visualised using an ultra-violet light 
box. Images were captured using AlphaDigiDoc image capture software. 
Molecular weight ladder VIII (Roche Applied Science, UK) was used as a size 
standard unless otherwise indicated. 
 
 Cloning 2.8
Cloning of DNA fragments for sequencing was performed using the TOPO TA 
cloning kit, with One-shot™ TOP10 chemically competent E.coli cells 
purchased from Invitrogen, UK (Catalogues number: K457501. TOP10). PCR 
products generated using Taq polymerase were ligated in to the plasmid 
vector (pCR™4-TOPO®) according to manufacturer’s instructions. Briefly, 1 µl 
of salt solution and 1 µl of the TOPO® vector were added to 4 µl of the PCR 
product. The 6 µl reaction was mixed gently and incubated for 5 minutes at 
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room temperature. The reaction was then placed on ice. E.coli cells were 
transformed according to manufacturer’s instructions. Briefly, 1 vial of One-
shot™ cells was thawed on ice. To these cells was added 4 µl of the TOPO® 
vector reaction. The sample was mixed gently then incubated on ice for 5 
minutes. Transformed cells were then immediately spread on pre-warmed 
nutrient agar plates containing 50 µg/mL of ampicillin. The plates were then 
incubated overnight at 37oC. A total of twenty individual colonies were picked 
from plates using sterile pipette tips. PCR amplification and sequencing of 
cloned products was performed using the TOPO TA vector primers which 
were supplied with the kit.  
 
 DNA sequencing 2.9
Sequencing of DNA fragments was performed using the Sanger method 
(Sanger et al., 1977). The Sanger chain-termination reaction carried out using 
BigDye™ Terminator 3.1 kits purchased from Applied Biosystems (Catalogue 
number: 4337455). The oligonucleotide primers used for PCR were also used 
for the Sanger dideoxy chain termination reaction. Chain termination reaction 
products were separated by capillary electrophoresis using an ABI310 
Genetic analyser (Applied Biosystems, UK). Sequence data were analysed 
using DNAstar™ Seqman II software. TP53 gene sequences were compared 
to wildtype reference sequence (TP53 sequence GenBank accession number: 
X54156). 
 
 Pyrosequencing 2.10
The primers used for analysis of the codon-31 polymorphism in CDKN1A 
were a forward, biotinylated primer 5′-CTC TTC GGC CCA GTG GAC-3′, a 
reverse primer 5′-CTC ACG GGC CTC CTG GAT-3′ and a pyrosequencing 
primer 5′-AGC GCA TCA CAG TCG-3′ designed using PSQ assay design 
software (Biotage, UK). DNA amplification was carried out in Bournemouth by 
Ian Tracy. Pyrosequencing was performed by B. Gregory. 
 
 76 
 Restriction fragment length polymorphism (RFLP) 2.11
Preliminary, low-cost analysis of single nucleotide polymorphisms (SNPs) was 
performed using restriction-fragment length polymorphism (RFLP) analysis on 
PCR amplified DNA (Kan and Dozy, 1978).  
2.11.1 Codon-31 of CDKN1A 
Primers and PCR protocols used for the analysis of the CDKN1A codon-31 
serine/arginine polymorphism were as described by (Johnson et al., 2009). 
The forward primer (5'-GTC AGA ACC GGC TGG GGA TG-3') and reverse 
primer (5'-CTC CTC CCA ACT CAT CCC GG-3') amplified a 273 basepair 
product. This was incubated with the restriction enzyme, B1pI, which 
recognises the restriction site 5'-GCTNAGC-3'. The serine allele retains the 
AGC of the restriction site, allowing cleavage by the enzyme. Alternatively, the 
arginine allele, AGA, eliminates the restriction site. 
2.11.2 3’UTR of CDKN1A 
Primers used to amplify target region and PCR protocols used for the analysis 
of the 3'UTR C>T single nucleotide polymorphism were as described by 
(Johnson et al., 2009). The forward primer (5'-AGT TCT TCC TGT TCT CAG 
CAG-3') and reverse primer (5'-CCA GGG TAT GTA CAT GAG GAG-3') 
amplified a 327 basepair product. This was incubated with the restriction 
enzyme, Pstl, which recognises the restriction site 5'-CTGCAG-3'. The C 
allele retains the restriction site, allowing cleavage by the enzyme. 
Alternatively, the T allele eliminates the restriction site. 
 
 Taqman assays 2.12
Taqman hydrolysis probes were utilised in two methodologies during this 
study, Endpoint genotyping and relative quantification. Whilst the two methods 
differ slightly there is good cause to explain the chemistry of Taqman probes 
first.  
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2.12.1 Endpoint Genotyping 
Endpoint genotyping is a robust real-time PCR methodology for determining 
the genotypes of previously characterised SNPs using fluorescent hydrolysis 
probes (Livak, 1999).  
A real-time PCR reaction is performed to amplify the region of DNA containing 
the SNP of interest. In addition to PCR primers the reaction solution contains 
an excess of two fluorescently labelled hydrolysis probes which are specific to 
either of the two SNP variants. During the annealing stage of the reaction the 
probes bind to their targets. During the subsequent extension phase the 
probes are degraded and a fluorescent signal is measured.  
Endpoint genotyping was performed on a 96-well Roche Lightcycler 480®. A 
total of 20ng of genomic DNA was genotyped according to manufacturer’s 
instructions using kits supplied by Applied Biosystems, directed to each SNP 
(Codon 31: Catalogue number C_14977_20; 3’UTR: Catalogue number 
C_7514111_10). The dyes used were HEX and FAM. 
2.12.2 Micro-RNA relative quantification 
The relative quantification of micro RNA was achieved by quantitative real-
time polymerase chain reaction (Q-RT-PCR), using Taqman™ hydrolysis 
probe technology. The experiments were performed using a 96-well Roche 
Lightcycler 480®. For each sample 20 ng of RNA was reverse transcribed 
using a high-capacity cDNA reverse transcription kit purchased from Applied 
Biosystems (Catalogue number: 4368814). Target specific reverse 
transcription primers were supplied with the taqman™ mircoRNA assays 
purchased from Applied Biosystems (Catalogue number: 4427975).  
The Taqman™ microRNA assay was performed in triplicate for each sample. 
Each reaction contained 1.33 µl of the cDNA reaction product, miRNA specific 
Taqman™ probes, and Roche probe master-mix (Roche Catalogue number: 
04707494001). Target and reference microRNAs for each sample were 
amplified in the same 96-well reaction plate in addition to negative controls 
and positive calibrators.  A seven point, 2-fold serial dilution (100%-1.56%) 
standard curve was generated in quadruplet for both target and reference 
genes using total RNA extracted from the cell line, MCF-7, and then saved as 
an external standard for application to all subsequent experiments. In order to 
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calibrate the subsequent experimental runs, MCF-7 RNA was frozen at three 
concentrations of the serial dilution standard curve (50%, 12.5% and 3.125%). 
Batches of thirty-six patient samples plus the three calibrators and a negative 
control were reverse transcribed together. The calibrator cDNAs were then 
used in three subsequent taqman assays, each containing twelve patient 
cDNAs, the reverse-transcription negative control and a taqman reaction 
negative control. The normalised values from the experiments were then 
increased by a factor of 100. The final figures generated therefore describe 
the percentage of hsa-Mir-34a found in the test sample relative to MCF-7 
cells, after correction for differences in the quantity of the reference gene 
(hsa-Mir-30d). 
 
 Fluorescent in-situ hybridisation 2.13
Fluorescent in-situ hybridisation was performed using Vysis CLL FISH probe 
kit, purchased from Abbot molecular, UK (Ref 4N02-020). FISH analysis was 
performed by A. Gardiner, S. Mould and S. Glide (specialist cytogeneticists) 
according to manufacturer’s guidelines. The technique allows for the 
visualisation of specific regions of DNA within a cell. Specifically, a single 
stranded, fluorescently labelled DNA probe, called a locus-specific identifier 
(LSI), anneals to its complementary target within the genetic material of a cell. 
This region can then be visualised directly using fluorescent microscopy. 
Figure 2-1 (next page) shows the regions of chromosomes 11 and 17 which 
are targeted by the Vysis probes LSI ATM and LSI TP53, respectively (Abbot 
Molecular Inc 2011). All single locus probes were co-hybridised with a control 
probe specific to the centromere of the targeted chromosome, either CEP11 
or CEP17. 
Briefly, the procedure involves attaching peripheral blood mononuclear cells, 
derived from CLL patients, to microscope slides. The cellular DNA is then 
chemically denatured using a sodium citrate salt solution and the fluorescently 
labelled probes are allowed to hybridise to their target loci. Any unbound 
probe is removed by a series of washes and then the nuclei are counter-
stained with the DNA specific dye, DAPI, which fluoresces blue. The probes 
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can then be viewed and counted using a fluorescence microscope with the 
required excitation and emission filters (Abbot Molecular Inc, 2011). 
 
Figure 2-1: Chromosomal regions detected by 
Vysis FISH probes. (Abbot Molecular Inc 2011) 
 
Figure 2-2 below shows five CLL nuclei stained using the LSI TP53 probe 
(orange/red) and the CEP17, chromosome-17 centromere-specific control 
probe (green). The proportion of cells missing one or both LSI TP53 signals 
can then be enumerated by counting a minimum of 200 cells.  
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Figure 2-2: CLL DAPI-stained nuclei 
(Blue) with LSI TP53 (Red) and CEP17 
(Green) probes 
 
 ATM/p53 pathway functional assay 2.14
To test the integrity of the p53-dependant DNA damage response pathway a 
functional assay was used that measures the change in levels of p53 and p21 
proteins in response to DNA damage and MDM2 inhibition.  
The functional assay used in this work was developed by Best et al (2008). 
Briefly, 2x107 frozen peripheral blood mononuclear cells (PBMCs), were 
thawed and washed once in RPMIc (RPMI-1640 media containing 10% foetal 
calf serum and 2mM L-glutamine). PBMCs were split equally into 3 wells of a 
24-well plate to a final volume of 1ml RPMIc per well containing either 1) no 
treatment control, 2) 50 µM final concentration etoposide or, 3) 5 µM nutlin3a 
and 50 µM etoposide. The cultures were incubated in a 5% CO2 atmosphere 
at 37oC for 24 hours. After harvesting cells were fixed in 2% 
paraformaldehyde solution for 30 minutes at 4oC followed by permeabilisation 
in ice cold ethanol for 2 hours at -20oC. Primary mouse-monoclonal 
antibodies, purchased from Dako UK, specific to human p53 (Clone DO-1), 
p21 (Clone EA-10) and an isotype matched control antibody (IgG2a) were 
incubated for 15 minutes. Samples were washed in phosphate buffered saline 
solution (PBS) and then a goat anti-mouse secondary antibody, conjugated to 
fluoro-isothiocyanate (FITC) was used to detect the primary antibody and 
amplify the signal. Antibody to CD2, conjugated to R-phycoerythrin (PE), was 
used to discriminate B-cells from T-cells. Data were gathered using a Becton 
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Dickinson FACScalibur™ flow-cytometer. The gating strategy used follows. 
Firstly light scatter properties were used to isolate the live lymphocytes. Within 
this gate CD2 negative cells (non T-cell) were selected for analysis. IgG2a 
antibody control was used to adjust laser voltages so the mean fluorescence 
intensity (MFI) in the FITC channel was set at 3.0. Further compensation of 
the PE channel was disregarded as the PE data was used qualitatively not 
quantitatively. Unless otherwise stated, 10,000 events were collected for each 
data acquisition. Data were analysed using CellQuest™ software.  
The MFI of target proteins in the control culture was recorded and the 
percentage increase over the control was determined for the etoposide and 
etoposide-plus-nutlin3a treated cultures. An MFI of greater than, or equal to, 8 
in the control culture was used to define abnormal over-expression of p53. 
Cut-off values for determining a normal increase of MFI, in relation to the 
control culture, for p53 and p21 were previously defined as 30% and 15% 
respectively (Best et al., 2008b). A flow chart showing the strategy for 
categorising samples is shown in Figure 2-3.  
 
 
Figure 2-3: Flow chart showing strategy for assigning samples to functional 
groups 
 
 
Control 
culture
Etoposide
+ nutlin
culture
Etoposide
culture
If p53 MFI  ≥ 8  
p53 over-expression 
(p53oe)
If p53 increase ≥30%
& p21 increase ≥15%  
Non-responderNutlin-responder
If p53 MFI  < 8  
Normal-responder
If p53 increases ≥30%
& p21 increases 
≥15%  
If p53 & p21 fail to 
increase  above 
cutoff
If p53 only increases 
≥30%  
p21 negative
1
2
3
Categories based upon the changes to mean fluorescence intensity observed after 
treating cells with and without etoposide or etoposide plus nutlin3a.  
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Those samples which displayed abnormal over-expression of p53 in the 
control culture were classed as ‘p53 over-expressers’ (p53oe). Samples which 
exceeded these cut-off values in response to etoposide alone and did not 
show abnormally expressed p53 in the control were categorised as ‘Normal-
responders’ on that basis alone (Best et al, 2008). All samples which failed to 
reach the cut-off for either p53 or p21 in the etoposide culture were 
considered as dysfunctional and the response to the etoposide plus nutlin3a 
culture was then used to assign these samples to specific dysfunctional 
categories. Samples which still failed to increase p53 and p21 expression 
were classed as ‘non-responders’. Any dysfunctional sample which increased 
p53 and p21 normally with the addition of nutlin was classed as a ‘nutlin-
responder’. Samples for which only p53 responded normally were classed as 
‘p21 negative’ or ‘p21-failure’.     
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3 Chapter Three: 
 
 
 
 
Results 
 
 
Functional Assay Performance  
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 Hypothesis 3.1
The primary hypothesis for this section is as follows: 
The functional assay response categories associate with specific 
abnormalities of ATM and p53. 
 
The null hypothesis is therefore: 
The functional assay response categories do not associate with specific 
abnormalities of ATM and p53. 
 
 Classifying the FISH results 3.2
Four hundred and seventy-two cases were selected for the following analysis. 
All cases had a confirmed diagnosis of CLL. No changes to diagnosis were 
reported at any time. Samples from the local clinic were selected on a 
consecutive basis and represented patients at all stages of disease. Patients 
recruited as part of the LRF study were selected if they had progressive 
disease and were at the point of requiring therapy, or, if they had relapsed 
after therapy. This was in order to increase the chances of obtaining as many 
cases with involvement of TP53 or ATM.  
All cases had FISH data on chromosomal loci 11q22.3 and 17p13.1 in 
addition to functional assay results. Deletion, detected using FISH, was 
determined by the proportion of examined cells with an abnormal number of 
fluorescent signals. The following, previously established, cut off values were 
used (Best et al. 2008). Cases with only one signal for 11q detectable in ≥5% 
of examined cells were classed as 11q-deleted. A cut-off of ≥10% was used 
for the detection of 17p deletion (TP53) as cases in the LRF CLL 4 trial with 5-
10% loss of TP53 were shown to be similar in terms of outcomes to those 
below 5% (Oscier et al., 2010). The main characteristics of the cohort used in 
this section are summarised in Table 3-1 below. Due to the use of samples 
from different centres, data was not complete for all cases. 
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Table 3-1: Characteristics of cohort used in this section n=472 
 
 
In addition to FISH analysis a subset of the cases had mutation screening 
and/or sequencing of the ATM and TP53 genes. Unfortunately, due to cost 
constraints it was not possible to screen every sample which had FISH data 
available. Due to this, the analysis of mutations in addition to FISH data will 
be considered in results section 3.5 in a much smaller cohort. 
 
 Classifying the assay results 3.3
The median fluorescent intensity (MFI) measurements corresponding to p53 
and p21 protein levels were recorded. Percentage increases over the control 
MFI were calculated for the etoposide and the etoposide plus nutlin3a 
cultures. These percentages were then used to assign a functional category 
according to the strategy laid out in Figure 2-3 (p81,) using previously defined 
cut-off values to define normal and dysfunctional p53 and p21 responses 
(Best et al., 2008b). 
3.3.1 Response to etoposide 
The increase in median fluorescent intensity (MFI) of p53 and p21 in the 
etoposide treated culture was calculated as a percentage over the control 
culture measurements. The data is shown in Figure 3-1.   
 
n=469
n=297
n=211
A C
n=327 248 41
n=234
n=320
n=147
IGHV:
Binet stage at diagnosis:
CD38 positivity:
CD49d positivity:
Previous therapy:
Cohort characteristics
<30%
84 236
Treated Untreated
63 84
Unmutated
130 81
≥30% <30%
62 172
B
38
Female
320 149
Median Range
63 24-91
Male
Mutated
≥30%
Sex:
Age at diagnosis:
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Figure 3-1: Showing the p53 and p21 responses to etoposide for 472 CLL 
cases. Markers indicating cut-off points for p53 and p21 are shown. Left panel shows 
all data. Right panel cropped to give greater detail of cases with dysfunctional 
responses.  
  
The p53 and p21 responses to etoposide were then categorised according to 
the responses described for ionising radiation based assays (Carter et al. 
2004). These results are shown in Table 3-2 and in Figure 3-2. A total of 
321/472 (68.9%) samples responded normally to etoposide as a single agent 
therefore the overall incidence of dysfunctional responses to etoposide was 
31.1%. 
 
Table 3-2: Responses classified using etoposide treatment data only. n=472.  
(Lin et al. 
2012) 
Response 
phenotype 
Frequency Percent 
Normal Normal 321 68 
Type-A p53oe 8 1.7 
Type-B No response 88 18.6 
Type-C p21 failure 47 10 
Type-D p53-p21+ 8 1.7 
Total - 472 100 
 
Basal over-expression of p53 in the control culture (p53oe) was observed in 8 
cases (1.7%). These are analogous to Carter’s Type-A cases. The Type-B 
response, failure to increase both p53 and p21, was the most frequently 
observed form of dysfunction, being recorded for 18.6% of cases (88/472). 
This represents 61.5% of the dysfunctional results (88/143). The p21-failure 
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response was detected in 47 (10%) cases. Finally, 8 cases (1.7%) failed to 
increase p53 above its 30% cut-off value despite increasing p21 sufficiently to 
reach its 15% cut-off. These responses were classified as Type-D due to a 
similar response having been previously described (Lin et al. 2012). 
 
 
Figure 3-2: Responses classified using 
etoposide treatment data only. n=472. 
 
 
 
These results, summarising the responses to the etoposide culture, are 
analogous to the types of results achieved using other single-agent functional 
tests of the ATM-p53-p21 DNA damage response pathway. As per the 
method laid out in 2.14, the normal-responding and p53 over-expressing 
cases were considered fully analysed. The remaining 143 dysfunctional cases 
were further categorised dependant on their p53 and p21 responses to the 
nutlin supplemented culture. 
 
 
3.3.2 Response to etoposide plus nutlin3a 
The 143 samples which did not sufficiently increase either p53 or p21 proteins 
in response to etoposide were re-evaluated using the p53 and p21 responses 
Categories are titled according to Carter et al, 2004. 
Type-A = p53 over -expression; Type-B=No 
response; Type-C=p21 failure; Type-D 
=p53failed/p21responded. 
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in the etoposide-plus-nutlin treated cultures. The data are shown in Figure 3-3 
and summarised in Table 3-3. 
 
Figure 3-3: p53 and p21 responses to etoposide plus nutlin in 
143 dysfunctional cases 
 
The addition of nutlin induced a normal p53 and p21 response in 65 (45.5%) 
of the 143 dysfunctional samples, classifying them as nutlin-responders. 
Thirty-nine samples were classified as non-responders, maintaining a p53 and 
p21 incompetent response despite the addition of nutlin (39/143; 27.3%). 
 
Table 3-3: Categorisation of 143 dysfunctional cases after 
evaluating nutlin response 
Category Frequency Percent 
Non-responder 39 27.3 
Nutlin responder 65 45.5 
p21 failure 35 24.5 
Category-4 4 2.8 
Total 143 100 
 
Thirty-five samples failed to sufficiently increase p21 despite a rescued p53 
response (p21-failures) and a further four did not raise p53 MFI above the cut-
off despite doing so for p21. These four cases were grouped together under 
the label Category-4; a similar outcome has been previously reported using a 
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functional test on a CLL patient cohort (Lin et al. 2012). Lin et al referred to 
this result as Type-D but to avoid confusion it has been termed Category-4 in 
this study. The overall distribution of all 472 samples across all categories is 
shown in Table 3-4. 
 
 
 
Table 3-4: Categorisation of whole dataset. N=472 
Category Frequency Percent 
Normal 321 68 
p53oe 8 1.7 
Non-responder 39 8.3 
Nutlin responder 65 13.8 
p21 failure 35 7.4 
Category-4 4 0.8 
Total 472 100 
 
In order to make a comparison that demonstrates the effect of nutlin on these 
results the etoposide and etoposide plus nutlin frequencies are cross-
tabulated in Table 3-5 below.  
 
Table 3-5: Comparison of etoposide responses and etoposide plus nutlin responses. 
n=472. 
 Nutlin response classification  
Normal Non-
responder 
Nutlin 
responder 
p21 
failure 
p53oe Category 
4 
Total 
E
to
p
o
s
id
e
 
re
s
p
o
n
s
e
 
c
la
s
s
if
ic
a
ti
o
n
 
Normal 321      321 
Type A     8  8 
Type B  39 36 11  2 88 
Type C   23 24   47 
Type D   6   2 8 
Total 321 39 65 35 8 4 472 
 
In order to test the usefulness of the assay as a tool for detecting and 
differentiating between abnormalities involving loss of the chromosomal 
regions containing the genes for ATM and TP53, their distribution amongst 
the functional categories was analysed. 
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 Assay responses and the incidence of cytogenetic 3.4
abnormalities detected using FISH 
The association between cytogenetic abnormalities of 11q and 17p detected 
by FISH and functional assay results was assessed. It was hypothesised that 
nutlin responders would be associated with ATM/11q abnormalities and non-
responders would be associated with TP53/17p abnormalities.  
The distribution of FISH results by functional category is shown in Table 3-6 
(p91). Abnormal FISH results for the loci containing ATM and TP53 were 
found in a total of 113 cases; their relative incidence in cases with or without 
dysfunction was analysed using Fisher’s exact test. A significant association 
was found between dysfunctional assay responses and the presence of FISH 
abnormalities which were detected in 44/321 (13.7%) of the normally 
functioning samples and in 69/151 (45.7%) of the dysfunctional samples 
(13.7% v 45.7%, p< .0001). The distribution of abnormalities within the 
different functional categories led to the following observations. 
 
3.4.1 TP53 deletion is significantly associated with the non-
responder and p21 failure categories 
Comparing the incidence of FISH results within the normal responders to their 
incidence in the separate dysfunctional categories found heterozygous loss of 
TP53 to be significantly associated with non-responders (3.1% v 35.9%, p< 
.0001), p53 over-expression (3.1% v 50%, p=.0001) and p21-failure (3.1% v 
20%, p=.0005). Loss of TP53 was detected in two nutlin-responders but this 
was not different to the incidence of TP53 deletion in the normal functioning 
cases (3.1% v 3.1%, p=1). One case with Category-4 dysfunction was found 
to have Del(17)p but this was not significant, probably due to the very low 
number of Category-4 cases, n=4 (3.1% v 25%, p=.129). 
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3.4.2 ATM deletion is significantly associated with the nutlin-
responder category  
Heterozygous 11q deletion was detected in a total of 68 cases, 31 of which 
(45.6%) responded normally to etoposide alone making it the most common 
FISH abnormality found in the Normal functional category (31/321; 9.7%). 
Deletion of 11q did not occur in the p53 over-expression or unclassified 
cases. 11q deletion was detected in, but not significantly associated with, the 
non-responder (9.7% v 7.7%, p=1) and p21-failure (9.7% v 17.1%, p=.236) 
categories. The nutlin-responder category was however significantly 
associated with 11q deletion (9.7% v 43.1%, p <.0001). One sample with 
tetraploidy, confirmed by the Cytogenetics department of Royal Bournemouth 
Hospital, was found to give a normal functional response, as did another 
sample which was found to have three copies of TP53. Of five cases with loss 
of both FISH probes, 4/5 (80%) gave a dysfunctional result.  
One explanation for the incidence of FISH abnormalities in the normal 
functional category could be that those cases have smaller deleted clone 
sizes, i.e. the proportion of cells examined with a missing/deleted FISH signal. 
A lower proportion of non-responding cells may be masked by a dominant, 
normally responding clone. Data on clone size was available for 29/38 cases 
with Del(17)p and 45/68 cases with Del(11)q and so this was investigated. 
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3.4.3 The proportion of 17p-deleted cells influences the functional 
assay result 
It was hypothesised that normal functioning samples with Del(17)p would 
have smaller deleted clone sizes than those which had the same FISH result 
and gave a dysfunctional assay response. To clarify, the terms ‘clone’ and 
‘clone size’ in this section refer to the proportion of examined cells which 
display only one FISH signal rather than the normal two. A deleted clone size 
of 100% refers to a sample in which all examined cells have only one allele. 
Figure 3-4 shows the clone sizes of 29 of the 38/472 cases that had 
heterozygous deletion of 17p; information on the clone size was not available 
for 9 cases. A non-parametric Kruskal-Wallis test showed a significant 
difference in the deleted clone sizes across the functional categories 
(χ2=10.339, df=3, p= .016).  
 
 
Figure 3-4: Size of 17p-deleted clone as determined by FISH, displayed according to 
functional category. N=29.  
 
A two-tailed Mann-Whitney test was used to compare the 17p deleted clone 
sizes of the normal responders to the individual dysfunctional groups. The 
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clone sizes of the normal responder group was significantly different to the 
non-responder (U=6, z=-3.1, p= .002) and p21-failure groups (U=1, z=-2.345, 
p= .019). There is still overlap in the range of clone sizes between the normal 
and dysfunctional categories which may result from the influence of other 
abnormalities such as TP53 mutation. 
3.4.4 The proportion of 11q-deleted cells does not influence 
functional status 
Figure 3-5, below, shows the range of clone sizes reported for all cases with 
11q deletion as a sole abnormality and for which data on the proportion of 
deleted cells was available (n=45). A non-parametric Kruskal-Wallis test 
showed no significant difference in the deleted clone sizes across the 
functional categories (χ2=2.886, df=3, p= .410). However, it can be seen that 
there is an apparent bi-modal distribution, with cases showing a large or small 
clone size and an absence of intermediate cases.  
 
 
Figure 3-5: Size of 11q-deleted clone as determined by FISH, 
displayed according to functional category. N=45     
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Broadly grouping the clone sizes as either Large (>50%) or Small (<50%) 
suggested that the lower clone sizes may occur more frequently in the normal 
response category (Table 3-7). However, comparing the relative frequency of 
large versus small clone size between the normal and nutlin responders using 
Fisher’s Exact test, did not find a significant difference, p=.1519.  
 
Table 3-7: Incidences of large and small 11q-deleted clone sizes across functional 
categories, n=45 
 Normal Non-responder Nutlin-responder p21-failure Total 
Clone size >50% 16 1 14 2 33 
Clone size <50% 9 0 2 1 12 
Total 25 1 16 3 45 
 
It was therefore decided to examine, in normal responder cases only, the 
etoposide induced increase of p53 between cases with no detected deletions 
(11q or 17p), and cases with 11q deletion. The aim was to determine whether 
the 11q deleted/normal responders still experienced a discernible impact on 
their p53 response to DNA damage or whether 11q deletion had no effect in 
those cases. 
Selecting cases from the main cohort, there were a total of 308 normal 
responders with no detectable 17p deletion. Of these, 31 had a detected 11q 
deletion. Figure 3-6 below shows a box plot of the data for these groups.  
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Figure 3-6: Boxplot showing p53 MFI induction in normal responders with (n=31) or 
without (n=277) deletion of 11q. 
 
The descriptive data on the average increase in p53 MFI after etoposide 
treatment for these two groups is shown in Table 3-8. A t-test for the equality 
of the means found that there was a significant difference in average p53 MFI 
increase between cases with 11q deletion (M=75.3, SD=27.4) and those 
without (M=101.8, SD=53.6, t(60)=4.5, p<.001).  
 
Table 3-8: Average increase in p53 MFI after etoposide treatment in samples with a 
normal assay response and no detected 17p deletion (n=307).  
Group N Mean % Std. Dev Median % Min-max 
No deletion 277 101.8 53.6 89 31-364 
11q deletion 31 75.3 27.4 69 32-139 
 
This data suggests that deletion of 11q attenuates the DNA damage response 
even in cases which were not classified as dysfunctional in response to 
etoposide. 
3.4.5 Summary 
It has been found that in terms of FISH results the assay detected a 
significant proportion of cases with deletion of either 11q22.3 or 17p13.1 and 
is able to discriminate between them by using nutlin to reactivate p53 in the 
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absence of functional ATM mediated signalling. Deletion of 17p13.1 was 
significantly associated with both the non-responder and p21-failure 
categories and deletion of 11q22.3 was significantly associated with the 
nutlin-responder category. These findings provide evidence of p21 failure 
being, in some cases, associated with abnormalities of TP53. 
Despite these associations however, 127 of the 472 analysed cases (26.9%) 
had functional assay results that were unexpected, given the actual FISH 
results; 14% (45/321) of the normal responder samples were found to have 
FISH abnormalities whilst 54% (82/151) of the dysfunctional samples had no 
detectable abnormalities. The size of the deleted clone was investigated and 
shown to have an effect on the functional assay results in cases with deletion 
of 17p13.1 potentially raising questions about the sensitivity of the assay. In 
contrast, the size of the 11q22.3 deleted clone did not associate with 
dysfunction but did display a bimodal distribution of clone sizes; an effect that 
was not seen in cases with deletion of TP53.  
The presence or absence of dysfunction in cases with loss of 11q22.3 
detected by FISH could also be influenced by the mutational status of the 
remaining allele suggesting that heterozygous loss of ATM in and of itself is 
not sufficient to cause a dysfunctional response to etoposide treatment and 
the presence of an ATM mutation may be a determining factor in nutlin-
responder dysfunction.  
Importantly, half of the eight p53 over-expression cases had no loss of 
17p13.1 or 11q22.3 detected by FISH. Abnormally stabilised p53 is an 
accepted marker of p53 abnormalities and so the question of whether 
mutations of TP53 are present in these samples was addressed. 
 
Table 3-9: Comparing the relative distribution of results between the present study 
and Lin et al (2012) 
 Normal Type-A Type-B Type-C Type-D 
Etoposide results 68 1.7 18.6 10 1.7 
(Lin et al. 2012) 30 2.2 52.5 4.7 10.4 
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 The assay identifies TP53 mutations but not ATM  3.5
mutations. 
For the reasons outlined above the mutational status of TP53 and ATM was 
investigated. Of the 472 cases used in the FISH analysis a total of 123 had 
complete genetic sequence screening of both the ATM and TP53 genes 
carried out.   
For a preliminary analysis the FISH and mutation results were combined. 
Cases with no abnormality of either gene detected were classed as normal. 
Cases were classed as having either a TP53 or ATM abnormality if they were 
found to have mutation and / or loss of that gene only. One case was classed 
as having involvement of both genes.  
The incidence of TP53 or ATM abnormalities in each dysfunctional category 
was compared to the normally functioning group using Fisher’s exact test to 
determine the p value with results of p<.05 being considered significant. The 
distribution of these results across the different functional categories is shown 
in Table 3-10. The normal response category (n=85) contained 3 cases 
(3.6%) with a detected abnormality of TP53 and 18 cases (21.2%) with an 
abnormality of ATM. The Non-responder group (n=11) was found to have 7 
cases (63.7%) with an abnormality of TP53 which was significantly different to 
the Normal function group (3.6%v63.7%, p<.0001).  
 
Table 3-10: Cross tabulation of genetic abnormalities according to functional 
category, n=123.  
 
 
The nutlin-responder category contained 1 case with TP53 involvement, 
which was not significant compared to the normal responders (3.6%v7.1%, 
p=.462). ATM abnormalities were detected in 7/14 nutlin-responder cases 
which was significantly different to the Normal functioning group (50%v21.2%, 
p=.041). 
Functional category Total
Full screening result N % N % p N % p N % p N % p
Normal 64 75.3 3 27.3 6 42.9 3 33.3 0 76
TP53 abnormality 3 3.6 7 63.7 <.001 1 7.1 0.46 4 44.4 0 4 100 <.001 19
ATM abnormality 18 21.2 0 7 50 0.04 2 22.2 1 0 27
ATM & TP53 involved 0 1 9.1 0.12 0 0 0 1
Total 85 100 11 14 9 4 123
Normal Non-responder Nutlin-responder p21-failure p53 oe
 99 
There was no significant difference in the incidence of ATM abnormalities 
between the p21-failure group and normal responders (22.2%v21.2%, p=1.0) 
but TP53 abnormalities were significantly differently distributed (3.6%v44.4%, 
p=.0013) and accounting for nearly half of the p21-failure cases. All four cases 
with p53 over-expression were found to contain TP53 abnormalities 
(3.6%v100%, p<.001). 
To summarise the incidences of abnormality, there were 20 cases with 
detected abnormalities of TP53 (including 1 with an additional mutation of 
ATM) and 85% of these (17/20) gave some form of dysfunctional response to 
the assay. Of the 27 cases with a detected abnormality of ATM, (excluding the 
aforementioned case with concurrent TP53 abnormalities), only 9 (33%) gave 
a dysfunctional result with the remainder giving a normal response to the 
assay. 
The mutation and FISH data are shown in greater detail in Table 3-11 and 
Figure 3-7 below. 
 
Table 3-11: Cross tabulation of screening results and assay responses showing bi-
allelic states. n=123 
 
Functional category Total
Full screening result N % N % N % N % N %
Normal 64 75.3 3 27.3 6 42.9 3 33.3 0 76
TP53 deleted 1 1.2 2 18.2 0 0 0 3
TP53 mutated 1 1.2 0 0 2 22.2 1 25 4
TP53 deleted/mutated 1 1.2 4 36.4 1 7.1 2 22.2 3 75 11
Biallelic TP53 mutation 0 1 9.1 0 0 0 1
ATM deleted 13 15.3 0 6 42.9 1 11.1 0 20
ATM mutated 5 5.9 0 1 7.1 0 0 6
ATM deleted/ mutated 0 0 0 1 11.1 0 1
TP53 deleted/ mutated + 
ATM mutated
0 1 9.1 0 0 0 1
Total 85 100 11 14 9 4 123
Normal
Non-
responder
Nutlin-
responder
p21-failure
p53 over-
expression
 100 
 
Figure 3-7. Bar chart showing the occurrences of all combinations of ATM and TP53 
abnormalities across the cohort, stratified by functional response to the 
etoposide/nutlin assay (n=123). 
 
 
 
 Analysis of the p53 over-expression category. 3.6
A commonly observed phenotype of TP53-mutated cells is the over-
expression of p53. It is most often used as a marker of TP53 mutation in cells 
that are assessed by histological examination or western blotting. The 
mechanism for this is thought to be loss of MDM2 transcription by p53 either 
through loss of function alone or coupled with a dominant negative effect as 
the mutated p53 inhibits the normal function of the wild-type protein. This then 
leads to absence of p53 proteolysis and cellular accumulation of the protein 
under unstressed conditions. 
In previous FACS based, functional assays the over-expression of p53 in the 
control culture cells was the defining characteristic for assigning a functional 
response (Carter et al, 2006). In many of the results that have been published 
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however, this Type-1 group is often very small in comparison to other 
dysfunctional groups and demonstrably does not detect all TP53 
abnormalities. 
In the nutlin assay, high baseline expression was identified for samples which 
had a p53 control MFI of greater than eight. This is quite a high value which 
reflects the high specificity that can be achieved using this marker but at a 
heavy cost in terms of sensitivity, indeed it would not be possible to detect 
TP53 mutation and/or loss of 17p in the majority of cases using this metric 
alone. In the categorisation of samples using the etoposide plus nutlin assay it 
is the pattern of responses to treatment that are used. In order to determine 
whether the detection of high baseline p53 protein levels is a necessary 
metric, all samples which have been tested using the assay were screened for 
samples with this phenotype. 
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3.6.1 High baseline p53 is not required for the detection of 
dysfunctional responses. 
 
From all the assay results that are available, regardless of any other genomic 
analysis or the disease diagnosis, there were 17 instances of a baseline p53-
MFI higher than 8.  FISH results for the ATM and TP53 loci were available for 
16 of these cases; 13/16 had TP53 mutation screening in addition. The one 
case without FISH results also did not have TP53 mutation results and was 
therefore removed. Of the remaining high baseline cases, 14/16 were 
diagnosed as CLL, in addition to one mantle cell lymphoma and a Burkitt’s 
lymphoma.  
All 16 cases displayed some form of structural abnormality of TP53 confirming 
the high level of specificity associated with this metric. Seven cases (43.75%) 
had loss of one FISH signal and a mutation of TP53, three (18.75%) had loss 
but no data on TP53 gene mutations and the remaining six (37.5%) had 
mutation of TP53 and no loss detected by FISH. Classifying the samples 
according to the p53 and p21 protein responses to drug treatments only, 
using the Best et al (2008) cut-offs, would have characterised 7/16 (43.75%) 
cases with p21-failure. The remaining nine cases all failed to upregulate both 
proteins above the cut-offs and would have been classified as Non-responder 
on that basis alone. In all 16 cases the etoposide plus nutlin culture did not 
activate the p53 pathway and so no cases would be categorised as nutlin-
responder. This shows clearly that the detection of high-baseline p53 protein 
is dispensable for the detection of p53 dysfunction and that samples with this 
phenotype do not respond differently to nutlin than other cases with p53 
abnormalities. So having established that these cases do not need to be 
identified on baseline p53 expression alone it was reasonable to question 
whether high baseline p53 is a stable marker. 
Pettitt et al (2011), have reported that the Type-A group was associated with 
treatment failure and that this association was not discernible in their Type-B 
group. This may therefore mean that the detection of high baseline –p53 may 
have value but as their Type-B category contains patients with ATM as well as 
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TP53 abnormalities it is possible they were unable to detect the effect of low 
baseline, p53 involved cases.  
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 Investigating previous therapies in this group 3.7
Within the fully characterised cohort, data on previous therapy was available 
for 121 samples. Fisher’s exact test was used to detect a difference in the 
incidence of prior therapy between the genetic sub-groups or functional 
categories (Table 3-12 and Table 3-13).  
Table 3-12: Showing the distribution of genomic abnormalities between the treated 
and treatment naïve patients 
 
 
Low numbers affected comparison of prior therapy within the different 
genotypic sub-groups. No groups achieved significance although a trend was 
observed in the bi-allelic TP53 cases (p=0.0566). When combining the 
genotypic groups, excluding the 2 cases with both ATM and TP53 
abnormalities, a significant association was seen for patients with any TP53 
abnormalities (p=0.0188) but not for any ATM abnormalities (p=0.0723). 
 
Table 3-13:Showing the distribution of functional responses between the treated and 
treatment naïve patients 
 
Similarly, the incidence of prior therapy in functionally normal cases versus all 
dysfunctional cases, regardless of category, showed a significant association 
(p=0.0103). However comparing the incidence of prior therapy in the 
individual categories of response found an association only for the Non-
responder responders (p=0.0286). 
 
 Summary 3.8
This result section has shown that the use of etoposide and etoposide plus 
nutlin to perform a functional analysis of the ATM/p53 pathway in CLL cells 
can be used to successfully detect cases with abnormalities of the p53 gene 
None
ATM 
mutation 
ATM 
deletion 
ATM 
biallelic
All ATM 
involved
TP53 
mutation 
TP53 
deletion 
TP53 
biallelic
All TP53 
involved
ATM & 
TP53
Total
No 44 4 6 0 10 1 1 3 5 0 59
Yes 30 4 11 1 16 2 4 8 14 2 62
p  value 0.7125 0.1042 0.4133 0.0723 0.5669 0.1592 0.0566 0.0188 0.174
Previously 
treated
TP53 or ATM abnormality
Normal Category-1 Category-2 Category-3 Category-4
All 
dysfunction
Total
No 48 4 3 1 3 11 59
Yes 37 12 5 3 5 25 62
p  value 0.0286 0.4605 0.3225 0.4605 0.0103
Previously 
treated
Functional category
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(either mutation and/or deletion of chromosome 17p) or deletion of 
chromosome 11q. The assay also successfully separates those cases with 
deletion of 11q from those with p53 abnormalities by using nutlin3a to activate 
p53 dependant signalling. The assay does not appear to be sensitive to the 
presence of mono-allelic ATM mutation and the cohort in general appears to 
lack cases with confirmed bi-allelic involvement of ATM. Deletion of 11q was 
the main type of abnormality detected in cases with normal function although 
the results show that these cases do have an attenuated response when 
compared to normal functioning cases without deletion.  
This section has also shown that despite over expression of p53 in unstressed 
cells being highly specific for the detection of p53 mutation it is not very 
sensitive. If used alone to detect p53 mutations this phenotype gives a high 
rate of false negative results, as is the case for immunohistochemistry 
(Colomer et al. 2003). It has been shown that all 16 samples with p53 over-
expression also displayed dysfunctional upregulation of p21. This took the 
form of either a non-responder or p21-failure categorisation. 
In light of these results it is possible to reject the null hypothesis for this 
section and accept the hypothesis: ‘The functional assay response categories 
associate with specific abnormalities of ATM and p53’. 
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4 Chapter Four: 
 
Results 
 
Investigating the p21-failure 
assay response 
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 Overview 4.1
The categorisation of CLL samples based upon the response of p53 and p21 
protein expression to the assay conditions aims to both detect and 
discriminate between genetic abnormalities of ATM and TP53 that have 
adverse impacts upon patient care. In Chapter 3: Results, (pp83-104), it was 
found that the p21-failure response is significantly associated with p53 
mutation and/or 17p-deletion, which is contrary to the currently published 
explanation (Johnson et al. 2009). This category requires further investigation 
to clarify its cause or causes.  
The only published explanation for a similar response to in-vitro DNA 
damaging assays suggests that approximately half of these cases are 
accounted for by the presence of two, interacting polymorphisms within the 
p21 gene (CDKN1A) (Johnson et al, 2009). The first is a non-synonymous 
transversion in codon 31 resulting in a serine/arginine substitution 
(rs1801270). The second, rs1059234, is a C/T transition within the 3’UTR of 
the gene (Figure 4-1).  
 
 
 
 
 
 
 
 
 
The authors of that study found that heterozygosity for the rare allele at 
codon-31, combined with the presence of homozygosity for the common allele 
at the 3’UTR, was highly associated with the p21-failure response. The 
authors suggest that the arginine variant mRNA is unstable and as such is not 
translatable and that the presence of the variant allele in the 3′UTR stabilises 
the mRNA allowing translation. The 3′UTR variant could also affect the 
translation of the mRNA if the variant altered interactions with any known or 
unknown miRNAs.  
~12kb
Codon 31 SNP
Rs1801270
AGC > AGA
Serine> Arginine
3’UTR SNP
Rs1059234
C > T
3 exons Location: chromosome 6p21
Intron
Exon: Untranslated
Exon: Translated
Figure 4-1: The CDKN1A gene structure. Image showing 
exons, introns and sites of codon-31 and 3′ UTR single 
nucleotide polymorphisms (SNPs) 
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It should be noted that although the assay is different, using ionising radiation 
alone to induce a DNA damage responses, it does describe similar 
responses. As this response pattern is observed when using the 
etoposide/nutlin assay it was decided to investigate the occurrence of 
CDKN1A polymorphisms in our p21-failure samples. 
 
 Hypothesis 4.2
 
The hypothesis for this chapter is as follows: 
Hypothesis: 
Cases displaying a p21-failure response to the assay associate with codon-31 
and 3′UTR polymorphisms in the CDKN1A gene. 
 
Null hypothesis: 
Cases displaying a p21-failure response to the assay do not associate with 
codon-31 and 3′UTR polymorphisms in the CDKN1A gene.  
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 The p21-failure response does not associate with 4.3
single nucleotide polymorphisms of the CDKN1A 
gene. 
 
In order to test for the effects of CDKN1A polymorphisms, which have 
previously been identified as associated with the p21-failure phenotype 
(Johnson et al. 2009), samples were selected from the cohort for which FISH 
results for del17p, TP53 mutation (exons 5-9) and functional data was 
available. 
Initially 23 p21-failure cases plus 20 abnormal (Non-responder or nutlin-
responder) and 80 normal cases were analysed using PCR-RFLP as 
previously described (Johnson et al, 2009). Example results obtained using 
the PCR-RFLP method are shown in Figure 4-2.  
 
 
 
 
 
.  
 
 
 
 
 
Sequencing of the PCR products revealed that the primers for the 3’UTR SNP 
amplified non-specific products and re-optimisation of the PCR protocol failed 
to improve the results. High molecular weight DNA in some of the samples 
also may have led to the 3’UTR-RFLP results being unclear. The analysis of 
the two polymorphisms was therefore repeated in an expanded cohort using a 
more sensitive and specific technique. 
A selected cohort of 180 cases, classified according to Best et al (2008) 
criteria, including 116 normal, 39 abnormal (non- or nutlin-responders) and 25 
p21-failure cases were genotyped by endpoint genotyping on a Roche 
B
208
119
327 ‘T’ allele
‘C’ allele
A
272 ‘A’ allele
186
86
‘C’ allele
A) Codon 31 digestion. Enzyme Blpl, cuts the ancestral Serine ‘C’ allele and not the 
rare Arginine ‘A’ allele. B) 3′UTR digestion. Enzyme Pstl, cuts the ancestral ‘C’ allele 
and not the rare ‘T’ allele.  
Figure 4-2: Restriction digests to determine genotypes 
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Genotyping of 180 mixed function cases. The two SNPs in all 180 
cases were found to occur as either a heterozygous or 
homozygous diplotype. No cases were found to be homozygous 
for the variant allele at either SNP. 
LC480®. Figure 4-3 below, shows the output from one of the genotyping 
experiments, showing 48 cases. 
 
 
 
 
 
 
 
 
 
 
 
The samples which were found to be heterozygous for one polymorphism 
were also heterozygous for the other, without exception. 
 
In all cases tested, heterozygosity at the codon-31 polymorphism was 
accompanied by heterozygosity at the 3’UTR polymorphism. Likewise, 
homozygosity occurred at both SNPs. No cases were found to be 
homozygous for the rare allele nor were any cases found to be homozygous 
at one SNP and heterozygous at the other. This is a strong indicator that the 
two polymorphisms are linked, meaning the rare SNPs are present on the 
same allele and are co-inherited. This is supported by several previous 
studies in which these two SNPs were always linked (Facher et al. 1997; 
Konishi et al. 2000; Taghavi et al. 2010). For this reason the results have 
simply been classified as a single diplotype: either hetero- or homozygous, 
and shall be referred to as such, and are shown in Table 4-1.  
Table 4-1: Frequency of genotypes determined by Endpoint 
genotyping. N=180. 
Etoposide 
response 
SNP diplotype 
Total 
Homozygous Heterozygous 
Normal 105 11 116 
Abnormal 32 7 39 
p21-failure 21 4 25 
Total 158 22 180 
 
 
Codon-31 3’-UTR
C/T
C/C
T/T
Ser/Arg
Ser/Ser
Arg/Arg
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Figure 4-3: LC480 output showing SNP genotypes at codon-31 and 
3’UTR for 48 samples.  
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The incidence of heterozygosity within the p21-failure response group was not 
found to be significantly different from its occurrence in the normal group (16% 
v 9.5%, p=.3063) or the abnormal group (16% v 18%, p =1.0). To confirm 
these results, 85 samples (including all p21-failure cases and all codon-31 
heterozygotes) were reanalysed at codon-31 by pyrosequencing. Results 
confirmed the previous observations. This analysis shows that in our cohort 
polymorphic variants of CDKN1A do not associate with the p21-failure 
response.  
 
 
 Mixing normal and p53 null cells in-vitro can replicate 4.4
a p21-failure response 
We hypothesised that a p53–null sub-clone emerging from a previously p53-
wildtype CLL would eventually result in a transition of category from a normal 
response to DNA damage, induced using etoposide, to a non-responder. 
During this transition, as the relative proportion of p53-null cells increases, it 
may be possible that a case could give a p21-failure response to DNA 
damage. This rationale was that the measured levels of p21 are lower than 
those for p53 in a typical normal responding CLL cell and that the recorded 
MFI values used to determine the percentage changes in protein are an 
average of several thousand measurements. As the background of null 
measurements increases the average p21 measurement would fall below its 
threshold of +15% before the p53 measurement falls below its threshold of 
30%. 
In order to test this, a non-responder CLL sample known to have loss of 17p 
detected in 68% of cells and a non-sense, 4 basepair insertion, within exon 5 
of the remaining allele of TP53, was mixed with samples known to have 
normal functional status and no abnormalities of TP53 or 17p. Normal cases 
were only selected if they were known to express lambda light-chains to allow 
discrimination from the non-responder sample, which was known to express 
kappa light chains.  
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The samples were cultured and prepared for FACS analysis separately 
according to the protocol in section 2.14 except for the addition of polyclonal, 
rabbit anti-human antibodies (Dako, Denamrk) specific to kappa (APC 
conjugated. Cat: C0222) or lambda (PE conjugated. Cat: R0437) light chains 
of the B-cell receptor. The PE conjugated antibody specific to the T-cell 
marker, CD2, was not used as kappa and lambda light chains are specific to 
B-cells. The samples were mixed in equal proportions immediately prior to 
data acquisition  
A software gating strategy was used to select varying proportions of 
kappa/lambda (dysfunctional/functional) cells for analysis. It was possible to 
mimic a p21-failure result with varying proportions of non-responder cells and 
two examples of this are shown in Table 4-2.   
 
Table 4-2: Results from two experiments mixing normal 
and non-responder CLL cells 
 
 
 
 
These preliminary experiments were not found to be always reproducible, 
even when selecting cells for repeat analyses from the same paired samples. 
It was decided that a less subjective analysis could be achieved by importing 
the raw data from a functional assay experiment into a spreadsheet where 
admixtures of cells from two datasets/samples could be created randomly, 
without bias and in any given proportions so that repeated random re-
sampling could be performed.            
Percentage of 
Category-1 
cells added
Percentage 
increase in 
p53 protein
Percentage 
increase in 
p21protein
Functional 
category
0 65 20 Normal
3.7 49 9 Cat-3
5 45 5 Cat-3
10 31 2 Cat-3
26 21 2 Cat-1
30 17 0 Cat-1
0 66 30 Normal
14.5 39 19 Normal
28 34 15 Normal
27 43 7 Cat-3
E
x
p
e
ri
m
e
n
t 
1
E
x
p
e
ri
m
e
n
t 
2
Experiments were designed to investigate whether an 
emerging non-responder sub-clone can cause the p21-
failure result. Non-responder cells were mixed with normal 
CLL cells which had no detectable abnormalities of 
TP53/17p  
Perc ntage of 
non-responder 
cells added 
p21-failure 
p21-failure 
p21-failure 
p21-failure 
Non-responder 
Non-responder 
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 In-silico dilution of p53-wildtype with p53-mutated 4.5
CLL cells 
CellQuest Pro™, reads and writes Flow Cytometry Standard (FCS) 2.0 binary 
data files which contain characters that cannot be read by programmes 
utilising the American Standard Code for Information Interchange (ASCII), 
including Excel. Conversion of FCS 2.0 files to an ASCII format was achieved 
using the downloadable third party software, FCSExtract Utility developed by 
Earl.F Glynn for the Stowers Institute of Medical research, USA 
(http://research.stowers-institute.org/efg/ScientificSoftware/Utility/FCSExtract/index.htm). 
This technique allowed the selection of any previously analysed patient 
samples and did not require re-analysing samples using the functional assay 
or restriction of sample choice due to surface immunoglobulin light chain 
restriction.  
FCS2.0 files were imported into FCSExtract utility and converted to ASCII 
format. This data was then exported to PASW™ statistics software package. 
The data corresponding to the forward and side light scatter results (P1 and 
P2 respectively) were plotted on a scatter-plot in order to generate an 
identical output to the forward / side scatter plot offered by the Cellquest 
software. This was used to determine the upper and lower values for P1 and 
P2 representing the ‘live’ cell fraction of the data for each patient sample 
used. The dataset for each patient was then cropped accordingly.  
The paired P3 and P4 values from the remainder of the dataset, 
corresponding to FL1 (Fluorescein-isothiocyanate) and FL2 (Phycoerythrin), 
were then exported to Microsoft Excel™ software, these are the values 
corresponding to the labelled IgG2a control, anti-p53 or anti-p21 anti-bodies 
(FL1), and the CD2 antibody (FL2). CD2 Data was plotted as a histogram in 
order to determine the presence of CD2 positive cells (T-cells/NK-cells), which 
were then also excluded from the dataset.  
In a representative in-silico mixing experiment one thousand data points were 
randomly selected from a p53 wildtype and a p53-dysfunctional dataset to 
produce a mixed dataset with 100, 75, 50, 25 and 0% dysfunctional cells. This 
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was replicated a total of ten times at each dilution. The mean of the ten 
replicates was then converted from channel values (0-1023) to linear ‘MFI’ 
values using the formula: 
 
Linear value = 10(Channel value/256)    (Cellquest Software Users 
Guide; p168) 
 
This procedure was performed using the data from the control and etoposide 
treated culture conditions for both p53 and p21. The data was then used to 
generate a percentage change in linear value between the control and treated 
samples at each dilution point. The p53 and p21 results were then plotted on 
separate graphs using the percentage change in linear value on the Y-axis 
and the dilution along the X-axis. From these two graphs it was possible to 
determine the percentage of p53-null cells required to cross the cut-off values 
of 30% and 15% for p53 and p21 respectively.  
Six samples were chosen for this analysis and four, separate, in-silico mixing 
experiments (a-d) were performed as described. The characteristics of the six 
cases (1-6) are shown in Table 4-3. 
 
Table 4-3: Samples selected for in-silico mixing experiments 
 
 
 
 
 
 Two samples which failed to respond to etoposide treatment and were known 
to have bi-allelic inactivation of the TP53 gene were selected. Four cases 
were selected which responded normally to etoposide treatment and had no 
detectable abnormalities of the TP53 gene. The results are shown in Figure 4-
4 and Figure 4-5. It can be seen that a p21-failure response could result from 
p53 p21
1 5% 3% Cat-1  94% Del 17p 2 basepair deletion
2 6% 0% Cat-1  68% Del 17p 4 basepair insertion
3 182% 100% Norm No loss Wildtype
4 177% 78% Norm No loss Wildtype
5 89% 36% Norm No loss Wildtype
6 106% 25% Norm No loss Wildtype
17p13.1 FISH 
result
TP53  mutation?
Etoposide induction of:
Sample Function
Two samples which failed to respond to etoposide treatment and were 
known to have bi-allelic inactivation of the TP53 gene were selected. Four 
cases were selected which responded normally to etoposide treatment and 
had no detectable abnormalities of the TP53 gene. NR= non-responder 
   NR 
   NR 
 115 
a p53 null clone emerging within a background of p53 wild type cells in 
experiments-a and -b (Figure 4-4). This contrasts with the other two examples 
shown in Figure 4 5. In experiment-c only a small p21-failure response range 
appeared before a Non-responder response was obtained. In experiment-d, 
no p21-failure response was seen and a normal response was maintained 
until approximately 85% of the data was from the p53 null sample. In this case 
the p53 wild type sample had particularly strong induction of both p53 and p21 
protein. (Table 4-3. Sample 3). These experiments provide evidence to 
support the theory that the p21-failure response may be a transitional state 
between a normal functional response and a non-responder. This leads to the 
inference that p21-failure cases could be associated with the same acquired 
genetic abnormalities that are associated with non-responders.       
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 The p21-failure samples are enriched for structural 4.6
abnormalities of TP53. 
Having shown that: (i) in this cohort the incidence of CDKN1A SNPs did not 
associate with p21-failure; and (ii) that an emerging p53-null clone could at 
least theoretically cause a p21-failure response; It was decided to test the 
incidence of both TP53 mutation and deletion of 17p in the p21-failure group 
against their incidence within the normal responding group and within the 
other abnormal response cases using the same 180 samples which had been 
analysed for CDKN1A polymorphisms. The frequency of results is shown in 
Table 4-4. The incidence of TP53 mutations in the p21-failure responders was 
significantly higher than in the normal responders (36% v 1.7%, p< .0001) but 
not the other abnormally responding cases (36% v 41%, p= .7951). Likewise, 
loss of the TP53 gene locus was significantly enriched in the p21-failure cases 
when compared to the normal cases (52.2% v 6.9%, p< .0001) but not when 
compared to the remaining abnormally functioning cases (52.2% v 38.5%, p= 
.4268).  
 
  
Table 4-4: Incidence of genetic abnormalities involving 
TP53 in 180 selected CLL cases 
 
Results of sequencing for mutations of TP53 within 
exons 4-9 and fluorescent in-situ hybridisation analysis 
to detect loss of chromosomal locus 17p13.1. 
 
This suggests that the p21-failure response is indeed associated with 
acquired genetic abnormalities rather than germline polymorphisms. Despite 
the significant involvement of TP53 abnormalities, some individuals have no 
detectable loss of chromosome 17p or mutations of TP53. However, in light of 
the known adverse prognosis of TP53 mutation and/ or deletion, a p21-failure 
Yes No Yes No
Normal 2 114 8 108
Abnormal 16 23 15 24
Cat-3 9 16 12 11
Total 27 153 35 143
TP53 mutation n=180 Del 17p13.1 n=178Etoposide 
response
p21-failure 
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result should prompt investigation of TP53 gene status. The existence of a 
subset of TP53 mutated CLL tumours which do not show high baseline p53 
expression nor a completely abrogated p53 response indicates that p21 
expression may be a more specific and sensitive readout of p53 function. 
 Summary 4.7
This section has shown that single nucleotide polymorphisms at codon-31 and 
in the 3’UTR of CDKN1A, previously found to be associated with a failure to 
express p21 in response to ionising radiation (Johnson et al., 2009), do not 
appear to be related to the analogous p21-failure response in this study. 
Therefore the null hypothesis for this section will be accepted: ‘Cases 
displaying a p21-failure response to the assay do not associate with codon-31 
and 3′UTR polymorphisms in the CDKN1A gene’.  
Different methods were used to genotype cases. Firstly the same RFLP 
method employed by Johnson et al (2009) was used to determine the 
genotypes of both SNPs in 123 cases. This was followed by genotyping using 
Taqman™ technology, again for both SNPs of interest, in 180 cases. 
Pyrosequencing was used to further confirm the results of codon-31 
polymorphism data. It was found that the two SNPs, codon-31 and 3’UTR, are 
linked, occurring together as a diplotype in all 180 cases tested. This was 
found to be in agreement with the majority of previously published studies 
involving these SNPs (Konishi et al. 2000; Mousses et al. 1995; Facher et al. 
1997; Taghavi et al. 2010) and directly contradicted the findings of the 
Johnson paper (Johnson et al. 2009). A significant association between the 
p21-failure response and TP53 abnormalities was observed and investigated. 
It was determined through experimental methods, and a novel computational 
method, that it is possible for an emerging non-responding / p53-null clone to 
cause the p21-failure response although this may vary from case to case. In 
addition this explanation does not account for all p21-failure cases within the 
cohort as TP53 abnormalities were undetectable in a subset of cases. 
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5 Chapter Five: 
 
 
 
Results 
 
 
Analysis of Hsa-miR-34a 
expression can detect TP53 
abnormalities but not ATM   
 121 
 Overview 5.1
The interest in mir34a analysis stems from its relationship with p53 and its role 
in the DNA damage response pathway (Zenz, Benner, et al. 2008). The 
finding that p53 mutation and deletion, either together or independently, affect 
the induction of this micro-RNA in response to DNA damage suggests that it 
could be an alternative indicator of p53 dysfunction in CLL (Zenz et al. 2009). 
Zenz et al also reported that a significant difference in baseline miR-34a 
expression could be detected in samples with or without TP53 abnormalities. 
This marker could be of interest as it would reduce the time to perform the 
analysis as cell samples would not require culturing or treating with drugs or 
ionising radiation. 
The micro-RNA, hsa-miR-34a, is under the direct transcriptional control of the 
p53 protein (Chang et al. 2007). It has been shown that the cellular 
concentration of this non-coding RNA is increased in response to cellular 
stresses including double stranded DNA damage. A constitutive level of hsa-
miR-34a in a resting cell is also maintained through continuous transcription 
by p53 (Zenz et al, 2009). It therefore follows that, in response to double 
stranded DNA damage, the status of the ATM gene also has an effect on 
miR-34a expression due to its role in p53 signalling (Hermeking 2010). It is 
unknown at this time whether abnormalities of the ATM gene have any impact 
upon the basal level of miR-34a expression. 
 
 Hypothesis 5.2
The hypothesis for this chapter is as follows: 
Hypothesis: 
Basal miR-34a expression is an indicator of ATM and p53 function in CLL. 
Null hypothesis: 
Basal miR-34a expression is not an indicator of ATM and p53 function in CLL. 
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 Selection of reference micro-RNA and standard RNA 5.3
source 
The relative quantification of expression requires standard curves to be 
generated for both the target and reference genes and both need to be 
derived from an RNA source (cell line) which ideally will express both target 
and reference genes at higher levels than the test samples. In addition the 
selected reference gene should be expressed at a similar level to the target 
gene in the test samples and the cell line to be used as a reference. Previous 
studies of hsa-miR-34a levels in CLL have used small nuclear RNA U6 as the 
reference gene for normalisation (Zenz et al, 2009). In a separate study, 
colleagues within our research group examined the uniformity of expression 
levels of a panel of micro-RNAs and small nuclear RNAs in CLL patient 
samples. The results of this work showed that within the candidates tested, 
the small nuclear RNA U6 did not have the most stable expression across the 
CLL samples tested. The results did highlight two potential candidate genes 
that were more stably expressed in CLL, hsa-miR-30d and RNU-43.  
To select a source of RNA for generating the standard curves and to 
determine which of the previously identified stable reference genes was most 
appropriate, two CLL patient samples and 13 cancer cell lines were screened 
in single reactions using for each mircro-RNA of interest. The p53 status of 
cell lines was checked against the literature (Berglind et al. 2008). 
Amplifications of hsa-miR-34a, hsa-miR-30d and RNU-43 were performed on 
each of the 15 samples and the crossing points (CP) values were then used 
to compare the relative expression levels of target and reference genes 
across the samples and cell lines tested. The results are shown in Table 5-1 
(p123).  
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Table 5-1: Crossing point values (CP) for thirteen 
cell lines and two patient samples showing the p53 
status. 
 
CP values are inversely related to the concentration of 
the sample. LRF 81 has no detected TP53 
abnormalities. LRF 74 has biallelic inactivation of TP53.  
 
The two patient samples (LRF 74 and LRF 81) were selected to represent the 
expected high and low extremes of mir34a expression in the cohort to be 
analysed. Case LRF 81 had no detected abnormalities of ATM or TP53 and 
was found to have a normal p53/p21 response to DNA damage induced by 
etoposide. In contrast, LRF 74 was found to have biallelic inactivation of 
TP53, confirmed by cloning and sequencing, and it was known to not 
upregulate p53 or p21 in response to DNA damage. Figure 5-1, Figure 5-2  
and Figure 5-3 reproduce the results shown in Table 5-1 for each of the 
measured microRNAs. The cell lines and CLL samples are arranged, left to 
right, on the x-axis in order of increasing CP value, which can be interpreted 
as decreasing concentration.  
Five of the thirteen cell lines gave miR-34a CP values higher than the lowest 
of the two CLL samples, indicating lower expression (Figure 5-1) and so would 
be unsuitable for generating a standard curve as the highest concentration 
possible would be lower than that expected of the CLL samples, these were: 
HBL-2, JVM-3, M901, MDA-MB-231 and Raji. 
miR-34a miR-30d RNU43
Patient p53 status CP CP CP
LRF 74 Mutant 33.2 26.32 27.15
LRF 81 Wildtype 31.1 27.61 27.16
Cell Line p53 status CP CP CP
HBL-2 Wildtype 36.82 30.82 28.9
HCT-116 Wildtype 27.99 27.63 28.38
JVM3 Wildtype 37.06 36.53 34.14
LS174T Wildtype 26.85 26.6 27.72
Lovo Wildtype 27.3 27.34 28.16
M901 Wildtype 37.36 28.19 28.81
MCF7 Wildtype 26.67 25.59 28.36
MDA-MB-231 Mutant 31.17 27.88 29.79
Raji Mutant 35.78 27.24 27.13
T47D Mutant 26.95 27.47 29.45
VLD-1 Wildtype 28.24 28.4 28.88
WiDR Mutant 27.81 24.25 28.71
ZR-75-01 Wildtype 26.65 26.1 28.74
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Of the eight remaining cell lines, none had CP values for RNU-43 lower than 
the two CLL samples. It was decided that RNU-43 could therefore not be used 
for the reference gene standard curve, as the CLL samples would potentially 
have higher RNU-43 expression than the highest concentration possible 
available in any of these cell lines (Figure 5-2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1: MiR-34a CP values for 13 cell lines and 2 samples 
arranged in ascending order. 
Figure 5-2: RNU43 CP values for 13 cell lines and 2 samples 
arranged in ascending order. 
Cell lines and CLL samples are arranged in order of ascending CP 
value (descending concentration). RNU43 was not expressed at a 
sufficiently concentration in any cell line for it to be used for standard 
curve. 
Cell lines and CLL samples are arranged in order of ascending CP 
value (descending concentration). Five cell lines (HBL-2, JVM-3, 
M901, MDA-MB-231 and Raji) were rejected for having lower 
concentration of the target, mir34a, than the CLL samples.  
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Three cell lines, ZR-75-01, MCF-7 and WiDR, had both lower miR-30d and 
miR-34a CP values, and therefore higher expression, than the CLL samples 
and so would be suitable for generating standard curves. The CP value for 
miR-30d in cell line, ZR-75-01, was only slightly lower than the lowest CLL 
sample, LRF-74, and was therefore removed in preference of either MCF-7 or 
WiDR (Figure 5-3),.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The decision to use MCF-7 cell line was made on the basis that the miR-34a 
and mir-30d CP values for MCF-7 were comparable to each other (less than a 
2-fold difference), whereas for WiDR, there was a CP difference of 3.56 
between the miR-34a and miR-30d results, suggesting that miR-30d has 
approximately 8-fold higher expression than miR-34a in that cell line. 
 
 
 
 
Figure 5-3: MiR-30d CP values for 13 cell lines and 2 samples 
arranged in ascending order. 
Cell lines and CLL samples are arranged in order of ascending CP 
value (descending concentration). Three cell lines had higher 
concentration of mir-30d than both CLL samples (ZR-75-01, MCF-7, 
WiDR). 
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 Generation of external standard curves for target and 5.4
reference genes. 
To maximise the number of samples that could be run in triplicate on each 96-
well plate and hence reduce cost, external standard curves were generated 
for application to subsequent experiments. A seven step, two-fold dilution 
series of MCF-7 RNA was used to generate standard curves for the target and 
reference genes, giving a 64-fold range of concentration. Each standard curve 
was generated in quadruplet reactions. The results for miR-34a are shown in 
Figure 5-4 and Table 5-2. The results for miR-30d are shown in Figure 5-5 
(p127) and Table 5-3 (p127). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5-2: Showing the CP values for miR-34a standard curve. The mean 
CP value of the four replicates and the standard deviation are also shown. 
 
 
mir34a
Percentage CP 1 CP 2 CP 3 CP 4 mean Std.Dev
100 22.99 23.15 23.16 23.14 23.11 0.080
50 23.88 23.77 23.87 23.84 23.84 0.050
25 24.82 24.74 24.85 24.85 24.82 0.052
12.5 26.66 26.6 26.67 26.66 26.65 0.032
6.25 27.09 27.02 27.19 27.22 27.13 0.092
3.125 28.83 28.91 28.9 29.02 28.92 0.079
1.562 29.66 29.67 29.79 29.85 29.74 0.093
Replicate No
Figure 5-4: miR-34a external standard curve. Seven step, two-fold 
dilution series assayed in quadruplet. An error of 0.0266 and PCR 
efficiency of 1.797 was recorded for this curve. 
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Table 5-3: Showing the CP values for miR-30d standard curve. The mean CP value 
of the four replicates and the standard deviation are also shown. 
 
 
The standard deviation from the mean of the mir-34a replicates was less than 
1% of the mean CP at each dilution. The standard deviation of the mir-30d 
replicates was higher than the miR-34a but was also less than 1% of the 
mean CP. Both of these results confirm that any variation between the 
replicates, for instance due to pipetting errors, was minimal. The efficiency 
computed for the miR-34a and mir-30d reactions were 1.797 and 1.979 
respectively. Efficiencies of approximately 1.8 are considered acceptable for 
relative quantification and both results satisfy this requirement with the latter 
being quite close to the theoretical maximum of 2.0. The error associated with 
mir30d
Percentage CP 1 CP 2 CP 3 CP 4 mean Std.Dev
100 22.64 22.94 22.92 23.11 22.90 0.195
50 23.63 23.94 23.95 24.14 23.92 0.211
25 24.59 24.85 24.91 25.12 24.87 0.218
12.5 26.12 26.25 26.18 26.48 26.26 0.158
6.25 27.11 27.36 27.36 27.56 27.35 0.184
3.125 28.58 28.82 28.89 29.03 28.83 0.188
1.562 30.16 30.48 30.55 30.71 30.48 0.231
Figure 5-5: miR-30d external standard curve. Seven step, two-
fold dilution series assayed in quadruplet. An error of 0.00574 
and PCR efficiency of 1.979 was recorded for this curve. 
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the standard curves was 0.0266 and 0.00574 for mir-34a and mir-30d 
respectively, which are both lower than the value of 0.2 which is given as the 
maximum acceptable error in the Roche LC480 handbook. These results 
showed the standard curves that were generated were acceptable for use in 
the subsequent relative quantification experiments. Aliquots of MCF-7 RNA at 
the 50%, 12.5% and 3.125% concentrations were stored at -70oC for use as 
calibrators in all test experiments. This methodology allows for mir-34a/mir-
30d analysis of 12 test samples to be run in triplicate on each 96-well 
Taqman™ reaction.  
 Concordance of measured levels of miR-34a DMSO 5.5
stored samples and RNAlater stored samples. 
In order to determine whether PBMC samples only available as 
FCS/10%DMSO frozen (-70oC) aliquots could be used, a selection of nine 
LRF samples were chosen to test for concordance of mir-34a results between 
matched cryopreserved cells and cells stored in RNAlater™. The samples 
were selected to represent different TP53/ATM genotypes and therefore 
expected to have a range of miR-34a expression, with sample aliquots in both 
storage conditions derived from the same whole blood specimen. After 
extraction of RNA from both storage media samples were assayed in parallel, 
with all reverse transcription reactions and amplifications carried out in the 
same run. The results are shown in Table 5-4.  
Table 5-4: Showing mir34a relative expression results for nine cases stored in either 
RNAlater™ or frozen at -70oC.  
 
 
RNAlater Frozen (-70C) 11q clone (%) 17p clone (%)
LRF 79            19.85 15.40 93 0 0
LRF 75            21.24 22.93 90 7 0
LRF 73            25.24 25.32 0 0 0
LRF 217           2.84 2.20 92 0 unk
LRF 142           43.18 60.55 0 0 0
LRF 130           0.13 0.14 0 96 0
LRF 127           13.59 10.16 0 25 1
LRF 116           4.74 1.46 97 0 0
LRF 112           4.48 3.27 0 0 0
Sample
mir34a FISH 
p53 mutation
FISH data is shown as percentage of cells examined showing loss of 
signal (clone size). Mutation data is shown as binary: 1=Mutated 0=No 
mutation. 
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The samples showed a significant correlation between RNAlater™ preserved 
cells and those stored in FCS/10%DMSO (-70oC) (r= .973, p< .001, R2= .947). 
These results, also shown in Figure 5-6, show that samples which are only 
available as FCS/10%DMSO (-70oC) stored cells could be included in the 
series in order to better understand the effects of ATM and TP53 gene 
abnormalities on basal miR-34a expression.  
 
 
Figure 5-6: Showing the correlation of mir34a relative expression results for 9 
matched samples stored in either RNAlater™ or cryopreserved at -70OC. 
Concordance of mir-34a expression in matched samples from the same case that 
were stored in both RNAlater and  FCS/10%DMSO at -70oC. These results show that 
DMSO frozen CLL samples could be used as surrogates in the absence of RNAlater 
stored samples. 
 
On the basis of this result it was decided to enrich the cohort with samples 
from the CLLIV trial for which the FISH and mutation status of ATM and TP53 
were known. The reason was to increase the number of samples with known 
biallelic inactivation of ATM and TP53 so that their relative effects upon basal 
mir-34a expression could be analysed. For further assurance that the CLLIV 
cell samples would give analogous results to the local and LRF samples the 
distribution of mir34a results in the ATM and TP53 wildtype genogroup (n-
=80) was compared across the three sets of samples and was not found to be 
significantly different (K=1.277, p= .528). This was also the case for the 
samples with ATM gene involvement of any form (n=36, K=2.701, p= .259) or 
 130 
TP53 gene involvement (n=51, K=5.471, p= .065). The mir34a results ranged 
widely with a 100,000-fold range (0.007-216) across the 166 samples tested. 
The 5% trimmed mean was 11.56 (SD=22.8) and the median was 9.02. The 
data were not normally distributed.  
 
 Description of cohort, markers and mir-34a units 5.6
Analysis of basal expression of mir-34a was performed on 166 samples 
representing 161 CLL patients, 5 of which had a subsequent sample from a 
later time-point tested. These samples were selected to represent as many 
sub-groups of interest as possible and they are not intended to represent a 
specific clinical cohort of CLL patients. The sample selection was enriched for 
cases with mono and bi-allelic abnormalities of ATM and TP53, samples 
which show dysfunction but do not have these poor prognosis markers, and 
samples with forms of dysfunction for which the mechanism responsible is in 
dispute (Type–C/p21failure).  
The aims of using this group are to determine whether the measurement of 
basal mir-34a is a reliable indicator of TP53 abnormalities, whether it can 
detect ATM abnormalities (both mono and bi-allelic) and also how it relates to 
the categorisation of samples using the etoposide/nutlin assay. 
 
 Mir-34a expression results 5.7
Of 161 individuals tested, 114 had FISH and mutation screening results for 
both ATM and TP53. Figure 5-7 (p131) shows the results of mir-34a analysis 
for these 114 cases split broadly into those with no involvement of either ATM 
or TP53 (n=55), ATM gene involvement (n=28) or TP53 involvement (n=31). 
The data for each of these groups was not normally distributed so they were 
analysed using non-parametric methods. The results, summarised in  
Table 5-5 (p131), show that despite differences in both the means and 
medians between the groups there is considerable overlap in the range of 
data. The comparison of median mir-34a results between each of the three 
groups (Figure 5-7 ,p131) suggests that abnormalities of TP53 (median 
mir34a=1.30) sufficiently alter mir-34a levels to make them discernible from 
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cases with no abnormalities detected (median mir34a=14.80, z=-5.356, p< 
.001) and cases with abnormalities of the ATM gene (median mir34a=11.41, 
z=-4.516, p<.001).  
 
Figure 5-7: Results of mir-34a analysis showing the three main genotypic 
groups (n=114). 
These results show that there is a significant difference in the mean mir-34a 
result for each of the three group comparisons. The median mir-34a result for 
the group with involvement of TP53 was significantly different to the group 
with no detected abnormalities and the group with abnormalities of the ATM 
gene. The difference between the ATM involved group and those samples 
with no abnormalities was not found to be significant.  
 
 
Table 5-5: Summary of mir-34a relative expression results (n=114). 
 
Mir-34a results for 114 cases with full FISH and mutation screening for ATM 
and TP53. Although the mean mir-34a results for each genotypic group were 
different between groups it can also be seen that there is considerable overlap 
between the groups. This suggests that a cut-off value for p53 related mir-34a 
under-expression may be difficult to determine. 
 
With regards the lower average mir-34a result for ATM involved cases 
compared to those with no detected abnormalities, the lack of a significant 
N=55 N=31N=28
P< .001
P< .001 
P= .292
ATM & p53 Wildtype 55 20.29 14.80 22.59 .616 133.200
ATM involved 28 13.22 11.41 10.46 1.040 43.980
p53 involved 31 3.81 1.30 5.21 .007 17.090
 
N Minimum MaximumMean Median
Std. 
Deviation
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difference in median (z=-1.055, p= .296) suggests that the difference is not 
sufficient to reliably separate the two genotypes although it is of note that the 
mean and median for those cases is intermediate to the no abnormality and 
TP53 involved groups. The ATM and TP53 involved group were analysed in 
more detail in order to determine whether different combinations of poor risk 
markers affected mir-34a expression differently. 
 
 Hsa-Mir-34a levels in samples with ATM  5.8
abnormalities 
It has been shown in recent analysis of the UKCLL4 trial cohort that there is a 
difference in outcome between cases with mono or biallelic ATM 
abnormalities (Skowronska et al. 2012). Therefore the 30 cases with ATM 
gene defects were subdivided into those with mono-allelic deletion detected 
by FISH (n=11), mono-allelic mutation (n=6) and biallelic inactivation (n=13). 
The results are displayed in Figure 5-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The median value of mir-34a in samples with bi-allelic inactivation of 
ATM was not significantly different to those with either monoallelic 
deletion or mutation. There was also no difference detected between 
cases with either type of mono-allelic abnormality. 
 
N=11 N=6 N=13
p= .639
p=1.0
p= .531
Figure 5-8: Boxplot showing mir-34a expression in the sub-categories 
of ATM abnormality (n=30) 
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It can be seen that there was no significant difference in the expression of mir-
34a regardless of the type of ATM abnormality. All of the cases with mono-
allelic mutation had non-truncating mutations but the cases with bi-allelic 
inactivation could be split into those with deletion of ATM accompanied by 
non-truncating (n=9) and truncating (n=4) mutations. None of the differences 
between any of these genotypic groups was significant although very low 
numbers may be responsible for this (Figure 5-9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to low numbers the lack of significance may not be due to an 
absence of effect but the figure would suggest that different 
combinations of ATM abnormality cannot be differentiated by the 
baseline level of mir-34 and therefore that ATM abnormalities do 
not affect the basal transcription of mir-34a. 
 
The results of this section show that the mir-34a levels in cases with 
involvement of the ATM gene are not significantly lower than those cases with 
no involvement of ATM or TP53 (detected by FISH or mutation screening) and 
the broad overlap of results means that they cannot be easily differentiated 
from one another. The analysis of median mir-34a levels in the different 
genotypic sub-groups of ATM abnormality suggests that the differing effects of 
truncating/ non-truncating mutations and mono-/ bi-allelic inactivation seen in 
the UKCLL4 cohort may relate specifically to the response to therapy and that 
N=11 N=6 N=9 N=4
P=1.0
P= .607
P= .710
P= .949
P= .456
P= .914
Figure 5-9: Mir-34a results for samples with ATM abnormalities 
subdivided to show the effects of truncating and non-truncating 
mutations (n=30) 
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these abnormalities have little distinguishable effects on the basal expression 
of mir-34a. In contrast, TP53 has previously been shown to impact upon the 
basal expression of mir-34a (Zenz et al. 2009) and so it was decided to 
confirm this previous finding within the cohort and test how the results of the 
functional assay relate to this. 
 
 Hsa-mir-34a levels in samples with TP53 5.9
abnormalities 
Of the 114 samples with full FISH and mutation screening of both ATM and 
TP53, thirty-three were found to harbour some abnormality of TP53 and this 
was shown, in section 5.7 (p130), to associate with lower levels of mir-34a 
than those found in those cases with no abnormalities or with ATM 
abnormalities. Subdivision of these 30 samples according to the combinations 
of gene defects is shown in Figure 5-10 (p136). The majority of cases 
displayed biallelic inactivation of TP53 (22/30; 72%) which in all except one 
case consisted of deletion of one allele detected by FISH and mutation of the 
second. The single exception to this was determined to have bi-allelic 
mutation of TP53, confirmed by cloning and sequencing of genomic DNA (one 
missense mutation on one allele and a 10bp deletion on the second allele). 
Mono-allelic deletion accounted for 18% of cases (5/30) and mono-allelic 
mutation 10% (3/30). No statistically significant difference was found between 
the three genotypes but this may be due to the lack of numbers in the different 
groups. The descriptive data for these sub-groups is shown in Table 5-6. 
Cases with mono-allelic deletion of TP53 do not have the very low levels of 
mir-34a that appear to be evident in the cases involving a mutation of TP53. 
This suggests that one wildtype allele of TP53 may be sufficient to maintain 
the basal level of mir-34a. Of the three cases with mono-allelic mutation of 
TP53, sequence data was available on two and this demonstrated that one 
case had loss of heterozygosity (LOH) resulting in no wildtype TP53 being 
present whilst the other had equal proportions of mutant and wildtype DNA, 
indicating that the entire CLL clone was mutated. 
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Table 5-6: Descriptive mir-34a relative expression data for 30 cases with 
abnormalities of TP53 
 
Summary showing the mean, median and range of mir-34a results 
obtained for sub-groups with abnormalities of TP53. Despite the low 
numbers in the groups with mono-allelic abnormalities there is a 
suggestion that cases that do not involve a mutation of TP53 have 
higher mir-34a expression. 
 
 
 
  
 
  
Genotypic group N Mean Median Minimum Maximum
p53 deletion only 5 9.27 7.96 .007 19.880
p53 mutation only 3 1.43 0.54 .222 3.530
p53 biallelic 22 3.68 0.95 .126 17.090
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In order to detect any effect of dosage, the clone sizes of the 20/30 cases with 
loss of TP53 detected by FISH for which the percentage of cells with loss was 
known were plotted against their matched mir-34a results (Figure 5-11).  
 
Figure 5-11:Scatter plot showing the matched mir-34a and Del(17)p FISH clone size 
data for 20 cases with involvement of TP53. 
The case labelled as ATM deletion-only had 90% loss of the ATM locus determined 
by FISH but also had a very small clone (7%) which appeared to have deletion of the 
TP53 locus. Pearson analysis found a significant negative correlation between the 
two variables (r[20]= -.760, p< .001).  
 
The results show that there is a clear trend for the cases with highest 
proportion of 17p-deleted cells to have the lowest mir-34a levels. These two 
variables were found to significantly correlate with each other (r[20]= -.760, p< 
.001).  
It can however be seen that some samples do not follow the trend. For 
example two bi-allelic cases are evident that have approximately equal FISH 
clone sizes (25 v 28%) but disparate mir-34a results (13.559 v 0.149). 
Relevant information on these two cases is shown in Table 5-7 and 
electropherogram images of the detected TP53 mutations are shown in Figure 
5-12.  
 
Percentage of 17p deleted cells 
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Table 5-7: Details of two cases with similar bi-allelic TP53 inactivation and differing 
levels of mir34a. 
 
 
It can be seen that there are differences in terms of the mutation identified, 
response to etoposide treatment, and published residual activity of the 
identified mutations towards both the CDKN1A (p21/Waf1) and MDM2 
promoters which was obtained from the IARC TP53 mutation database. This 
suggests that the nature and location of the mutation has an effect upon the 
differing levels of basal mir-34a transcription with some being similar to 
wildtype.  
 
 
Figure 5-12: Electropherograms of two 
cases with similar bi-allelic TP53 
inactivation and differing levels of mir34a. 
 
 
The overlapping distribution of the results for both the ‘wildtype’ and TP53 
involved groups is shown in Figure 5-13 as a pyramid diagram, where it can 
be seen that setting a cut-off value for mir-34a expression to detect a majority 
of TP53 abnormalities will likely include a substantial number of the ‘wildtype’ 
cases. This shows that in the majority of cases the basal expression of mir-
34a is negatively affected. However, despite many of the cases with mono- or 
bi-allelic inactivation of TP53 having very low mir-34a levels, nearly a quarter 
(7/30; 23%) had mir-34a levels in excess of 10 which would place them within 
the interquartile range of the samples with no detected abnormalities of ATM 
or TP53.  
Case No Mir-34a 17p Clone sizeTP53 mut MDM2 Waf1 p53 p21 
127 13.559 25% S241Y 0 10.8 349 21
108 0.149 28% M237I 11.5 0.7 0 0
Promoter activity (% 
of W/T)*
Increase over baseline in 
response to Etoposide
LRF 108 LRF 127
p.M237I
ATG>ATA
p.S241Y
TCC>TAC
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Figure 5-13: Pyramid diagram comparing the distribution of mir-34a relative 
expression results of p53 and ATM wildtype cases with p53 involved cases. 
 
Receiver Operator Characteristics (ROC) were used to attempt to set a cut-
off, using all 114 mir-34a relative expression results, to detect cases with any 
involvement of TP53. The ROC curve is shown in Figure 5-14. To maximise 
sensitivity and specificity a mir-34a cut-off of 2.30 would give 85.5% sensitivity 
and 66.7% specificity, correctly identifying 66% (20/30) of the cases with 
abnormalities of TP53 and incorrectly identifying 14% (12/84) of the cases 
with no abnormalities of TP53.  
 
Figure 5-14: Receiver Operator Characteristics curve 
Area = 83.6%
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 Hsa-Mir-34a levels in samples with no detected 5.10
abnormalities of ATM  or TP53. 
A total of 54 samples had no abnormalities of ATM or TP53 detected by FISH 
and mutation screening/sequencing and they are displayed in Figure 5-15, in 
descending order of mir34a relative expression results with markers to show 
the median and interquartile range. 
 
Figure 5-15: All samples with no detected FISH loss or 
mutation of ATM or TP53 (n=54) 
Samples are arranged in descending mir-34a value. The 
median (mir-34a=15.92), 25th (mir-34a=4.63) and 75th 
(mir-34a=25.24) percentiles are shown, delineating an 
interquartile range of 20.61. 
 
The mean and median mir-34a results for this group were 21.16 and 15.92 
respectively (SD=22.88). The comparison of the range (0.616-133.2) and 
interquartile range (4.63-25.24) shows that this sample group contained one 
outlier case with very high mir-34a and a substantial number of cases with 
very low mir-34a results and this was also previously observed in Figure 5-13 
(p139). A timeline of clinical events for the case with very high mir-34a 
expression, LRF 145, is described in Figure 5-16. This patient was diagnosed 
at Binet/Rai stage B3 in December 2008, three months previous to donating 
the sample that was analysed. It can be seen that this patient did not respond 
to treatment with fludarabine and cyclophosphamide and in-vitro testing with 
the etoposide/ nutlin functional assay identified the sample as a non-
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responder They were subsequently treated with the mono-clonal, antibody 
therapy, Alemtuzumab, to which they had a general partial response. At their 
last follow-up (24th August 2010), they had not required further treatment. 
 
Figure 5-16: Case LRF145 displayed unusually high expression of mir34a (mir-
34a=133.6). The case was functionally classed as a non-responder. 
 
This suggests that exceptionally high levels of mir34a may also predict DNA 
damage response pathway failure in cases with no other high risk 
abnormalities.  
Functional analysis results were available for 44/54 of the p53 and ATM 
wildtype samples. They are shown in Figure 5-17, grouped according to 
functional assay result and showing the interquartile range. 
 
Figure 5-17: Mir-34a results for 44/54 (81%) of cases that 
had no detected abnormalities of ATM or TP53 by FISH 
stratified by functional assay result and showing 
interquartile range. 
 
Diagnosis
Stage B3
20.12.2008
Last Follow-up
24.08.2010
Sampled 
18.03.2009
Category-1
No abnormalities 
of ATM or TP53
Mir-34a=133.6  
Treated 1
06.01.2009
Fludarabine + 
Cyclophosphamide
No Response
Treated 2
24.04.2009
Alemtuzumab
General partial 
response
LRF 145- Timeline
Functional response category
Normal Category-1 Category-2 Category-3 Category-4Non-responder p21-failureNutlin-responderNormal Unclassified
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Dysfunction was detected in 13/44 (30%) cases and these were unequally 
distributed towards the lower (5/13, 38%) quartile as opposed to the upper 
quartile (3/13, 23%) and the interquartile range (5/28, 18%). This suggests 
that baseline mir-34a expression may be deregulated by mechanisms apart 
from ATM or TP53 gene loss and/or mutation and that this results in the low 
basal expression seen in cases with TP53 abnormalities. The cases which 
showed dysfunction despite no TP53 or ATM gene defects being detected by 
FISH or mutation screening were further investigated using all data that was 
available of those cases.  
Alternatively it could be hypothesised that the low level of mir34a in cases 
with no detected mutation of TP53 or loss of 17p detected may be due to 
deregulation of the DNA damage response through a p53-independent 
mechanism. In total 16/55 samples with no detected abnormalities of either 
gene had mir-34a levels that measured within the 99% confidence interval for 
cases with detected involvement of p53 (1.42-6.97, n=33). These cases were 
examined further. Of those with data available it was known that 8/13 had 
been previously treated, of whom 7/8 were then subsequently treated after the 
date of the sample tested. One further case, not previously treated was 
treated after the date of the sample.  
 
 Summary 5.11
This section has shown that measuring the relative expression of the micro 
RNA hsa-miR-34a in unstressed CLL cells can identify cases with 
abnormalities of the TP53 gene but not ATM. Therefore the null hypothesis for 
this section will be accepted: ‘Basal miR-34a expression is not an indicator of 
ATM and p53 function in CLL’. There is however considerable overlap 
between groups with and without TP53 involvement. An attempt to set a miR-
34a cut-off value for detecting TP53 abnormalities was made using receiver 
operator characteristics (ROC). A cut-off of 2.30 would give 85.5% sensitivity 
and 66.7% specificity, correctly identifying two thirds of the cases with 
abnormalities of TP53 but incorrectly identifying 14% of the cases with no 
abnormalities of TP53.  
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6 Chapter Six: 
 
 
Results 
 
Validating assay samples 
  
 145 
 Overview 6.1
It was decided to investigate the effects of storage and transport upon 
peripheral blood mononuclear cells derived from whole blood specimens 
delivered from a number of centres around the UK. In the case of LRF study 
samples this involved the transport of venesectioned whole blood in 
vacutainers containing Lithium/heparin preservative. Samples sent from 
Leicester were cryo-preserved aliquots of peripheral blood mononuclear cells 
(PBMCs). 
 
 Hypothesis  6.2
The hypothesis for this chapter is as follows: 
Hypothesis: 
Assay results will be affected by prolonged time between venesection of blood 
sample and storage of PBMCs. 
Null hypothesis: 
Assay results will not be affected by prolonged time between venesection of 
blood sample and storage of PBMCs. 
  
 
 Preliminary investigation on ambient effects 6.3
Whole blood from local CLL patients (n=10) was collected and then aliquots 
were taken into 5 ml sterile plastic tubes and resealed. These aliquots were 
stored at different temperatures (room temperature, 37oC and 4oC) and for 
different time periods (24 and 48 hours) before separation of the PBMC 
fraction and cryo-preservation as described in section 2.3. The remainder of 
the whole blood sample was processed for PBMCs as normal. A portion of 
2x10^7 cells were taken after centrifugal separation of blood. These were 
immediately placed into the functional assay culture conditions and are further 
described as ‘fresh’. Finally, an aliquot of fully processed PBMCs (2x10^7 
cells.ml-1) was frozen in an ultra-low temperature freezer (-80oC) instead of a 
liquid nitrogen container (-175oC). All assay conditions (excluding the ‘fresh’) 
from each separate whole blood sample were kept frozen for a minimum of 
 146 
one week before being retrieved, thawed and tested concurrently using the 
functional assay as described in the methods section.  
Cell viability was assessed on cells sampled before, and cells sampled after, 
overnight incubation in the functional assay control culture using the Trypan-
Blue dye exclusion test as described in section 2.4. Viability is defined as the 
percentage of cells excluding the dye. The results of all replicates for six 
patients are shown in Figure 6-1. This preliminary data shows that storage at 
37oC is the most detrimental variable introduced. It can also be seen that 
there is a repeated negative impact on viability introduced by the process of 
overnight culture as per the functional assay methodology described in 
section 2.14. CLL cells do die spontaneously in-vitro however. 
 
Figure 6-1: Mean percentage of viable cells after storage under 
different conditions 
Results of viability testing using Trypan blue exclusion test. All replicates for 6 
individuals are shown. LN2 = Liquid nitrogen storage. 
 
 
Table 6-1 below shows the functional assay results of 10 whole blood 
samples, handled and stored as previously described. These include the 
individuals in Figure 6-1 plus four other individuals for whom the Trypan-Blue 
data had not been collected.  
  
0.0% 
20.0% 
40.0% 
60.0% 
80.0% 
100.0% 
120.0% 
Fresh LN2 -70C 24hr 4oC 24hr 37oC 24hr rt 48hr rt 
Cell viability pre-culture Cell viability post-culture 
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Table 6-1: Functional assay results for sample storage study. 
 
 
 
 
 
Storage at 37oC is again shown to be the most detrimental factor. The single 
discordant result for a sample stored for 24 hours at 4oC came from patient (a) 
who has returned a p21-failure result on all other occasions of testing (n=3) 
and is known to have low level loss of 17p13.1 (~10%). Patient (h) is a normal 
functioning sample with no currently identified abnormality that has shown a 
normal result previously. Patient (j) has on all other occasions (n=3) returned 
either non-responder or p21-failure results and is known to have loss of 
17p13.1. Notwithstanding the three samples from patients a, h and j 
highlighted in Table 6-1, it is clear that temperature is a more immediate 
critical factor than duration of storage. Although some testing is still required, 
the reduced sample viability after 48 hrs at room temperature and pressure 
(RTP) does not seem to affect reproducibility. Therefore samples which are up 
to two days old and that have not been stored in excessive heat may still be 
acceptable for the assay. 
 
 Investigating effects caused by delays between 6.4
venesection and processing  
6.4.1 Samples used in this section 
The patient cohort used in this study was derived from samples that were 
obtained from the local CLL clinic, n=112, and also from referring participant 
clinics across the UK, n=134 (LRF group). Samples derived from the latter 
Sample
Immediate 
assay 
Immediate 
cryo-storage 
Immediate 
storage -70°C
24hours 
at 4°C *
24hours 
at 37°C *
24hours 
at RTP *
48hours 
at RTP *
a 3 3 3 1 1 3 NT
b 2 2 2 2 2 2 2
c N N N N 1 N N
d 2 2 2 2 2 2 2
e N N N N N N N
f N N N N N N N
g N N N N N N N
h N 1 N N 1 N N
i N N NT N 2 N NT
j N 1 1 1 1 1 1
Lymphocytes were separated from aliquots of whole blood immediately or after storage at 
different temperatures and for different time periods. Conditions returning an aberrant result 
are highlighted.  
RTP: room temperature and pressure; * before cryo-storage in liquid nitrogen; NT not tested. 
1 = Non-responder; 2 = Nutlin-responder; 3 = p21-failure; N = normal 
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were delivered to the Bournemouth laboratory as lithium/heparin preserved 
whole blood samples and would have spent a minimum of one day in transit. 
It was not assumed that the analysis of these samples would generate the 
same functional results as locally sourced samples. In order to control for any 
differences introduced by the transport of samples this section will look at 
whether viability of the samples and/or the expression of p53 and p21 from 
these two subsets differed. The measure of cell viability used in this section 
was derived from the light scattering properties of the cells. This data was 
recorded by the FACScalibur flow cytometer at the same time as 
measurements of p53 and p21 protein was made for the etoposide and nutlin 
functional assay.  
 
6.4.2 Comparison between two techniques for measuring cell 
viability 
In order to compare the two techniques available for measuring cell death, the 
percentage of cells determined as live using the Trypan Blue exclusion test 
was compared to the percentage of cells determined to be viable by their light 
scattering properties. Trypan blue data was collected for 64 cases and a 
correlation with the percentage of cells in the live gate was tested for. The 
matched results are shown below in Figure 6-2.  
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Figure 6-2: Scatter plot showing the matched Trypan-blue 
and live-gate data for 64 paired data points. The data display 
a linear, positive correlation between the two measurements 
(n=64, r=.676, p<.001) 
 
The mean percentages of live cells determined by the Trypan-Blue exclusion 
test (x̄=69%, SD=20.07) and the percentage of events in the FACS live gate 
(x̄=70%, SD=15.92) were similar and the two variables were not found to differ 
significantly in terms of distribution (p=0.701). The average difference 
between each matched result was not significantly different to zero (x̄=-0.72%, 
95% CI=-4.46-3.02, t=-0.384, p=0.702). The percentage of cells considered to 
be alive based upon their light scattering properties will therefore be referred 
to as the viability for the remainder of this result section. 
Establishing that the viability data correlates with assessment of cell viability 
determined using the Trypan Blue exclusion test meant it was possible to use 
this data to test for effects on cell viability which may have been introduced 
during the time between venesection and sample processing. 
6.4.3 Effects on cell death by drug treatments 
 
Analysis of cell death rates was performed on the 112 samples which had 
viability data calculated for the control, etoposide and etoposide plus nutlin 
cultures, and which also had no detected abnormalities of either the ATM or 
TP53 genes as determined by FISH and mutation screening/ sequencing. The 
Komorgorov-Smirnov statistic was significant (p<.05) for both control and 
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etoposide plus nutlin treated culture data therefore they were treated as not 
normally distributed. The etoposide treated culture data was normally 
distributed (p=.2). It was assumed there would be some spontaneous 
apoptosis in the control culture and that additional cell death would be 
detected in the etoposide culture which would be further enhanced by the 
addition of nutlin. The paired data are shown in Figure 6-3, arranged, left to 
right, in descending order of calculated viability in the control culture.  
 
Figure 6-3: Paired viability data for control, etoposide and etoposide + nutlin 24hr 
cultures (n=112). Showing the paired data for the three treatment conditions and 
displayed in order of descending percentage of viable cells in the control culture. 
              
As expected, the percentage of live cells in the control (Mean=69.3%; SD=16) 
was significantly higher than in the etoposide treated culture (Mean 53.4%; 
SD=17.3; p< .001) and the etoposide plus nutlin culture (Mean 
48.4%;SD=18.1; p< .001). The figure also shows that there is considerable 
variation in the reduction of live cells caused by etoposide (Mean=-15.8%; 
SD=10.9%; Median=-13.5%; Range=-48-6). The additional reduction in live 
cells due to nutlin3a can also be observed and it appears closely related to 
the effect of etoposide (Mean=-5%; SD=4.5%; Median=-4%; Range=-20-6). 
Bivariate analysis of the 112 paired cases found the amount of cell death in 
N=112
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the control culture to be significantly correlated with the level of cell death in 
the both the etoposide (n=112, r= .787, p< .001) and etoposide plus nutlin 
(n=112, r = .742, p< .001) cultures. A much stronger correlation was seen 
between the drug treated cultures (n=112, r = .969, p< .001). 
The paired data were then clustered according to the recorded time between 
sample venesection of the whole blood sample at the contributing centre and 
arrival in the laboratory (Figure 6-4). This was to determine whether the 
variation in effect of the drug treated cultures was introduced during this time.    
 
Figure 6-4: Paired viability data (n=112) stratified by the number of days between 
venesection and processing. Panels show data for the three treatment conditions. 
Data is displayed in descending order of viability in the control culture. 
 
 
It can be observed that viability tended to drop with increasing time since 
venesection. It can be seen that the variation in effect on viability caused by 
etoposide is not attributable to time since venesection. This variation may 
probably be due to inherent differences between samples. This is of interest as 
approximately one-third of patients who relapse after therapy do not have any 
detectable abnormalities of ATM or TP53. 
6.4.4 Spontaneous apoptosis is higher in samples which have 
spent a day or more between venesection and processing 
 
One-way ANOVA was used to compare the level of cell death between the 
samples which were processed the same day as venesection (n=58) and the 
N=58
N=28
N=22
N=4
 152 
samples which had an intervening period of one day or more (n=54). A 
boxplots of the results are shown in Figure 6-5, (panel A). This showed a 
significant reduction in live cells in the one day or more group for the control 
(73.6%v65%; F=9.279; p= .003), etoposide (58%v48.6%; F=8.744; p= .004) 
and etoposide plus nutlin (53.6%v42.9%; F=10.481; p= .002) culture 
conditions. A similar comparison of the samples which had a one-day interval 
between venesection (n=28) and those which had an interval of two-days or 
more (n=26) is shown in Figure 6-5 (Panel B). A significant reduction in the 
two days or more group was only found for the control culture (68.8%v60.5%; 
F=4.471; p= .039) although viability was still reduced in both the etoposide 
(51%v46%) and etoposide plus nutlin (44.2%v41.5%) conditions. These 
results suggest that the effect of time between venesection and processing on 
cell death may be cumulative but is most pronounced during the first 24hours. 
Having shown an effect upon the level of cell death caused by some 
mechanism related to the time between venesection and sample processing it 
was decided to test for the same effects in those cases which had detectable 
abnormalities of ATM and/or TP53. Defects of these genes, in particular 
TP53, and their respective protein products may modulate the cellular 
responses to stress insults during this time. 
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6.4.5 Spontaneous cell death is higher in samples with 
abnormalities of TP53 
The samples with abnormalities of ATM or TP53 were analysed to determine 
whether these abnormalities had any impact upon the rate of cell death in 
samples which had been in transit for a day or more. Given the role of p53 
protein in response to many diverse cellular stresses it seems reasonable to 
assume that genetic abnormalities involving TP53 might affect the rate of cell 
death in transported samples. Control culture viability data was available for 
64/97 samples which had detected abnormalities. Figure 6-6 shows that for 
the group with abnormalities (ATM and/or TP53) there is a lower median 
viability in the samples that have been transported (Median=63%, n=35) than 
those that had not (Median=72%, n=29). This difference was not significant 
(z= -1.363, p= .173). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: For 29 samples which took less than a day, the 
median control viability was 72% (range 13-94%), compared 
to a median of 63% (range30-90%) for the 35 samples which 
took a day or more. Despite this reduction in median value the 
difference was not statistically significant (z= -1.363, p= .173). 
 
In order to determine whether the lack of effect was due to differences 
between the ATM and TP53 involved cases these two genotypic groups were 
tested individually. Data for cases with ATM involvement is shown in Figure 
6-7, grouped according to time between venesection and processing in the 
P= .173
Figure 6-6: Control culture viability data for sixty-four samples 
with abnormalities of ATM or TP53. 
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laboratory. It can be seen that samples which took one day or more (n=13, 
median=68%, range=30-87%) had lower viability than those cases which took 
less than one day (n=10, median=83.5%, range=18-94%) but the difference 
was not significant (z=-1.799, p= .077 [Exact Sig.]).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The viability data for the control cultures in cases with known abnormalities of 
TP53 is shown in Figure 6-8, grouped according to time between venesection 
of the sample and processing in the laboratory.   
 
Figure 6-8: Differences in control culture viability for 
cases with TP53 gene abnormalities. 
Figure 6-7: Differences in control culture viability for cases 
with ATM gene abnormalities. 
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Samples with deletion and/or mutation of the TP53 gene which took one day 
or more to be processed (n=22, median= 60.5%, range=38-90%) had only a 
slighter lower level of cell viability than those cases which took less than a day 
(n=19, median=66%, range=13-84%) and the difference was not significant 
(z=-0.549, p= .583). 
Despite no statistically significant difference between the 0-Day and 1-Day or 
more groups for either genotype the difference between the two groups for the 
ATM involved cases was starkly different to those cases with TP53 
involvement. 
In addition to the finding that cases with TP53 defects may have different 
levels of spontaneous cell death than cases with ATM gene defects, 
comparison of the 0-day group with no abnormalities to the 0-day groups in 
each of these genotypes (Figure 6-9, p158) showed that the percentage of 
live cells in the cases with ATM abnormalities (n=10, median=83.5%, 
range=18-94%) was not significantly different to that observed in the cases 
with no detected abnormalities (n=60, median=79%, range=20-93%, z=-
1.050, p= .294). In contrast the percentage of live cells in the TP53 involved 
cases (n=19, median=66%, range=13-84%) was significantly lower than the 
cases with no abnormalities (z=-2.428, p= .015) and those with ATM 
involvement (z=-2.158, p= .031 Exact). This difference was lost when 
performing the same analysis on samples which had taken a day or more. 
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6.4.6 Analysis of basal p53 and p21 protein levels 
Having shown a significant effect upon cell death between samples which had 
or had not been transported using the live cell percentage data, the median 
fluorescent intensity (MFI) data was similarly analysed to determine if the 
transport of samples also affected the expression of p53 and p21 proteins. 
This analysis was performed on the samples which had no detected 
abnormalities of ATM or TP53 first (n=149). The results in Figure 6-10 (p159) 
and Table 6-2 shows that the level of p53 and p21 in the control culture was 
not significantly affected by transport suggesting that any possible activation 
of p53 controlled stress responses during transport and storage did not carry 
over into the culturing of cells. 
Table 6-2: Descriptive data for basal p53 and p21 protein levels in samples. 
 
 
 
MFI variable
Days since 
venesection
N
Mean 
MFI
Std. 
Deviation
t -score Sig. (2-tailed)
Zero Days 72 3.85 0.79
One Day or More 77 3.73 0.68
Zero Days 72 3.23 0.51
One Day or More 77 3.14 0.38
p21 Control 1.156 .249
p53 Control 1.027 .306
Group statistics t-test for Equality of Means
 158 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A
B
0
-D
a
y
 g
ro
u
p
1
-D
a
y
 o
r 
m
o
re
 g
ro
u
p
P
=
 .
2
9
4P
=
 .
0
1
5
P
=
 .
0
3
1
P
=
 .
8
9
6
P
=
 .
4
5
0 P
=
 .
6
2
5
Percentage live cells
Percentage live cells
A
B
0
-D
a
y
 g
ro
u
p
1
-D
a
y
 o
r 
m
o
re
 g
ro
u
p
P
=
 .
2
9
4P
=
 .
0
1
5
P
=
 .
0
3
1
P
=
 .
8
9
6
P
=
 .
4
5
0 P
=
 .
6
2
5
F
ig
u
re
 6
-9
: 
C
o
m
p
a
ri
s
o
n
 o
f 
th
e
 p
e
rc
e
n
ta
g
e
 o
f 
liv
e
 c
e
lls
 in
 t
h
e
 c
o
n
tr
o
l c
u
ltu
re
 a
c
ro
s
s
 th
e
 d
iff
e
re
n
t 
g
e
n
o
ty
p
ic
 s
u
b
-g
ro
u
p
s
. 
P
a
n
e
l 
A
) 
In
 s
a
m
p
le
s
 t
h
a
t 
to
o
k 
le
s
s
 t
h
a
n
 a
 d
a
y 
to
 a
rr
iv
e
 i
n
 t
h
e
 l
a
b
, 
8
9
 h
a
d
 d
a
ta
 o
n
 c
o
n
tr
o
l 
vi
a
b
ili
ty
. 
T
h
e
 p
e
rc
e
n
ta
g
e
 o
f 
liv
e
 c
e
lls
 i
n
 s
a
m
p
le
s
 
w
ith
 n
o
 a
b
n
o
rm
a
lti
e
s
 d
e
te
c
te
d
 (
n
=
6
0
, 
m
e
d
ia
n
=
7
9
%
, 
ra
n
g
e
=
2
0
-9
3
%
) 
w
a
s
 n
o
t 
s
ig
n
ifi
c
a
n
tly
 d
iff
e
re
n
t 
to
 t
h
o
s
e
 s
a
m
p
le
s
 w
ith
 A
T
M
 in
vo
lv
e
m
e
n
t 
(n
=
1
0
, 
m
e
d
ia
n
=
8
3
.5
%
, 
ra
n
g
e
=
1
8
-9
4
%
, 
z=
-1
.0
5
0
, 
p
=
 .
2
9
4
),
 h
o
w
e
ve
r,
 s
a
m
p
le
s
 w
ith
 T
P
5
3
 i
n
vo
lv
e
m
e
n
t 
(n
=
1
9
, 
m
e
d
ia
n
=
6
6
%
, 
ra
n
g
e
=
1
3
-8
4
%
) 
w
e
re
 s
ig
n
ifi
c
a
n
tly
 d
iff
e
re
n
t 
to
 b
o
th
 t
h
e
 c
a
s
e
s
 w
ith
 A
T
M
 i
n
vo
lv
e
m
e
n
t 
(z
=
-2
.1
5
8
, 
p
=
 .
0
3
1
 E
xa
c
t)
 a
n
d
 t
h
o
s
e
 w
ith
 n
o
 d
e
te
c
te
d
 a
b
n
o
rm
a
lit
ie
s
 (
z=
-
2
.4
2
8
, 
p
=
 .
0
1
5
).
 P
a
n
e
l 
B
) 
In
 s
a
m
p
le
s
 w
h
ic
h
 t
o
o
k 
a
 d
a
y 
o
r 
m
o
re
 t
o
 a
rr
iv
e
 in
 t
h
e
 B
o
u
rn
e
m
o
u
th
 la
b
o
ra
to
ry
, 
9
1
 h
a
d
 d
a
ta
 o
n
 c
o
n
tr
o
l 
vi
a
b
ili
ty
. 
T
h
e
 
p
e
rc
e
n
ta
g
e
 o
f 
liv
e
 c
e
lls
 i
n
 s
a
m
p
le
s
 w
ith
 n
o
 a
b
n
o
rm
a
lit
ie
s
 d
e
te
c
te
d
 (
n
=
5
6
, 
m
e
d
ia
n
=
6
9
%
, 
ra
n
g
e
=
3
2
-9
2
%
) 
w
a
s
 n
o
t 
s
ig
n
ifi
c
a
n
tly
 d
iff
e
re
n
t 
to
 t
h
e
 
A
T
M
 i
n
vo
lv
e
d
 c
a
s
e
s
 (
n
=
1
3
, 
m
e
d
ia
n
=
6
8
%
, 
ra
n
g
e
=
3
0
-8
7
%
, 
z
=
-0
.1
3
0
, 
p
=
 .
8
9
6
) 
o
r 
th
e
 T
P
5
3
 in
vo
lv
e
d
 c
a
s
e
s
 (
n
=
2
2
, 
m
e
d
ia
n
=
6
0
.5
%
, 
ra
n
g
e
=
3
8
-
9
0
%
, 
z=
-0
.7
5
5
, 
p
=
 .
4
5
0
).
 T
h
e
re
 w
a
s
 a
ls
o
 n
o
 s
ig
n
ifi
c
a
n
t 
d
iff
e
re
n
c
e
 b
e
tw
e
e
n
 t
h
e
 c
a
s
e
s
 w
ith
 A
T
M
 a
n
d
 T
P
5
3
 i
n
vo
lv
e
m
e
n
t 
(z
=
 -
0
.4
9
5
, 
p
=
 .
6
2
5
 
 159 
 
 
 
 
 
 
 
 
  
P
 =
 .
3
0
9
 
P
 =
 .
2
4
9
 
A
B
P
 =
 .
3
0
9
 
P
 =
 .
2
4
9
 
P
 =
 .
3
0
9
 
P
 =
 .
2
4
9
 
A
B
F
ig
u
re
 6
-1
0
: 
B
a
s
a
l p
5
3
 a
n
d
 p
2
1
 M
F
I 
le
ve
ls
 i
n
 c
a
s
e
s
 w
ith
 n
o
 a
b
n
o
rm
a
lit
ie
s
 o
f 
A
T
M
/T
P
5
3
 g
ro
u
p
e
d
 b
y 
tim
e
 in
 t
ra
n
s
it.
 (
n
=
1
4
9
) 
T
h
e
s
e
 f
ig
u
re
s
 s
h
o
w
 t
h
a
t 
th
e
re
 w
a
s
 n
o
 s
ig
n
ifi
c
a
n
t 
e
ff
e
c
t 
o
n
 t
h
e
 e
xp
re
s
s
io
n
 o
f 
e
ith
e
r 
p
ro
te
in
 in
 t
h
e
 c
o
n
tr
o
l c
u
ltu
re
s
, 
s
u
g
g
e
s
ti
n
g
 t
h
a
t 
th
e
re
 w
a
s
 
n
o
 i
n
a
p
p
ro
p
ri
a
te
 a
c
tiv
a
tio
n
 o
f 
T
P
5
3
. 
P
a
n
e
l 
A
) 
T
h
e
 l
e
ve
l 
o
f 
p
5
3
 p
ro
te
in
 i
n
 s
a
m
p
le
s
 t
h
a
t 
to
o
k 
le
s
s
 t
h
a
n
 a
 d
a
y 
to
 a
rr
iv
e
 i
n
 t
h
e
 l
a
b
o
ra
to
ry
 
(n
=
7
2
, 
m
e
a
n
=
3
.8
5
, 
S
D
=
0
.7
9
) 
w
a
s
 n
o
t 
s
ig
n
ifi
c
a
n
tly
 d
iff
e
re
n
t 
fr
o
m
 t
h
o
s
e
 s
a
m
p
le
s
 w
h
ic
h
 t
o
o
k 
a
 d
a
y 
o
r 
m
o
re
 (
n
=
7
7
, 
m
e
a
n
=
3
.7
3
, 
S
D
=
0
.6
8
, 
t=
 
1
.0
2
7
, 
p
=
 .
3
0
6
).
 
P
a
n
e
l 
B
) 
T
h
e
 l
e
ve
l 
o
f 
p
2
1
 p
ro
te
in
 i
n
 s
a
m
p
le
s
 t
h
a
t 
to
o
k 
le
s
s
 t
h
a
n
 a
 d
a
y 
to
 a
rr
iv
e
 i
n
 t
h
e
 l
a
b
o
ra
to
ry
 (
n
=
7
2
, 
m
e
a
n
=
3
.2
3
, 
S
D
=
0
.5
1
) 
w
a
s
 a
ls
o
 n
o
t 
s
ig
n
ifi
c
a
n
tly
 d
iff
e
re
n
t 
to
 t
h
o
s
e
 t
h
a
t 
to
o
k 
a
 d
a
y 
o
r 
m
o
re
 (
n
=
7
7
, 
m
e
a
n
=
3
.1
4
, 
S
D
=
0
.3
8
, 
t=
1
.1
5
6
, 
p
=
 .
2
4
9
).
 
 
 160 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
P
 =
 .
0
1
5
 
P
 =
 .
0
2
4
 
A
B
P
 =
 .
0
1
5
 
P
 =
 .
0
2
4
 
A
B
F
ig
u
re
 6
-1
1
: 
E
to
p
o
s
id
e
 r
e
s
p
o
n
s
e
 p
5
3
 a
n
d
 p
2
1
 M
F
I 
le
ve
ls
 i
n
 c
a
s
e
s
 w
ith
 n
o
 a
b
n
o
rm
a
lit
ie
s
 o
f 
A
T
M
/T
P
5
3
 g
ro
u
p
e
d
 b
y 
ti
m
e
 in
 t
ra
n
s
it.
 (
n
=
1
4
9
) 
A
) 
T
h
e
 e
xp
re
s
s
io
n
 o
f 
p
5
3
 p
ro
te
in
 i
n
 s
a
m
p
le
s
 w
h
ic
h
 t
o
o
k 
le
s
s
 t
h
a
n
 a
 d
a
y 
to
 a
rr
iv
e
 i
n
 t
h
e
 la
b
o
ra
to
ry
 (
n
=
7
2
, 
m
e
a
n
=
 8
.6
3
, 
S
D
=
3
.5
2
) 
w
a
s
 
s
ig
n
ifi
c
a
n
tly
 d
iff
e
re
n
t 
to
 t
h
o
s
e
 s
a
m
p
le
s
 w
h
ic
h
 t
o
o
k 
a
 d
a
y 
o
r 
m
o
re
 (
n
=
7
7
, 
m
e
a
n
=
7
.3
5
, 
S
D
=
2
.8
4
, 
t=
 2
.4
5
5
, 
p
=
 .
0
1
5
).
 B
) 
T
h
e
 e
xp
re
s
s
io
n
 
o
f 
p
2
1
 p
ro
te
in
 i
n
 s
a
m
p
le
s
 w
h
ic
h
 t
o
o
k 
le
s
s
 t
h
a
n
 a
 d
a
y 
to
 a
rr
iv
e
 in
 t
h
e
 la
b
o
ra
to
ry
 (
n
=
7
2
, 
m
e
a
n
=
5
.2
2
, 
S
D
=
2
.0
4
) 
w
a
s
 s
ig
n
ifi
c
a
n
tly
 h
ig
h
e
r 
th
a
n
 t
h
o
s
e
 s
a
m
p
le
s
 w
h
ic
h
 to
o
k 
a
 d
a
y 
o
r 
m
o
re
 (
n
=
7
7
, 
m
e
a
n
=
4
.5
8
, 
S
D
=
1
.3
6
, 
t=
 2
.2
7
9
, 
p
=
 .0
2
4
).
 
 
 161 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P
 =
 .
0
1
0
 
A
P
 =
 .
0
2
1
 
B
P
 =
 .
0
1
0
 
A
P
 =
 .
0
2
1
 
B
S
h
o
w
in
g
 d
a
ta
 f
o
r 
1
4
9
 s
a
m
p
le
s
 w
ith
 n
o
 d
e
te
c
te
d
 a
b
n
o
rm
a
lit
ie
s
 o
f 
A
T
M
 o
r 
T
P
5
3
. 
 A
) 
T
h
e
 e
xp
re
s
s
io
n
 o
f 
p
5
3
 p
ro
te
in
 in
 s
a
m
p
le
s
 w
h
ic
h
 t
o
o
k 
le
s
s
 t
h
a
n
 a
 d
a
y 
to
 a
rr
iv
e
 i
n
 t
h
e
 l
a
b
o
ra
to
ry
 (
n
=
7
2
, 
m
e
a
n
=
 1
3
.4
6
, 
S
D
=
6
.8
7
) 
w
a
s
 s
ig
n
ifi
c
a
n
tly
 d
iff
e
re
n
t t
o
 t
h
o
s
e
 s
a
m
p
le
s
 w
h
ic
h
 t
o
o
k 
a
 d
a
y 
o
r 
m
o
re
 (
n
=
7
7
, 
m
e
a
n
=
1
0
.8
4
, 
S
D
=
5
.2
8
, 
t=
 2
.6
1
3
, 
p
=
 .
0
1
0
).
 B
) 
T
h
e
 e
xp
re
s
s
io
n
 o
f 
p
2
1
 p
ro
te
in
 i
n
 s
a
m
p
le
s
 w
h
ic
h
 t
o
o
k 
le
s
s
 t
h
a
n
 a
 d
a
y 
to
 
a
rr
iv
e
 i
n
 t
h
e
 l
a
b
o
ra
to
ry
 (
n
=
7
2
, 
m
e
a
n
=
6
.1
0
, 
S
D
=
3
.0
3
) 
w
a
s
 s
ig
n
ifi
c
a
n
tly
 d
iff
e
re
n
t 
to
 t
h
o
s
e
 s
am
p
le
s
 w
h
ic
h
 t
o
o
k 
a
 d
a
y 
o
r 
m
o
re
 (
n
=
7
7
, 
m
e
a
n
=
5
.1
6
, 
S
D
=
1
7
.2
, 
t=
 2
.3
3
9
, 
p
=
 .
0
2
1
).
 
F
ig
u
re
 6
-1
2
: 
A
n
a
ly
s
is
 
o
f 
p
5
3
 a
n
d
 p
2
1
 p
ro
te
in
 r
e
s
p
o
n
s
e
s
 t
o
 e
to
p
o
s
id
e
 p
lu
s
 n
u
tl
in
. 
 162 
6.4.7 Analysis of p53 and p21 protein responses in treated 
cultures 
Having shown that the baseline expression of p53 and p21 in the control 
cultures was not significantly affected by transport Figure 6-10 (p159), the 
responses of these two proteins to the treated cultures was examined in the 
149 cases with no detected abnormalities of ATM or TP53. This data is 
summarised in Table 6-3. The results in Figure 6-11 (p160) show that in 
response to etoposide a significant difference in p53 protein expression was 
observed between the samples which had taken more than a day to arrive in 
the laboratory (n=77, mean=7.35, SD=2.84) and those which had been 
processed the same day (n=72, mean= 8.63, SD=3.52, t= 2.455, p= .015). 
The same effect was observed for p21 protein expression (n=77, mean=4.58, 
SD=1.36 versus n=72, mean=5.22, SD=2.04, t= 2.279, p= .024). Figure 6-12 
(p161) shows the data for protein expression in response to etoposide plus 
nutlin. The same significant difference was observed between the two groups 
for both p53 expression (n=77, mean=10.84, SD=5.28 versus n=72, mean= 
13.46, SD=6.87 t= 2.613, p= .010) and p21 expression (n=77, mean=5.16, 
SD=17.2 versus n=72, mean=6.10, SD=3.03, t= 2.339, p= .021). What is not 
clear from this data is whether the effect is due to an actual difference in 
protein expression per cell between the two groups or if the increased cell 
death in the samples which took a day or more to arrive caused the mean to 
be lowered. 
Table 6-3: Descriptive statistics for p53 and p21 protein responses to 
etoposide and etoposide plus nutlin treated culture conditions. 
 
 
 
 
MFI variable
Days since 
venesection
N
Mean 
MFI
Std. 
Deviation
t -score Sig. (2-tailed)
Zero Days 72 8.63 3.52
One Day or More 77 7.35 2.84
Zero Days 72 13.46 6.87
One Day or More 77 10.84 5.29
Zero Days 72 5.22 2.04
One Day or More 77 4.58 1.36
Zero Days 72 6.10 3.03
One Day or More 77 5.17 1.72
p21 E+Nutlin 2.339 .021
p21 Etoposide 2.279 .024
p53 E+Nutlin 2.613 .010
Group statistics t-test for Equality of Means
p53 Etoposide 2.455 .015
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6.4.8 Effect of transport upon functional categorisation of samples 
In order to determine whether the reduced p53 and p21 protein responses 
might be sufficient to cause miss-categorisation of normal samples as 
dysfunctional, the MFI data for the treated cultures was converted into four 
variables representing the percentage increase above the respective control 
for p53 and p21, in both treatment cultures. These are the same metrics used 
for categorising sample responses according to Best et al. (2008b). Cut-offs of 
30% and 15% increase above the control for p53 and p21 respectively were 
used to define a normal response. The 99% confidence interval for the 149 
cases with no abnormalities was plotted. The results are shown in figures 
Figure 6-13 (p164) and Figure 6-14 (p165). When the data is displayed on a 
day-by-day basis, as shown in Figure 6-14, there appears to be a risk of three 
day old samples being capable of enough variation so as to be misclassified 
as dysfunctional. It should be noted however that the low numbers in the 
three-day group (n=6) may be responsible for the large confidence interval. 
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 Samples from different centres did not differ in 6.5
frequency of FISH results or assay results 
It was decided to retrospectively examine the frequency of FISH results and 
functional assay results across the different groups of samples which were 
tested in the main assay results in section 3 (p83). The distribution of 11q and 
17p FISH abnormalities across the three contributing centres is shown in 
Table 6-4. The proportion of normal vs abnormal FISH results did not differ 
significantly between the three centres (x2=11.321, df=10, p =.333). 
 
Table 6-4: Summary of FISH results grouped by contributing centre. (n=472) 
FISH results 
Contributing centre   
Bournemouth Leicester LRF study Total 
No loss 82 148 129 359 
Del(11)q 19 26 23 68 
Del(17)p 10 10 18 38 
x3 (17)p signals 1 0 0 1 
Tetraploidy 1 0 0 1 
Loss of both loci 1 3 1 5 
  114 187 171 472 
 
The distribution of functional assay results across the three sources of 
samples used is shown Table 6-5. The incidence of dysfunction was not found 
to differ significantly across the three centres (x2=9.547, df=10, p =.481). 
This shows that the three cohorts were generally similar to each other. 
 
Table 6-5: Summary of functional assay results grouped by contributing centre. 
(n=472) 
Functional assay 
classification 
Contributing centre   
Bournemouth Leicester LRF study Total 
Normal 83 121 117 321 
p53 over expression 2 1 5 8 
Non-responder 7 16 16 39 
Nutlin responder 13 32 20 65 
p21-failure 9 14 12 35 
Unclassified 0 3 1 4 
  114 187 171 472 
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 Evolution of dysfunction observed in patient samples 6.6
 
Longitudinal analysis of samples using the functional assay was available for 
48 CLL patients who provided two specimens of blood, a month or more 
apart. The intervals between sampling ranged from 1-44 months. The 
frequency of intervals is shown in Figure 6-15 
 
Figure 6-15: The distribution of interval times for 48 CLL 
patients sampled and tested twice. 
 
 
A total of 38/48 cases (79%) gave concordant assay results at both sampling 
points. The remaining 10 cases were further investigated to determine 
whether the changes were a result of changes in the patients tumour clone or 
if the assay was returning non-reproducible results in 21% of tests. Half of the 
10 cases which changed functional classification had displayed a normal 
response when first sampled and so may represent de novo dysfunction due 
to either acquired defects or then expansion of a dysfunctional sub-clone. 
Table 6-6 (p168) shows some details for those cases displaying acquired 
dysfunctional responses. It can be seen that two cases acquired deletion of 
17p at some point between sampling 
 
The figure highlights the 10 cases which changed response 
upon the second test. 
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Table 6-6: Details of five CLL cases which appeared to acquire dysfunction 
between two sampling points. 
 
 
The 5 remaining cases gave differing dysfunctional responses to the assay at 
both time-points tested. Details for these cases are shown in Table 6-7. It can 
be seen that there were two cases in this group which also acquired an 
abnormal FISH result after previously testing normal. 
 
Table 6-7: Details of CLL cases which appeared to change dysfunctional 
category between two sampling points (n=5).  
 
 
 
 Summary 6.7
The work in this chapter has attempted to address any impact on assay 
results which arise from the logistical matters of assessing cases referred 
from other centres. It was initially determined that extremes of temperature or 
excessive handling may have an impact on results and so a more in depth 
assessment was made. It was first established that using the light scattering 
properties of cells determined by flow cytometric analysis to ascertain viability 
was correlated to more conventional methods. This metric was then used to 
analyse cell viability in samples from different sources (local and referred) 
which had been used in the present study. It was found that as a group 
samples which had been transported from other centres did have attenuated 
cell viability and this association was significant. Interestingly this significant 
association was lost for the subgroup with TP53 abnormalities. In addition to 
Sample 
Number Assay 1 result Assay 2 result
Interval 
(months) FISH 1 FISH 2 Mutations
1 Normal Nutlin-responder 2 83% Del(11)q 83% Del(11)q
2 Normal Non-resonder 7 Normal Normal TP53 Miss-sense
3 Normal Non-responder 11 46% Del(17)p 60% Del(17)p TP53 Miss-sense
4 Normal Non-responder 29 Normal 34% Del(17)p TP53 2bp deletion
5 Normal p21-failure 30 Normal 75% Del(17)p TP53 Miss-sense
Sample 
Number Assay 1 result Assay 2 result
Interval 
(months) FISH 1 FISH 2 Mutations
1 Nutlin-responder Normal 2 20% 17p 25% 17p TP53 miss-sense
2 p21-failure Non-responder 8 45% 17p 68% 17p TP53 4bp insertion
3 p21-failure Non-responder 12 Normal Tetraploidy TP53 Miss-sense
4 Nutlin-responder Non-responder 23 Normal 68% 17p
5 Nutlin-responder Normal 46 78% 11q 88% 11q
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this the impact on p53 and p21 protein expression was investigated using the 
functional assay response data form cases with no detected abnormalities of 
ATM or TP53. Comparison of the 0-day group results to the 1-day or more 
group found that both p53 and p21 measurements were significantly different 
in all culture conditions. Investigating whether this attenuation would result in 
miss-classifying assay responses seemed to show that a delay of up to 2 days 
would not introduce sufficient change to result in falsely attributing 
dysfunction. However, the fact that the viability of samples was affected 
means that the null hypothesis for this section is accepted: ‘Assay results will 
be affected by prolonged time between venesection of blood sample and 
storage of PBMCs’.   
It has also been shown, by analysing sequential samples from the same 
individuals, that it is possible for the response obtained using the assay to 
change over time. It was also shown that this may represent the emergence of 
underlying genetic abnormalities or expansion of existing ones.  
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7 Chapter Seven: 
 
 
 
Discussion & Conclusion  
 171 
 Introduction 7.1
This section will be split in to several smaller discussions dealing with the 
individual results chapters and particular topics that are relevant to the thesis / 
project as a whole. 
 
 Assay Discussion 7.2
 
The main stated aim of this project was to determine the validity of the 
functional assay, described herein, as a means to detect abnormalities of two 
important DNA damage response pathway genes (TP53 and ATM) in primary 
CLL cells with the additional benefit of discriminating between the two. When 
the assay was first developed there were solid reasons for this aim. 
Fluorescent in-situ hybridisation (FISH) was and still is the only routine clinical 
test performed prior to therapy. FISH can detect with high sensitivity and 
specificity loss of the chromosomal loci containing genes of interest; which in 
the routine clinical setting often include TP53 and ATM. It has been shown in 
section 3.4 (p90) that the assay can detect a dysfunctional response in cases 
which are known to have loss of 17p13.1 (TP53) or 11q22.3 (ATM). The data 
displayed in Table 3-6 (p91) shows that the response classification made 
possible by the addition of nutlin3a did discriminate between loss of either 
gene in cases which failed to respond to etoposide, fulfilling one of the main 
aims of this project. It was noticeable however that a large proportion of cases 
with deletion of 11q22-23 (31/68) did not display a dysfunctional response, or 
rather the response was not so severely impaired that the sample did not 
exceed the previously defined cut off values (Best et al. 2008). It is important 
to note that of 359 cases with a normal FISH result, 82 (23%) were found to 
have a dysfunctional response to the assay. These 82 cases did not display 
uniform dysfunction and were found in each of the different categories of 
dysfunction and it can be seen in Table 3-6 that they account for at least half 
of the cases in each category. This could be due in part to mutations of ATM 
or TP53, although this cannot explain all the cases as mutations of these 
genes are most commonly associated with deletion of the other allele and it is 
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unlikely that the cohort contains such a high proportion of cases with mutation 
in the absence of deletion (Skowronska et al. 2012; Austen et al. 2007; Zenz, 
Kröber, et al. 2008).  
The results in section 3.5, (Table 3-11, p99) make it apparent that the ability 
of the assay to detect deleterious mutations was markedly different for ATM 
and TP53 mutants. Mutations of TP53 were regularly found to cause either 
high basal expression of the resting CLL cells or were associated with failure 
of p21 as either a non-responder or a p21-failure phenotype. In this study 
ATM mutations failed to account for cases with a nutlin-responder phenotype 
which contradicts the findings of previously published papers which have 
associated ATM mutations with failure to induce a DNA damage response 
(Best et al. 2008; Lin et al. 2012; Navrkalova et al. 2013). 
Aside from the unexpected results there are also a number of other factors 
which require some discussion.  
 Categorisation 7.3
Categorisation of the sample responses using the assay described herein is 
complicated by taking into account data for two proteins, p53 and p21, which 
have been exposed to three different culture conditions (one control and two 
treated). For example one sample, after etoposide treatment, gave a p21-
failure / Type-C response however after treatment with etoposide plus nutlin 
the sample gave a normal response. The question is therefore raised as to 
whether this case should be considered a p21-failure or a nutlin-responder? 
Most cases displaying a p21-failure response did so in both culture conditions 
and most cases classed as nutlin-responders gave a fully dysfunctional 
response to etoposide alone and a normal response to etoposide plus nutlin. 
Should the case in question be put in to a new group for cases such as 
these? If so then it would have been likely that across the whole cohort extra 
groups would have needed to be generated for a number of cases and given 
that these were rare instances there would have been no option to statistically 
analyse these groups. It is for this reason that it was decided to simply 
evaluate the sample response twice. Once on etoposide alone in order to call 
broadly normal and abnormal, and secondly a detailed categorisation of 
dysfunction that is independent. This independence keeps the analysis 
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simpler as it reduces the possible number of dysfunctional categories. The 
only exceptions to this rule were the cases with abnormal p53 over expression 
in the control culture which, as shown in the results section 3.6.1 (p102), is 
probably disposable for detecting p53 mutation if also measuring p21 
expression.  
Those few cases which displayed a non-classical response and were difficult 
to classify could have been retested. The reason for them not being retested 
was that the study aimed to test each individual case only once as this is 
closer to how the assay was envisaged to be used.  
 
 
 TP53 mutation, 17p deletion and non-responders: 7.4
discussion 
The functional assay was able to detect TP53 abnormalities with considerable 
success. The observation that there are different dysfunctional phenotypes 
associated with these defects deserves further investigation to determine 
whether they are clinically distinct from each other in any way. The work by 
Lin et al (2012) has demonstrated differences in outcomes between their 
identified Type-A and Type-C cases, which are analogous to the p53-over 
expression and p21-failure categories, respectively.  
Of the 20 cases in results section 3.5 (Table 3-11, p98) which were found to 
harbour some form of detected TP53 abnormality, 16 (80%) were assigned to 
one of the functional categories associated with TP53 defects. Of the 
remaining four only one was assigned to the nutlin-responder category. Three 
were classified as normal. It would be of interest to follow the progress of 
these cases. In particular the three normally functioning cases are of interest 
as it has been previously reported that some CLL cases with TP53 
abnormalities follow a benign clinical course (Best et al. 2009).  
One important observation that was made was that 4/5 cases harbouring 
TP53 mutations in the absence of 17p-deletion were successfully assigned to 
one of the TP53-associated dysfunctional categories. This is highly relevant 
as mutation screening is still not routinely performed and this identification of 
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cases with TP53 mutation in the absence of 17p-deletion demonstrates the 
ability of the assay to detect high-risk patients who may be missed by 
conventional screening methods. 
The raw data showing the spectrum of TP53 mutations detected across our 
cohort was not included in the main results section. It was hoped to 
individually assess the impact on the DNA damage response of mutations 
occurring at different ‘hotspots’ within the TP53 gene. A breakdown of 
mutation types including insertions and deletions would have been very 
interesting but unfortunately this was not directly relevant to the reporting of 
the assay results or the validation of the assay. 
   
 
 
 ATM mutation, 11q deletion and nutlin responders: 7.5
discussion 
The results in Table 3-6 (p91) show that of 68 cases with del11q22-23 as the 
sole abnormality detected using FISH, 31 (46%) returned a normal functional 
response to the assay. A similar observation has been made before (Carter et 
al., 2006). It could be that mutation of the remaining ATM allele is required for 
the nutlin-responder response and that the cases with normal function lacked 
a mutation on the remaining allele. Indeed ATM mutation alone was posited 
as the driving force behind the Type-2 response when the assay was first 
developed (Best et al., 2008b) but there is little evidence to support this 
hypothesis within the current study. Of the confirmed ATM mutations detected 
so far only those which result in a frame shift (presumably leading to a non-
sense or truncated protein) can be linked to a dysfunctional response.   
One possible explanation for different assay responses in cases with 11q 
deletion could be differences in the size of the lost region of chromosomal 
material on 11q22-23. Several other genes are known to reside in this region, 
including Mre11 and H2AX. Importantly, Mre11 forms part of the MRN 
complex which has a primary role in the sensing of double stranded DNA 
breaks and is upstream in the signalling cascade from ATM. It is therefore 
reasonable to hypothesise that loss of this gene, either in addition to, or 
 175 
instead of, ATM may lead to a similar dysfunctional phenotype as seen in 
ATM dysfunctional cases. This could also be theoretically rescued by nutlin. 
Published results from the UK LRF CLL4 trial found reduced survival in 
patients with bi-allelic ATM abnormalities (Skowronska et al., 2012). The 
previous work using the etoposide and nutlin assay had associated ATM 
mutations with dysfunctional responses (Best et al., 2008b). This section has 
shown that the nutlin-responder response is not as clearly linked to ATM 
abnormalities as was previously thought. In particular, the lack of cases with 
detected bi-allelic inactivation of ATM (mutation and deletion) was surprising. 
The only case in this restricted analysis with a confirmed biallelic ATM 
abnormality was categorised with a ‘p21 failure’ response; this genetic 
abnormality would have been predicted to give a ‘nutlin-responder’ 
categorisation and being the only example of its kind in this restricted analysis 
it seems to pose a problem. It is important to point out that this case illustrates 
one of the challenges of using a cut-off based system in combination with a 
mutli-step classification system. The case in question gave a dysfunctional 
response when cultured with etoposide only, eliciting no increase in the 
measured level of p21 protein and only a modest p53 increase (9% over 
control). The culture with etoposide plus nutlin gave a very strong p53 
response (131%) yet p21 protein showed an increase to only 14%. Therefore 
despite the addition of nutlin eliciting a very strong p53 response this case 
failed to make the nutlin-responder category based solely on the p21 
response being short of the cut-off by just 1%. This highlights that subjectivity 
as well as objectivity can be important in attempting to categorise functional 
responses.  
Collaborators in Birmingham carried out mutation screening of the ATM gene. 
This work was performed by them due to their expertise in working with this 
gene. They have a previously published and peer-reviewed protocol for the 
screening of this large (68 exon) gene which employs high-performance liquid 
chromatography (HPLC) (Austen et al., 2008). The results provided to us 
covered exons 4-65 of the ATM gene. Those with an abnormal result were 
then sequenced to identify the exact sequence change.  
Data was returned on 155 of the cases that were sent for testing. The data set 
however is not complete for all exons across all samples tested. Six exons in 
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particular appeared to be susceptible to failure. Data was only available for 
exons 4, 5, 11, 15, 26 and 39 for approximately half of all cases (46%, 50%, 
51%, 47%, 46% and 56% respectively). For the 72 cases with results for 
exons 4 and 26 there was a very high incidence of polymorphism detection, 
58/72 (81.6%) and 52/72 (72.2%) respectively. Of the 155 cases sent for 
analysis only 17 (11%) had results returned for every exon tested. Figure 7-1 
shows the number of exons missing across the 155 samples in descending 
order. Samples for which data was missing on more than 20% of exons were 
recorded as untested for the purposes of the analyses in results section 3.5 
(p98). The rationale for setting a cut point at 20% was simply that lowering it 
further would result in a drastic reduction in numbers. One case, which was an 
exception to this rule, had 2 mutations of ATM detected even though 27/62 
(43.5%) of the exons had not given results. This was recorded as mutated, as 
further analysis would not alter the result, and entered in to the analysis. 
Novel sequence changes could not be verified as non-germline.    
 
 
 
Figure 7-1: Histogram showing the number of exons with missing data across the 
155 samples tested. 
 
In general a sequence change was considered to be a mutation if it fulfilled 
any of the following criteria: previously reported as causative in A-T patients, 
predicted to affect a splicing site, lead to a premature truncation of the protein 
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(either through frameshifting or miss-sense introduction of Stop codon), was a 
short in-frame insertion or deletion, affected a residue conserved between 
Human and Mouse and/or affected a conserved domain within the protein. 
Despite the lack of data the incidence of ATM mutations in the cases included 
in section 3.5 (p98) was approximately what would be expected (~10%). 
In addition to cases with ATM abnormalities and normal function it is also 
necessary to address those nutlin responding cases which were found to be 
free from any ATM abnormalities. There may be other gene or genes involved 
in the nutlin-responder response. This may be remote from ATM involving an 
abnormality somewhere else within the genome or it may be within or close to 
the 11q22-23 loci. Interesting candidates for the latter hypothesis are the 
genes for MRE11 and H2AFX which both reside on chromosome 11q and 
have been recently shown to be often deleted in addition to ATM (Ouillette et 
al, 2010). Mutations of MRE11 have been associated with ataxia 
telengiectasia-like disorder (Stewart et al, 1999). It may therefore be that 
del11q involves multiple genes in the same region and FISH cannot 
discriminate between loss that does or does not involve all three genes. 
Nutlin responders with no detected ATM abnormalities could also possibly be 
due to over expression of MDM2, which would/could affect the damage 
response to etoposide and yet it would be overcome by nutlin. The activation 
of some oncogenes such as SKI, has been shown to increase SUMOlyation 
of MDM2 and subsequently increase the polyubiquitination of, and therefore 
degradation of, p53 (Ding et al., 2012). If an MDM2 related mechanism was 
repressing p53 activation in response to etoposide it could be reasonably 
assumed that nutlin would interrupt this, resulting in p53 activation and a 
nutlin-responder response to the assay conditions.  
Another interesting observation, made in section 3.4.4 (Figure 3-5, p94), was 
that the proportion of cells with 11q-deletion was invariably either large 
(>70%) or small (<30%) with a lack of intermediate clone sizes like those seen 
for cases with 17p-deletion (Figure 3-4, p93). One explanation for this lack of 
cases with intermediate clone size is that cases with ATM deletion fall into 
relatively stable groups with either large or small clone sizes and that when or 
if a secondary event occurs it causes a relatively rapid expansion of the 
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deleted clone such that patients rarely present at clinic during the expansion 
event. 
 Investigating p21-failure: discussion   7.6
Although the findings of Chapter 4 (p106) highlighted the role of TP53 
mutation and deletion of 17p13.1 in the p21-failure response, and suggested 
one mechanism by which this phenotype can occur, there remain p21-failure 
cases with no detected abnormality of TP53 or 17p13 and therefore no 
obvious means of explaining the response in this way. This does not 
necessarily rule out a diluted p53/p21 dysfunctional clone emerging within a 
responding clone as the Non-responder group also contains cases with a fully 
dysfunctional result yet no detected abnormalities of TP53. 
One explanation for the discrepancy between the published results obtained 
using ionising radiation (Johnson et al. 2009) and results reported herein 
using etoposide is the possibility that the DNA damage responses elicited by 
these different mechanisms are not identical. The original work developing the 
etoposide and nutlin assay compared etoposide to IR and found them to be 
similar in terms of DNA damage induced, as detected by gamma-H2AX 
phosphorylation (Best et al., 2008b). Other comparisons of p53-dependant 
protein expression changes in response to ionising radiation or etoposide 
have shown them to be synonymous and similarly affected by p53 mutation 
(Jäämaa et al., 2010, Saleh et al., 2011). For example the pro-apoptotic 
protein BID has been shown to be activated by both IR and etoposide (Maas 
et al, 2011). Comparison of IR, UV and etoposide in a murine cell line has 
also shown that IR and etoposide provoke similar ATM and p53 dependant 
responses. These were themselves different to the response induced by UV, 
which resulted in phosphorylation of p53 protein at serine-389, a modification 
that neither IR or etoposide produced (Lu et al., 1998). However UV has been 
shown to differ from ionising radiation with a bias against the transcription of 
p21 in UV treated cells as opposed to IR treated cell (Bodzak et al., 2008). 
Post-translational modification has been shown to inhibit p53 transcriptional 
activity at the CDKN1A promoter in HCT116 cells after treatment with 
gemcitabine or chromium, creating a pro-death phenotype (Hill et al., 2011). 
However, treatment with IR or doxorubicin resulted in expression of p21 and a 
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pro-cell cycle arrest phenotype. It was shown that this difference in p53 
transcription of the CDKN1A gene was achieved through altered 
phosphorylation of the p53 protein via interaction with DNA-PKcs. These 
studies would suggest that no difference between IR and etoposide 
responses should be expected, however the work is all performed on cell 
lines. There does therefore remain the possibility that altered post-
translational modification of p53 may be a factor in the p21-failure / Type-C 
responses for which no TP53 gene abnormalities are detected. 
Another possible reason for any discrepancy is that the responses are the 
same but the rates at which they occur are different, resulting in the sample 
being analysed at a point when the apoptotic targets of p53 are being 
expressed (late), not the cell cycle regulation targets (early). The difference in 
the incidence of p21 failure between that reported using the IR functional 
assay and the etoposide based assay could also be related to the different 
cut-off values used in the respective assays. The most comprehensive way to 
address this question would be a sample sharing scheme between two or 
more centres using the alternative assays.  
Another issue that was encountered in section 4.3 (p109) was the different 
incidences in CDKN1A polymorphisms detected in our cohort and the 
previously published work which identified single nucleotide polymorphisms as 
the cause of the Type-C response (Johnson et al. 2009). In particular, 
determining that the two SNPs were linked in our cohort contradicts the 
original work by Johnson. After determining that the RFLP technique used 
initially gave unclear results the work was repeated using a much more 
sensitive and specific methodology, namely genotyping of both SNPs using 
Taqman™ technology. Pyrosequencing was also used to confirm the codon-
31 results in a subset of those cases. Previously published studies also 
informed us that the finding of linkage between the two SNPs of interest was 
to be expected (Facher et al. 1997; Konishi et al. 2000; Taghavi et al. 2010). 
Taken together, our work here and previous studies provided us with the 
confidence required to suggest that the hypothesis relating CDKN1A SNPs to 
the p21-failure response may require revision.   
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 miR-34a Discussion 7.7
The investigation of miR-34a confirmed the finding that basal expression is 
affected by TP53 abnormalities in CLL. It was also demonstrated that the 
measurement of miR-34a could not detect abnormalities involving the ATM 
gene. This is not entirely unsurprising and does suggest that ATM does not 
play a significant part of miR-34a regulation in the absence of DNA damage. It 
may have been possible to detect ATM abnormalities if the response of miR-
34a to DNA damage was investigated. This however would lead to a number 
of issues. The cells would need to be treated in a similar fashion to the 
etoposide and nutlin assay with relative quantification of the micro RNA being 
taken in each separate culture. It may well be likely that the same results 
would be seen as are seen with the flow cytometric measurement of p53 and 
p21. If this was the case then the same result would be achieved except that 
the analysis would be more costly, take longer to perform and would have 
been less reliable due to the increased handling of samples and the labile 
nature of RNA itself. 
As a possible target for future work, the cluster of differentiation 44 (CD44) 
has recently been shown in prostate cancer cells to be directly repressed by 
miR-34a (Liu et al., 2011). That study also showed that knockdown of mir34a 
lead to increased expression of CD44. A comparison of leukocytes from 
healthy individuals and CLL patients has previously shown there to be no 
significant difference in the expression of CD44 (Belov et al., 2001). CD44 
over-expression on CLL cells and its release as a serum marker has 
previously been shown to associate with advanced disease by both Binet and 
Rai scales and also the need for chemotherapy (Eisterer et al., 2004). CD44 
expression in CLL has not yet been directly linked to TP53 loss or mutation 
but the downregulation of miR-34a seen in the TP53 mutated samples in this 
result section could lead to the hypothesis that those samples may display 
over-expression of surface and serum CD44 compared to the TP53 wildtype 
cases. This could be of interest as a cell surface target that can be used to 
infer p53 abnormalities could potentially be added to flow cytometry 
assessments much more easily than intra-cellular staining for protein.  
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 Sample validation discussion 7.8
The preliminary work shown in section 6.3, (Figure 6-1, p146), suggested that 
the ambient conditions blood samples experienced between venesection of 
the peripheral whole blood and storage of the isolated PBMCs may have 
some impact on the viability of samples. The most pronounced effect was 
seen when the ambient temperature was allowed to reach 37oC. 
Unsurprisingly, the data also show a general reduction in viability of CLL cells 
after 24 hours in culture. CLL cells experience spontaneous apoptosis ex-vivo 
and so this reduction is most likely a result of this. The data displayed in Table 
6-1, again suggest that it may be possible for handling to affect functional 
assay results. The main problem with this preliminary work is the low numbers 
tested precludes statistical analysis. In addition, the extra handling of a 
sample required to set up the different ambient conditions for that experiment 
could have had an effect on the responses of the samples. 
It was decided to analyse the assay data on the cohort for evidence of 
reduced cell viability or impaired assay responses between local and referral 
samples. To achieve this, data relating to the light scattering properties of the 
cells acquired during FACS analysis was used as a surrogate method of 
estimating the proportion of non-apoptotic, viable cells in the sample. A 
comparison of the light scatter data to results obtained using the trypan-blue 
exclusion test of viability was made for 64 samples and the results found a 
significant correlation between to two methods (Figure 6-2, p149). 
Establishing that the use of light-scattering properties could be interpreted as 
a guide to cell viability in section 6.4.2 (p148) facilitated the subsequent 
analysis in sections 6.4.3-6.4.5 (pp149-154). This was an attempt to make the 
most of the available flow cytometric data and also to find a method for 
investigating cell viability retrospectively. It would have been preferable to be 
able to use a more rigorous method during the actual experimental work, for 
example staining with Annexin V and propidium iodide can give very detailed 
information concerning the stage of apoptosis and it is a flow cytometry based 
technique which would have been ideal for use. However given the numbers 
of samples to be tested it would have likely led to a considerable cost 
increase and further complicated the benchwork associated with the assay. 
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It was decided to analyse the assay data on the cohort for evidence of 
reduced cell viability or impaired assay responses between local and referral 
samples. To achieve this, the light scattering properties of the cells during 
FACS analysis were used as a surrogate method of estimating the proportion 
of non-apoptotic, live cells in the sample. Firstly this data was compared to 
results obtained using the trypan-blue exclusion test of viability. Data was 
generated for 64 samples and the results found a significant correlation 
between to two methods (Figure 6-2, p149). This allowed for potential effects 
upon viability and assay response to be assessed retrospectively on a larger 
number of previously assayed samples. This was also a money saving 
alternative to retesting those samples which had already been analysed using 
the assay. In addition to the percentage of live cells, the measured MFI data 
for p53 and p21 was also analysed for differences between local and referred 
samples. 
Within the samples that had taken less than a day to be processed it was 
interesting to note that those with TP53 abnormalities had lower viabilities 
than those samples with ATM abnormalities or those with no abnormalities of 
either gene (Figure 6-9, p158). This relationship wasn’t seen in the samples 
which had taken a day or more to arrive in Bournemouth. In addition the 
viabilities of wildtype or ATM abnormal cases seem to be reduced in samples 
with a day or more between venesection and processing, whereas the cases 
with TP53 involvement had similar viabilities regardless of the duration of time 
between venesection and arrival in Bournemouth. A possible explanation for 
this observation is the involvement of p53 in the cellular response to oxidative 
stress and hypoxia. Wildtype p53 has a cyto-protective role to play under 
these conditions and so its loss of action may have a short term 
disadvantage. Alternatively, the higher lymphocyte count of whole blood 
samples with TP53 abnormalities may simply mean that the samples became 
depleted of oxygen faster than other samples and this led to a more acute 
short term impact on viability. 
Whilst there was a statistically significant effect introduced by transport on 
both the viability of cells and the responses of p53 and p21 to drug treatment 
it was demonstrated that this is not likely to be severe enough to cause the 
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misclassification of normal responding samples as abnormal (Figure 6-13, 
p164 & Figure 6-14, p165). The question of whether ex-vivo analysis of the 
DNA damage response in primary CLL cells meaningfully relates to the in-vivo 
responses of the same cells is not possible to address. Certainly the role of 
the micro-environment in tumour cell behaviour cannot be over-estimated in 
terms of cell activation and proliferation but any effects concerning the 
acquisition of therapy resistance are not understood. The effects of 
chemokine inhibitors such as CAL-101 and PC-2375 in flushing CLL cells 
from lymphoid tissues suggests that in some if not many cases the CLL cells 
circulating in the peripheral blood may not be completely akin to those 
residing in lymphatic tissues. This therefore, is a criticism of all in-vitro 
analysis.  
The work in the sample validation chapter demonstrates that there is some 
impact upon functional analysis introduced by transporting blood samples. 
Testing samples that have spent three or more days in transit is feasible but 
not recommended and an element of caution would need to be taken. Any 
results that are close to the established cut-offs would require further analysis.  
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 Functional assay in a clinical versus research setting 7.9
The potential use of functional assays in a clinical setting may be limited. 
Despite the significant relationships seen between response patterns and 
cytogenetic or genetic abnormalities, there are sufficient cases with 
unexpected responses to suggest that there are unknown factors involved. 
It had been hoped to analyse treatment and response data for the cohort to 
determine if the assay was able to predict the response to therapy. Whilst this 
data was available for a proportion of the cases tested with the assay there 
were complications which made generating meaningful results difficult.  
An analysis of the incidence of previous treatment was made in Table 3-12 
and Table 3-13 in section 3.7 (p104) for 121 cases with that data available. It 
was shown that there was a slight trend for the previously treated group to 
contain more cases with either a genetic abnormality of TP53 or a 
dysfunctional assay response than the treatment naïve group. However the 
low numbers in many of the groups may have had an effect on statistical 
analyses. 
An analysis of the response to therapy which occurred subsequent to the 
patient being sampled was not included. Data on subsequent treatment type 
and response was available for 91 cases; 45 who at the time of sampling 
were ‘treatment naïve’ and 46 who had been treated previously. It was 
however realised that the patients would have been treated by clinicians who 
would have based treatment decisions on existing FISH results and other 
clinical data available to them. Therefore it was highly likely that the cases 
with deletion of 17p or 11q may be skewed towards particular therapy 
regimens containing antibody therapy such as alemtuzumab or rituximab. In 
addition to this there were a total of sixteen different therapies or 
combinations of therapies used and this meant that many groups had very low 
numbers, again making reliable statistical analysis unlikely. What this problem 
does highlight is that testing and validating an assay such as that used in this 
work would be best achieved with the controls on therapy choice and data 
collection associated with a clinical trial. 
One further issue regarding the potential clinical relevance of the assay used 
in this project is how it relates to the current advances in treatment therapies. 
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Clinicians are now able to access a greater variety of drugs for patients 
through clinical trials which do not employ DNA damage to kill tumour cells. In 
addition to immunotherapies such as rituximab, drugs targeting pro-survival 
signalling in CLL are showing great promise. A recent multicentre, phase 3 
study, randomly assigned 391 patients with relapsed or refractory CLL or SLL 
to receive either ibrutinib or the anti-CD20 antibody ofatumumab (Byrd et al., 
2014b). The analysis of progression-free survival in these two groups showed 
that ibrutinib had an advantage over the antibody therapy. Median 
progression-free survival was not reached after a median follow-up of 9.4 
months whilst the median progression-free survival for the ofatumumab 
treated arm was reached at 8.1 months. The sub-group of patients with 
deletion of 17p13.1 in the ibrutinib arm also did not reach median progression-
free survival, compared to a median of 5.8 months for the 17p deleted 
patients in the ofatumumab arm. However it has to be noted that patients on 
ibrutinib did eventually progress with approximately a third having progressed 
after 12 months. In addition to this a reported case of ibrutinib resistance in a 
patient lead to the characterisation of a novel, selected, functional mutation of 
the BTK gene which disrupts the binding of ibrutinib to the Bruton’s tyrosine 
kinase protein (Cheng et al., 2014). As new pathways are exploited for 
therapeutic benefits it becomes necessary to find new ways to study them. It 
is quite appropriate to think that a flow cytometry based assay could be 
adapted to monitor the efficacy of drugs like ibrutinib. This may be especially 
warranted as ibrutinib is a daily, oral medication that patients currently stay on 
for as long as benefits persist.  
 
 
  
 186 
 Future Direction 7.10
Ideally the next stage of development for the assay used in this work would be 
for it to be performed in tandem with a stage III clinical trial involving any 
therapy of combination therapy which contains a drug that is reliant upon the 
ATM/p53 pathway for efficacy. It should also be performed prospectively 
rather than retrospectively to eliminate any issues of sample viability due to 
long term storage. This would allow the assay results to be compared with the 
outcome data when the follow-up period is over. The main issue with this 
would be that the testing of samples would therefore be performed five or 
more years before the survival and outcome data is released. Despite that, 
this would be the most powerful way of answering questions about the 
different functional categories and their relationship to outcomes, especially 
for dysfunctional cases with no high risk markers. With increasing ease of 
access to, and the gradually reducing cost of, next generation sequencing 
technologies, it may be possible to look for new mutations in CLL cells which 
affect the ATM/p53 pathway by investigating those cases with dysfunction in 
the absence of known high risk markers if they are found to have poorer 
outcomes than normal cases. 
Another direction in which this kind of project could be taken would be to 
investigate adapting the assay to predict treatment responses for the newer 
classes of drugs which are becoming increasingly more relevant in CLL 
therapy. This includes inhibitors of proteins in B-cell receptor signalling 
pathways or apoptosis/ cell survival pathways as well as immunotherapies. 
This would therefore involve the detection of activation, or inhibition, of the 
cellular pathways relevant to these new therapies, for example detecting the 
successful inhibition of Bruton’s tyrosine kinase (BTK) mediated BCR-
signalling in CLL cells treated by ibrutinib or acalabrutinib. However, detection 
of p53 abnormalities may remain relevant even to these new treatments as 
mutant p53 is likely to have an impact on cellular pathways other than just the 
DNA damage response. 
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 Conclusion 7.11
The stated aims of this project were to (i) determine the value of the 
etoposide/nutlin3a functional assay for detecting patients with abnormalities of 
the ATM/p53-dependant DNA damage response which would contra-indicate 
treatment with alkylating agents or purine analogues; and, (ii) test the ability of 
the assay to discriminate between ATM and p53 abnormalities as these have 
differing prognostic impact in CLL.  
Broadly, the project fulfilled these aims. It has been determined that the assay 
does detect TP53 mutations and deletion of 17p and that the use of nutlin is 
effective at separating the p53 dysfunctional cases from ATM dysfunctional 
cases. Despite this many cases with ATM abnormalities were classified as 
having normal responses to the assay conditions with ATM mutations in 
particular not showing the impaired DNA damage response to etoposide that 
had been expected. The assay also detected many cases with apparent 
dysfunction of the DNA damage response for reasons other than involvement 
of p53 or ATM. 
This work has also shown that p21 failure is a characteristic of all the 
dysfunctional categories described herein. It should be considered that p21 
protein expression is a more uniform indicator of a failure of the ATM-p53 
pathway than p53 protein expression. 
It is likely that the functional assessment of primary CLL cells may serve 
better as a research tool rather than a clinical test simply because the 
therapeutic options available for clinicians are rapidly developing. However, 
until these assays are performed prospectively, as an associated part of a 
clinical trial, it will be difficult to tell for sure how well the dysfunctional 
responses relate to patient outcomes. This is particularly true for those cases 
with no other high risk markers.  
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The following 3 pages are a copy of the ‘Research Participant Information 
sheet’, Version 2, 26/04/06.  
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Research Participant Information Sheet 
 
 
STUDY TITLE 
 
Identification and characterisation of prognostic factors in chronic B cell 
lymphoproliferative disorders. 
 
WHAT IS THE PURPOSE OF THE STUDY AND WHY I HAVE BEEN CHOSEN? 
 
Blood normally contains a variety of white cells which defend us against infection.  
One type of white cell, called a B lymphocyte, produce antibodies which recognise 
and help to destroy bacteria.   
 
A group of diseases called the chronic B cell lymphoproliferative disorders are 
characterised by an over-production of B lymphocytes. The numbers of B 
lymphocytes in the blood and bone marrow are frequently increased and sometimes 
there is enlargement of lymph glands and/or the spleen. 
The commonest of these disorders is chronic lymphocytic leukaemia. Other rarer 
conditions include splenic marginal zone lymphoma, mantle cell lymphoma and 
prolymphocytic leukaemia. 
 
These disorders are often picked up by chance on a routine blood test performed for 
another reason, such as before surgery. Many patients never require treatment.  In 
other patients, the diseases progress slowly and eventually need treating, while in a 
minority, treatment is required soon after diagnosis. Currently these conditions are 
incurable but they respond well to the many types of treatment that are now available. 
 
The Haematology Department at the Royal Bournemouth Hospital has an 
international reputation for research carried out on the B cell chronic 
lymphoproliferative disorders over the past 20 years. We have developed blood tests 
which help to distinguish between those patients likely to have stable disease and 
those whose disease will progress and require treatment. The tests are also helpful in 
choosing the right treatment for each patient. 
We should like to continue our research to try and discover the cause of these diseases 
and to develop simple, more reliable and inexpensive tests that can be used in 
laboratories worldwide to help predict the course of these diseases and the likely 
response to treatment. 
 
We would like to offer the opportunity to take part in this research project to all 
patients with a chronic lymphoproliferative disorder who have been referred to the 
Haematology Department at the Royal Bournemouth Hospital. 
 
 
 
The Royal Bournemouth and  
Christchurch Hospitals  
NHS Foundation Trust 
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DO I HAVE TO TAKE PART? 
 
Taking part in research is entirely voluntary. If you do decide to take part you will be 
asked to sign a consent form.  If you decide to take part and then change your mind 
you are free to withdraw at any time without giving a reason.  Samples that have been 
stored in our laboratory would either be thrown away or returned to you in accordance 
with your wishes. A decision to withdraw from the study at any time or not to take 
part at all will not affect the standard of the care you receive. 
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? 
 
Most of the research studies will be performed on residual cells (from blood, bone 
marrow or occasionally lymph node or spleen) that have been taken as part of your 
routine clinical care. Occasionally requests may be made for an additional 20ml blood 
sample purely for research purposes. Most of the tests will be performed in the 
Haematology Department at Bournemouth but anonymised samples may also be sent 
to other specialist laboratories that are working with us on the same diseases. We are 
also asking for your consent to store any unused samples for future ethically approved 
studies into the chronic B cell lymphoproliferative disorders. If you do not wish this 
to happen you can state this on the consent form.   
 
WHAT ARE THE RISKS/BENEFITS OF TAKING PART? 
 
There are no risks to taking part in this study apart from the mild discomfort of having 
blood taken. Since many of our patients are followed up for more than ten years it is 
possible but not guaranteed that the results of our research may be helpful to you. We 
hope this research will also help patients in the future. 
 
WILL MY TAKING PART IN THIS STUDY BE KEPT CONFIDENTIAL? 
 
All the information which is collected about you during the course of the research will 
be kept strictly confidential. Any information about you would only be accessed by 
the doctor or their support team involved in your normal clinical care. 
 
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY? 
 
We anticipate that these studies will provide new information and that the results will 
be presented at scientific meetings and published in scientific journals. To date our 
department has published over 150 papers on B cell chronic lymphoproliferative 
disorders in major scientific journals. 
 
 
 
WHO IS ORGANISING AND FUNDING THE RESEARCH? 
 
The chief investigator is Dr D G Oscier at the Royal Bournemouth Hospital.  The 
research is currently funded by the Leukaemia Research Fund, Tenovus ( a Cardiff-
based charity supporting research into chronic lymphoproliferative disorders and 
cancer) and the Bournemouth Leukaemia Fund.   
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WHO HAS REVIEWED THE STUDY? 
 
The study has been reviewed scientifically by the Leukaemia Research Fund and 
Tenovus, and ethically by the Somerset Research Ethics Committee. 
 
 
 
 
 
CONTACT FOR FURTHER INFORMATION 
 
Dr D G Oscier 
Consultant Haematologist 
Royal Bournemouth Hospital 
Castle Lane East 
Bournemouth 
Dorset BH7 7DW 
 
Telephone   01202 704790 
 
FAX            01202 300248 
 
Email          david.oscier@rbch.nhs.uk 
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 Appendix II: Patient consent form 10.2
The following 2 pages are a copy of the standardised consent template used, 
Version 2, 26/04/06.  
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STANDARDISED CONSENT TEMPLATE FOR STUDIES USING  
Human Biological Samples 
 
 CONSENT FORM (staged) 
 
Thank you for reading the information about our research project. If you would 
like to take part, please read and sign this form. 
 
Title of project: Identification and characterisation of prognostic factors in 
chronic B cell lymphoproliferative disorders 
Name of researcher: Dr D G Oscier. 
Contact details for research team: 01202 704790 
 
PART A: Consent for the current study  
(Samples to be destroyed on study completion unless part B completed) 
 
PLEASE INITIAL THE BOXES IF YOU AGREE WITH EACH SECTION:  
                     
1. I have read the information sheet dated 26/04/06, version 2 for the above study 
and have been given a copy to keep. I have been able to ask questions about the 
study and I understand why the research is being done and any risks involved. 
 
2. I agree to give a sample of (blood/ tissue/ other as appropriate) for research in this 
project.  
I understand how the sample will be collected, that giving a sample for this research 
is voluntary and that I am free to withdraw my approval for use of the sample at any 
time without my medical treatment or legal rights being affected. 
 
3. I give permission for someone from the research team to look at my medical 
records to get information. I understand that the information will be kept confidential. 
 
4. I understand that my Doctor and I may be informed if any of the results of tests 
done as part of the research are important for my health. However, I also understand 
that the research may not directly benefit my health. 
 
5. I understand that I will not benefit financially if this research leads to the 
development of a new treatment or test. 
 
6. I know how to contact the research team if I need to. 
 
 
________________________ _________________       
___________________ 
Name of patient    Date         
Signature 
 
 
________________________ _________________       
___________________ 
Name of person taking consent  Date         
Signature 
The Royal Bournemouth and  
Christchurch Hospitals  
NHS Foundation Trust 
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Samples for storage and use in possible future studies 
 
PART B Linked or linked anonymised samples: 
 
7. I give permission for my sample and the information gathered about me to be 
stored by Dr D.G. Oscier at the Royal Bournemouth Hospital for possible use in 
future projects, as described in the information sheet. I understand that some of 
these projects may be carried out by other researchers, including researchers 
working for commercial companies. I understand that future studies will be 
reviewed and approved by a Research Ethics Committee prior to my sample 
being used, and that I can alter these decisions at any stage by letting the 
research team know. 
 
a) I give permission for the sample to be used for research about 
chronic lymphoproliferative disease. 
 
b) I give permission for the sample to be used for other unrelated 
research studies the precise nature of which will depend upon future 
scientific advances. 
 
 
8. I want / do not want (delete as applicable) to be told the results of any future test 
which may have health implications for me. 
 
9. I give permission for sections of my medical notes to be looked at by responsible 
individuals where it is relevant to such future study. I expect that my medical notes 
will be treated confidentially at all times. 
 
 
 
 
 
________________________ _________________       
___________________ 
Name of patient    Date         
Signature 
 
 
________________________ _________________       
___________________ 
Name of person taking consent  Date         
Signature 
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 Appendix III: Antibodies 10.3
 
ANTIBODY Use CLONE SUPPLIER CODE 
Beta actin rabbit Pab WB  Abcam, UK Ab8227-50 
Beta actin-HRP mouse Mab WB  Abcam, UK Ab20272-100 
CD2-RPE mouse Mab FC MT910 DAKO, Denmark R080701 
CD5-FITC mouse Mab FC DK23 DAKO, Denmark F079501 
CD5-APC mouse Mab FC DK23 DAKO, Denmark C7242 
CD7-PE mouse Mab FC MT701 BD biosciences, UK 332774 
CD19-RPE/CY5 mouse Mab FC C706601 DAKO, Denmark C706601 
CD38-PE mouse Mab FC HB7 BD biosciences, UK 345806 
CD49d-PE mouse Mab FC -- BD biosciences, UK 340296 
Goat anti-mouse secondary-FITC FC  BD biosciences, UK 349031 
IgG1 isotype control AlexaFluor-
488 mouse Mab 
FC  Caltag, US MG120 
IgG2a isotype control FC  DAKO, Denmark 094301 
Kappa-APC rabbit Pab FC  DAKO, Denmark C0222 
Lambda-PE rabbit Pab FC  DAKO, Denmark R0437 
p53 (Ab-6) mouse Mab FC D0-1 Calbiochem, UK OP43 
p21 (Ab-1) mouse Mab FC EA10 Calbiochem, UK OP64 
p53 mouse Mab WB D0-1 SantaCruz, US SC126 
p21 mouse Mab WB -- Zymed, US 33-7000 
p53 mouse Mab WB D0-11 Serotec, UK MCA1704 
Zap-70 AlexaFluor-488 mouse 
Mab 
FC  Caltag, US MHZAP7020 
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 Appendix IV: Reagents and materials list 10.1
Item Supplier Code 
Agarose LE analytical grade Promega, ES V3125 
Ammonium chloride NH4Cl(S) 500g Sigma Aldrich, UK A9434 
BigDye® Terminator v3.1 cycle sequencing kit Applied Biosystems, UK 4336917 
BigDye® Terminator v3.1 buffer Applied Biosystems, UK 4336697 
DMSO (DiMethyl Sulphoxide) Sigma Aldrich, UK D8418 
Dulbeccos Modified Eagle Medium 500ml Sigma Aldrich, UK D6546 
Elkay 2ml cryovials Simport, Canada T311-3 
Etoposide™ [25mM] 400µl Trevigen Inc, USA 4886-400-01 
Fast-Read 102® cell counting slides Immune Sytems Ltd, UK BVS100 
FBS (foetal Bovine Serum)  BioSera, UK 51900 
GelRed
TM
 Nucleic Acid Gel Stain, 10,000X 
500µl 
Biotium, USA 41003 
Glycerol, ≥99% 500ml Sigma Aldrich, UK G-5516 
Heparin 1000u/ml ampoules CP Pharmaceuticals, UK PL04543/0221 
Hi-DI™ Formamide Applied Biosystems, UK 4311320 
Histopaque®-1077 500ml Sigma Aldrich, UK 10771 
Immobilon™ PVDF membrane Millipore, UK IPVH00010 
L-glutamine 200mM 100ml Sigma Aldrich, UK G7513 
NuPage® MES-SDS Running buffer (20x) Invitrogen, UK NP0002 
NuPage® transfer buffer (20x) Invitrogen, UK NP0006-1 
Nutlin3a 1mg Calbiochem, UK 444143 
Paraformaldehyde BDH lab supplies, UK 294474L 
Phosphate buffered saline solution (PBS) 
500ml pH7.4 
Invitrogen, UK 10010 
Pierce Supersignal® Chemiluminescent 
substrate 
ThermoScientific, USA   
Propidium Iodide solution 10ml Sigma Aldrich, UK P4864 
RNAlater® solution 250ml Ambion, UK AM7024 
RPMI 1640 media + HEPES 500ml Gibco® Invitrogen, UK 42401 
SeeBlue® Plus2 Prestained standard Invitrogen, UK LC5925 
Sodium Acetate buffer solution Sigma Aldrich, UK S-7899 
Sodium Azide Sigma Aldrich, UK S2002 
Sureclean 25ml Bioline, UK 37046 
TAE (Tris-Acetate/EDTA) buffer (50x) Alpha Laboratories, UK EL0077 
Titanium™ taq PCR kit Clontech, USA 639210 
TrackIt™ Cyan/Orange loading buffer Invitrogen, UK 10482-028 
Trizma®-base Sigma Aldrich, UK T1503 
Trypan Blue solution 100ml (0.4%) Sigma Aldrich, UK T8154 
Tween-20 BDH lab supplies, UK 66368 
Water-bath treatment Sigma Aldrich, UK 55525 
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 Appendix V: Primers 10.2
 
Code Sequence 5′ → 3′ Target 
Fragment 
size 
5/6 UB CTC TGT CTC CTT CCT CTT CCT ACA 
TP53  
exons 5 & 6 
462bp 
5/6D AGG GCC ACT GAC AAC CAC CCT TA 
7/8 UB CCT CAT CTT GGG CCT GTG TTA TCT 
TP53  
exons 7,8 & 9 
820bp 
789D CTT TCC ACT TGA TAA GAG GTC CC 
P21GCOD31F GTC AGA ACC GGC TGG GGA TG 
CDKN1A  
exon 2 
272bp 
P21GCOD31R CTC CTC CCA ACT CAT CCC GG 
P21GUTRF AGT TCT TCC TGT TCT CAG CAG 
CDKN1A 
3′UTR 
327bp 
P21GUTRR CCA GGG TAT GTA CAT GAG GAG 
Cod31PyroFBio CTC TTC GGC CCA GTG GAC A 
CDKN1A  
exon 2 
81bp Cod31PyroSeq AGC GCA TCA CAG TCG 
Cod31PyroRev CTC ACG GGC CTC CTG GAT 
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Type C p53 Pathway Dysfunction Resulting From The 
Presence Of An Emerging TP53 Mutated Subclone In CLL
Ian Tracy(1), Anton Parker(2), Giles Best(3), Aneela Majid(4), Tanya Stankovic(5), Martin Dyer(4), David Oscier(2)
1)University of Bournemouth, Bournemouth, UK. 2)Royal Bournemouth Hospital, Bournemouth, UK. 3)CLL Research Consortium, Northern Blood Research Centre, Kolling Institute, Royal North 
Shore Hospital, Australia. 4)Medical Research Council Toxicology Unit, Leicester University, Leicester, United Kingdom. 5)CRUK Institute for Cancer Studies, University of Birmingham, 
Edgbaston, Birmingham, UK.
Background
Mutation and or loss of TP53 are known adverse prognostic markers in CLL, frequently associated with aggressive and chemo-refractory disease. Increased expression 
of p53 and its downstream target p21 are essential for effective response to DNA damage. 
Functional assays have been developed to test CLL cells for their in-vitro response to DNA damage using either ionising radiation [1] or radio-mimetic drugs [2] Levels 
of p53 and p21 before and after DNA damage are used to assign samples to one of four functional categories (figure 1). 
Johnson et al [3] recently reported an association between type C response and the genotype of single nucleotide polymorphisms (SNP) at codon 31 and in the 3’UTR 
of the p21 gene. 
Conclusion
This study describes an association between the previously described type C response and the presence of TP53 loss or mutation. 
Further detailed follow up will be required to establish the clinical significance in these patients
There remains a number of cases for which the cause of the type C dysfunction remains to be explained. Longitudinal analysis of these cases coupled with clinical 
information will elucidate the true prognostic relevance of this functional category and whether it should be stratified further. 
Observed evolution of dysfunction
In longitudinal analysis of 49 samples, 4 cases were observed to change functional 
category. Figure 2 Shows information and assay plots from a selection of these cases. 
Changes in response were accompanied by either an increasing clone size as evidenced by 
FISH or direct sequencing, or karyotypic evolution and/or intervening treatment.
Patient 4080: A 4 base pair deletion in exon 5 of TP53 was detectable at both time points. 
FISH analysis showed a modest increase in clone size over a 7 month period. 
Sample 10039: Normal function when first tested and no loss of 17p observed. Post 
Fludarabine sample (10099) showed type C function. Direct sequencing detected a 
missense mutation in exon 7 of this sample which was then found to be present at lower 
levels in the original sample.
P21 genotypes and type C dysfunction
Genotyping of the p21 codon 31 and 3’UTR SNPs in all 25 type C cases plus enlarged cohorts 
comprising 6 type A, 32 type B, and 117 normal response cases by TaqMan genotyping (ABI) assays 
showed no significant association between either genotype and the type C response (Table 1). 
In addition all cases were observed to fall into one of only two diplotypes, being either heterozygous 
or homozygous at both SNPs, precluding direct association of our data with that of Johnson et al who 
suggest the type C response is associated with heterozygosity at codon 31 and homozygosity at 
3’UTR.
Incidence of p53 abnormalities and type C dysfunction.
Genotyping of samples was carried out as previously described. Mutation detection 
was achieved through a combination of mutational screening by DHPLC and direct 
sequencing in a total of 135 cases. Loss of chromosomal locus 17p was detected by 
fluorescent in situ hybridisation in 31/173 cases. Associations between tp53 mutation 
status, chromosomal loss and the type C functional response were calculated using 
Fisher’s exact test, all p values are two-tailed.
A highly significant association was seen between the type C response and both 
TP53 mutation and loss of 17p when compared to normal cases. This association 
was lost when comparing type C cases to either type A or B.
p53 levels p21 levels
Figure 1: Typical response patterns derived from flow cytometric analysis of CLL cells for levels of P53 
and P21 after 24hours incubation with or without 50µM etoposide. 1) Normal response. Low baseline level 
of p53 in control cells and both p53 and p21 increase in response to etoposide. 2) Type A response, 
elevated baseline level of p53 in control cells 3) Type B response, Both p53 and p21 fail to increase by 
>30% and >15% respectively. 4) Type C response, p21 fails to increase by >15% despite normal p53 
response.  
=untreated =etoposide 
table1
1
2
3
4
Replicating the effect of an emerging p53 abnormal clone.
We hypothesised that the presence of a type B, TP53 mutated, sub-clone 
would dilute the measured response of normal CLL cells so that p21 fell 
below its cutoff before p53 fell below its cutoff.
CLL cells from normal function cases were mixed with CLL cells from type B 
cases with known TP53 abnormalities. Paired samples were chosen with 
respect to their surface immunoglobulin light chain restriction so that cells of 
different origin could be distinguished from one another. Manipulation of the 
proportion of lambda versus kappa cells facilitated approximation of various 
clone sizes (Figure 3). Using type B cells it was possible to achieve a type C 
result. This was not possible when using type A cells. 
Functional Analysis
Functional analysis of 513 unselected local and referral CLL cases using the radio-mimetic drug, 
Etoposide and FACS analysis of p53 and p21 expression showed 16 type A, 118 type B, 25  type C 
and 354 normal response cases using cutoffs defined in [2].
Table 1: A) Distribution of SNP diplotypes, TP53 mutation and chromosome 17p loss within series. Codon 31 SNP (rs1801270) 
Ser/Ser or Ser/Arg occurs with 3’UTR SNP (rs1059234) C/C or C/T respectively. TP53 mutations detected by DHPLC and direct 
sequencing. Chromosome 17p13.1 loss detected by fluorescent in situ hybridisation (Vysis LSI TP53).
B) Associations between the type C phenotype and TP53 mutation or 17p13.1 loss compared to each functional category. All tested 
using Fishers exact test, significance is two-tailed.
Figure 3: Examples of two mixing experiments. The table above shows 
data on the chosen samples. The images to the right show the final plots 
after manipulating the percentages of cells for analysis. TOP: Samples 
47 and 4080; BOTTOM: Samples 32 and 89
[1] CARTER,A., LIN,K., SHERRINGTON,P., PETTITT,A., 2004. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukemia. British Journal of haemotology. (127) pp425-428.
[2] BEST,O., GARDINER,A., MAJID,A., WALEWSKA,R., AUSTEN,B., SKOWRONSKA,A., IBBOTSON,R., STANKOVIC,T., DYER,M., OSCIER,D., 2008. A novel functional assay detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia. (22) pp1456-1459
[3] JOHNSON,G., SHERRINGTON,P., CARTER,A., LIN,K., LILOGLOU,T., FIELD,J., PETTITT,A., 2004. A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene
p53 functional cells
4080-2006 Type 3 
response
Cloning and 
sequencing of the 2007 
sample identified a 4 
base pair insertion in 
exon 5.
4080-2007 Type 1 response
p53 response
p21 response
Figure 2: 1) Summary of three cases in which a change in functional response has been observed. 2) Flow plots and 
electropherograms of mutations showing the changes over time in two patients.
10039
10099
1
2
A B
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